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Abstract 
Epilepsy is a serious neurological disorder, affecting 2-3% of the population. Over 
30% of people with epilepsy do not respond to currently available medications. It is crucial 
to have a better understanding of epilepsy pathology and pharmacology. The inhibitory 
GABAA receptor (GABAAR) and excitatory NMDA receptor (NMDAR) are key to understand 
epilepsy mechanisms and treatments. Hereditary mutations to those receptors are 
underlying causes of epilepsy and major therapeutic target for epilepsy medications. Hence, 
the physiological and pharmacological properties of mutant GABAAR and NMDAR play vital 
role in epileptogenesis and its possible reversal. In this study, I investigated the functional 
effects of epilepsy mutations on GABAergic inhibitory postsynaptic currents (IPSCs) and 
NMDAR mediated excitatory postsynaptic currents (EPSCs).  
To do so, traditional electrophysiology was combined with an ‘artificial’ synapse 
preparation consisting of co-cultures of neurons and heterologous cells transfected with 
defined receptor isoforms. With the help of this preparation, the characterisation of IPSCs 
and EPSCs mediated by pure populations of α1β2γ2 GABAARs and GluN1/2A, GluN1/2B, 
GluN1/2A/2B NMDARs, which are the major synaptic isoforms in vivo.  In this thesis, I firstly 
examined the functional effects of three mutations to the α1 subunit (α1T10’I, α1D192N and 
α1A295D). Then, to investigate pharmacology property, mutant channel IPSCs were also 
recorded in the presence of the anticonvulsant drugs, carbamazepine and midazolam. 
Those mutations significantly reduced the surface expression (α1A295D), reduced the number 
of synaptic contacts (α1D192N), and significantly accelerated the decay rate of IPSCs (α1T10’I, 
α1D192N), contributed to neuronal inhibition reduction in multiple ways. α1T10’I was insensitive 
to midazolam and carbamazepine, providing potential insights as to how clinical medications 
could be tailored to particular epilepsy genotypes.  
Then, the functional effects of three NMDAR mutant (GluN2AN615K, GluN2BN615I and 
GluN2BV618G) subunits was investigated in the similar preparation. Those mutant di- and 
triheteromeric receptor isoforms greatly attenuated the Mg2+-induced receptor blockade of 
EPSCs and rendered the receptors active in the presence of extracellular Mg2+. These 
resulted in an enhanced cation influx rate, which would dramatically increase neuronal 
excitability and contribute directly to the epilepsy phenotype. For pharmacology part, 
GluN2BV618G mutant NMDAR was insensitive to memantine (currently used to treat 
Alzheimer’s disease, epilepsy and autistic spectrum disorders), suggesting other subtype-
selective NMDAR antagonists that bind outside the channel pore should be explored as 
candidates for personalised therapeutics. 
III 
 
Finally, I did some physiological and pharmacological works on α5-GABAAR, as it 
plays a particularly important role in epilepsy and many other diseases. Using artificial 
synapse preparation, I found significantly different channel properties for three α5-GABAAR 
isoforms in vivo (α5β1γ2, α5β2γ2 and α5β3γ2). Then, I quantified the effects of four α5-
specific inverse agonists (TB-21007, MRK-016, α5IA and L-655708) and other three newly 
developed inverse agonists (RM68, RM69 and RM70) on IPSCs mediated by the three 
isoforms. The first four compounds had effect on α5GABAAR, albeit with distinct isoform 
specificities. RM68 had a selective effect on α5β3γ2. These results provide a reference for 
future studies seeking to identify and characterize the properties of IPSCs mediated by α5-
containing GABAAR isoforms in neurons and drugs targeted on α5 receptors. 
This thesis enhanced our understanding of genotype-phenotype correlations in GABAAR- 
and NMDAR-linked epilepsies, leading to new insights into how epilepsy medications to 
target these two important ligand-gated ion channels. Ultimately, this study will provide a 
framework for devising personalised pharmacological interventions for patients with 
epilepsy. 
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Introduction 
 Epilepsy is a serious neurological disorder, affecting 2-3% of the population. It is 
characterised by ‘seizures’ resulting from abnormal, hyper-synchronised electrical activity in 
neurons. Over 30% of people with epilepsy do not respond to currently available 
medications. This is partly because the underlying causes of many epilepsies are unknown 
(Berg et al., 2010; Merwick et al., 2012). With the development of next-generation DNA 
sequencing, the rate of identification epilepsy susceptibility genes has increased 
considerably (Merwick et al., 2012). Many of these genes encode synaptic proteins, 
including excitatory N-methyl-D-aspartic acid receptor (NMDAR) subunits (Endele et al., 
2010; Lemke et al., 2013; Lesca et al., 2013) and inhibitory γ-aminobutyric acid (type A) 
receptor (GABAAR) subunits (Macdonald et al., 2010; Janve et al., 2016; Kodera et al., 
2016). It is essential to resolve the mechanisms by which these mutations affect NMDAR-
mediated excitatory postsynaptic currents (EPSCs) and GABAAR-mediated inhibitory 
postsynaptic currents (IPSCs) to both understand epileptogenic mechanisms and design 
optimal therapies for particular epilepsy genotypes. Thus, the aims of this thesis is to 
investigate the pharmacological and physiological properties of GABAA and NMDA 
receptors containing epilepsy mutations. 
 
Ⅰ: Inhibitory and excitatory synaptic transmission  
A synapse is a specialised cell-to-cell junction contributed by both the presynaptic 
cell and its postsynaptic partner. Synaptic transmission occurs when neurotransmitter (e.g. 
GABA or glutamate) is released by the presynaptic neuron, into the synaptic cleft, where it 
binds to ion channel receptors (GABAARs and NMDARs) in the postsynaptic neuron (Fig. 1-
1 from antranik.org). The binding reaction initiates a sequence of structural rearrangements 
in the receptor, altering its functional state from closed to activated (Fig. 1-1). In the activated 
state, the receptor forms an ion conduction pathway, allowing selective diffusion of ions 
across the postsynaptic cell membrane to generate an electrical signal known as synaptic 
currents. Synaptic currents mediate neuronal communication and act to modulate the 
electrical excitability of the postsynaptic cell. The postsynaptic receptor determines whether 
the modulation is inhibitory or excitatory. Chloride-permeable receptors mediate inhibitory 
postsynaptic currents (IPSCs), whereas sodium-permeable receptors mediate excitatory 
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postsynaptic currents (EPSCs). GABA is the dominant inhibitory neurotransmitter (Fig. 1-2) 
and glutamate is the dominant excitatory neurotransmitter (Fig. 1-2) (Kandel et al., 2000).  
Synapse formation is mediated by a binding interaction between the presynaptic 
protein, neurexin, and the postsynaptic protein, neuroligin 1-3 (Ichtchenko et al., 1990; 
Ichtchenko et al., 1996; Dean et al., 2003; Nguyen and Sudhof., 1997; Song et al., 1999; 
Dong et al., 2007; Fritschy et al., 2012). The other key postsynaptic elements are the self-
multimerising scaffolding proteins, such as gephyrin and postsynaptic density-95 (PSD 95) 
(Fig 1-2A and 2B). Gephyrin is expressed intracellularly, where its main function is to cluster 
the intracellular portions of the receptors with neuroligin-2 (Fritschy et al., 2012) at inhibitory 
synapses (Fig. 1-2A). In addition, there is a native tripartite complex (Fig 1-4 A) formed 
between inhibitory GABAA receptors, GABAAR regulatory Lhfpl (GARLH) protein LH4 and 
the postsynaptic cell adhesion protein neuroligin 2 (NL2) to anchor GABAARs within 
inhibitory synaptic cleft (Yamasaki et al. 2017) (Fig 1-4). PSD 95, which is also intracellular, 
is a member of the membrane-associated guanylate kinase (MAGUK) superfamily (Garner 
et al., 2000; Kornau et al., 1997; Fu et al., 2003). In excitatory postsynaptic densities, NMDA 
Fig 1-1. The main components of neuronal synapse (from antranik.org) 
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receptor subunits associate with PSD 95 (Garner et al., 2000; Kennedy, 1998; Kornau et al., 
1997), whereas PSD 95 also interacts with the C terminus of neuroligins 1 (Hunt et al., 1996; 
Irie et al., 1997; Fu et al., 2003) (Fig. 1-2B).  
Fig 1-2 Example structure of a prototypical excitatory (glutamate)/inhibitory (GABA) 
synapse. A. Structure of GABAergic inhibitory synapse. B. Structure of Glutamatergic 
excitatory synapse. 
The overall excitability of a single cell, and by extension a neuronal network, depends 
on a fine balance between excitatory and inhibitory inputs. The balance between neural 
excitation and inhibition (E/I balance) is crucial to healthy cognition and behaviour. 
Schizophrenia, for example, has been associated with a low E/I ratio caused by weakly 
active glutamate receptors (Vladimir et al., 2011). Autism, on the other hand, has been 
associated with a high E/I ratio caused by weakly active GABA receptors (Buzsaki and 
Gyorgy, 2006). Even greater excesses of excitation or inhibition may result in epileptic 
seizures or brain coma, respectively. Individuals with autism are more likely to have epilepsy 
(Buzsaki and Gyorgy, 2006). Epileptic seizures for sure has been associated with a high E/I 
ratio. 
 
Ⅱ: High neural excitation and inhibition ratio---Epilepsy  
Epilepsy is a spectrum of neurological disorders that involves recurrent seizures 
(Engel et al., 2007; Scharfman, 2007; Fisher et al., 2014; Moshé et al., 2015). Around 30 % 
of patients are refractory to pharmacological treatments (Regesta and Tanganelli, 1999; 
Luciano and Shorvon, 2007) partly because epilepsy is not a single neurological condition, 
but a diverse set of disorders (Fisher et al., 2005). Numerous pathophysiological 
mechanisms coexist and act simultaneously (e.g., gene mutations leading to abnormal ionic 
channel function, superimposed on aberrant network connectivity) in epilepsy (Fisher et al., 
2005). Each mechanism is subject to different developmental regulation, with different 
B A 
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seizure susceptibility or manifestations at different stages of brain maturation (Bradford, 
1995; Fisher et al., 2005).   
Epilepsy description  
Seizures can be described in terms of their type (e.g., generalized tonic–clonic, 
absence, myoclonic, clonic, tonic, or atonic) and by their underlying cause (genetic versus 
structural/metabolic versus unknown) (Brodie et al, 2016). For instance, epilepsies that arise 
from identifiable causes such as brain injury, infection and tumours, are referred to as 
symptomatic (Berg et al., 2010; Brodie et al, 2016). Many syndromes are also defined, such 
as juvenile myoclonic epilepsy and Lennox–Gastaut syndrome, which are characterized by 
complex and specific clinical features, signs, and symptoms that frequently cluster together 
(Berg et al., 2010; Brodie et al, 2016). Epilepsy can also be described broadly based on its 
origin in the brain, such as focal and generalised. Focal seizures originate in one or more 
loci in one hemisphere and are confined to neuronal networks within that hemisphere (Berg 
et al., 2010; Brodie et al, 2016). Brain regions that have been identified as sites of epileptic 
activity include the neocortex, thalamus, hypothalamus and amygdala (Rogawski and 
Loscher, 2004; Brodie et al, 2016). Generalised seizures involve both brain hemispheres 
and bilateral neuronal networks (Berg et al., 2010) and mostly have no identifiable cause. 
Genetic generalised epilepsy (GGE) accounts for about half of all diagnosed cases of 
epilepsy. GGE can range in severity from febrile seizures alone to Dravet syndrome 
(Rogawski and Loscher, 2004) and are thought to be associated with genetic alterations in 
the sufferer (Hirose et al., 2005; Brodie et al, 2016).  
Investigation of the cellular and neurochemical events underlying seizure causation 
in normal brain is likely to give strong clues about the mechanisms causing episodic 
spontaneous seizures, the characteristic feature of the epileptic brain (Bradford, 1995). The 
abnormal amplification and synchronisation of neuronal firing that leads to seizure episodes 
and their subsidence, and the ability of sub-groups of neurons to generate intrinsic burst-
firing patterns is likely to involve interaction of GABAergic inhibitory mechanisms and 
glutamatergic excitatory mechanisms, particularly those involving NMDA receptor types 
(Bradford, 1995; Rogawski and Loscher, 2004).  
Links between epilepsy, GABAARs and NMDARs 
As the major excitatory and inhibitory neurotransmitters are glutamate and GABA, 
respectively (Kandel et al., 2000; Brodie et al, 2016), GABAARs and NMDARs are crucial to 
the mechanism of epileptogenesis and are targeted by many anti-epileptic drugs (Brodie, 
2010). For instance, in keeping with a simple model, blockers of GABA-mediated 
transmission generate seizures in a wide range of preparations and in humans and strong 
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activation of glutamatergic synapses generates seizures (Cossart and Bernard, 2005). 
However, GABA neurotransmission acts a way more complicated role in neural excitation 
and inhibition and epileptic seizures.  
GABAergic synapses are indeed endowed with a unique and fundamental feature – 
resulting from their Cl- permeability – that enables them to shift from an inhibitory mode of 
operation to one that mainly excites (Cossart and Bernard, 2005), which case GABA acts 
as a depolarizing neurotransmitter (Dzhala and Staley, 2003; Sipila et al, 2005; Stafstrom, 
2006). For example, in adults with temporal lobe epilepsy (TLE), firing of neurons in the 
subiculum caused by depolarizing GABAergic responses contribute to hyper-excitability and 
interictal discharges (Cohen et al, 2002; Stafstrom, 2006). Studies of thalamo cortical 
connections of the brain have demonstrated that epileptic states are a result of impaired 
GABAergic inhibitory input (Beenhakker and Huguenard, 2009). Selective knock out of 
thalamic β3-GABAARs induces epilepsy-like symptoms (DeLorey et al., 1998). Inheritable 
mutations to the GABAAR α1 and γ2 subunits have been identified in family pedigrees with 
GGEs (Farrant and Nusser, 2005; Macdonald et al., 2010). No doubt to say, GABAergic 
pathways permit dynamic regulation of neuronal function and had critical function roles in 
epileptic networks (Cossart and Bernard, 2005). 
Epilepsy is linked to dysfunction of the glutamate system at different levels: genetic, 
neurotransmitter release, and receptor expression (Bradford, 1995; Barker-Haliski and 
White, 2015; Brodie et al, 2016). Increased plasma levels of glutamate in epilepsy have 
been reported (van Gelder et al., 1980; Janjua et al., 1992) and sustained increases in 
extracellular glutamate levels during seizures in the epileptogenic hippocampus also have 
been found (During and Spencer, 1993; Brodie et al, 2016). Focal brain cooling, which can 
suppress epileptic seizures in refractory epilepsy, has been shown to significantly decrease 
glutamate levels in patients who have elevated glutamate in the cortex or hippocampus 
during seizures (Nomura et al., 2014; Brodie et al, 2016). An initial seizure acutely increases 
excitatory synaptic transmission, which potentiates NMDAR dependent EPSCs, enhancing 
excitability and elevating the intracellular Ca2+ concentration (Sayin et al, 1999).  
Individuals who harbor mutations in NMDAR subunits present with epilepsies ranging 
in severity from benign focal epilepsy to epileptic encephalopathies, with the latter often 
associated with impaired speech development, intellectual disability, autism and psychiatric 
disorders (Endele et al., 2010; Lesca et al., 2012; Lemke et al., 2013; Lesca et al., 2013; 
Kenny et al., 2014). It is essential to resolve the mechanisms by which these mutations 
affect NMDAR-mediated EPSCs to both understand epileptogenic mechanisms and design 
optimal therapies for particular epilepsy genotypes.  
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Ⅲ: GABAARs and GABAAR epilepsy mutations 
GABAAR are ligand-
gated chloride ion channels that 
mediate major synaptic and 
extrasynaptic inhibition in the 
central nervous system (Olsen 
and Tobin, 1990). Similar with 
many other types of ion channel, 
their biophysical and 
pharmacological properties and 
their cellular and subcellular 
distribution patterns vary 
according to their subunit 
stoichiometry. In addition to the 
GABA binding site, the GABAAR 
also has a number of other sites 
which bind compounds that 
modulate its activity, which 
make it being an important drug 
target in the treatment of major 
neurological disorders, such as 
depression, anxiety and epilepsy. For instance, many sedative and anaesthetic drugs, such 
as alcohol, propofol and neurosteroids as well as the therapeutically important anti-epileptic 
drugs, barbiturates and benzodiazepines, work by modulating GABAARs (Loscher and 
Rogawski, 2012; Riss et al., 2008).  
GABAAR structure and subunits 
GABAARs are pentameric oligomers constructed from a family of 19 different subunits 
(α1-6, β1-3, γ1-3, π, θ, ε, δ, ρ1−3). The number of possible stoichiometries is enormous 
(Olsen and Sieghart, 2009). The subunit molecular structure has been solved to a resolution 
of 0.3 nm (Miller and Aricescu, 2014; Laverty et al., 2019) (Fig 1-3) and a considerable 
amount is known about its normal function, pharmacology and pathology (Sine and Engel, 
2006). Each GABAAR subunit comprises a large extracellular domain, an intracellular 
domain and four transmembrane domains (Olsen and Sieghart, 2009). Binding sites for 
modulators are located either in the extracellular domain or at the interface between extra- 
and transmembrane domains. GABA binds at the two interfaces between β and α subunits 
Figure 1-3 GABAAR structure (pdb (6I53). Schematic 
representation of an NMDAR and sites of agonists, 
antagonists, and modulators binding (Masiulis, et al., 
2019) 
 
8 
 
of GABAARs in the extracellular domain of the receptor and anti-epileptic drugs, 
benzodiazepines, bind at the homologous, single α–γ subunit interface (Olsen and Sieghart, 
2009).  
 
Figure 1-4. GABAAR synapse structure, phasic and tonic activation. A. Key synaptic 
adhesion, scaffold and signalling proteins that mediate lateral diffusion of GABAA receptors 
in and out of the synaptic and extra-synaptic cleft (Lorenz-Guertin and Jacob, 2018). B. 
IPSCs. C. The tonic (extra-synaptic) current. 
GABAARs mediate both synaptic and extrasynaptic currents (Figure 1-4). Synaptic 
GABAARs mainly consist of isoforms of α (α1-6), β (β1-3) and γ (γ1-3) subunits (Farrar et 
al., 1999) arranged in a pentameric ring as, β-α-β-α-γ. The most abundant synaptic subtype 
comprises α1, β2 and γ2 subunits (Pirker et al., 2000). Extrasynaptic GABAergic currents 
can be mediated either by a low concentration of extrasynaptic GABA activating high affinity, 
non-desensitizing receptors (Lee and Maguire, 2014) or by spontaneously-activating 
Phasic (Synaptic) current 
Tonic (extra-synaptic) current 
A 
B C 
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receptors in the absence of GABA (Wlodarczyk et al., 2013). There are two main classes of 
extrasynaptic GABAARs. One class consists of receptors containing α4 or α6 subunits, plus 
β1−3 subunits and a δ subunit (i.e., α4βδ, α6βδ), where δ subunit incorporation ensures that 
the receptors are not localised at synapses. The α5 subunit does not assemble with the δ 
subunit in vivo (Olsen and Sieghart, 2009, Brickley and Mody, 2012, Lee and Maguire, 
2014). The second major class is the α5-containing GABAARs (α5GABAARs). αβ 
diheteromers without the γ subunit also contribute to extrasynaptic currents found in 
cerebellum (Brickley et al., 1999) and hippocampus (Mortensen and Smart, 2006).  
GABAARs mediated IPSCs 
The activation of GABAARs by GABA leads to a chloride flux, which hyperpolarises 
the cell membrane potential, moving it away from the action potential threshold. Because 
synaptic currents last only 20−40 ms, this increase in conductance is known as phasic 
inhibition (Farrant and Nusser, 2005). The duration and shape of the synaptic current is 
determined by 1) the neurotransmitter concentration and its release and clearance time-
course, 2) the number of receptors clustered at the synapse, and 3) their inherent ligand 
affinity, single channel conductance and activation kinetics (Nusser et al., 1997).  
Experiments have shown that GABA in the synaptic cleft clears with a time constant 
of 100−500 μs (Nusser et al., 1997) and the clearance is augmented by active GABA 
transporters (GATs), principally GAT1, situated in the presynaptic membrane (Richerson 
and Wu, 2003). With the release of GABA through multiple vesicles, the concentration in the 
cleft reaches saturating levels, leading to near synchronous binding and activation of tens 
to hundreds of receptors. This process underlies the rapid onset phase of the synaptic 
current, which develops in the order of 0.5 ms, and is mainly determined by the receptors’ 
rate of transition from the resting to the activated state (or opening rate) (Keramidas and 
Harrison, 2010; Maconochie et al., 1994). After the current reaches a peak, GABA 
concentrations drop to zero and the current decays (deactivates) back to baseline. 
Deactivation is a reflection of the shutting rate of the receptors and their affinity for GABA. 
At low concentrations of GABA, the binding affinity will be a key determinant of the mean 
duration of discrete periods of receptor activity (bursts), and it is these durations that reflect 
the time-course of synaptic current deactivation (Keramidas and Lynch, 2012).  
Epilepsy mutations related to a1β2γ2 GABAARs 
The prevailing hypothesis is that GABAergic inhibitory input is critical in restraining 
the inherent tendency of recurrently connected excitatory neurons to transition, via positive 
feedback, into synchronous epileptiform firing (Rogawski and Loscher, 2004). Genetic 
generalised epilepsy (GGE) accounts for about half of all diagnosed cases of epilepsy. 
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GGEs can range in severity from febrile seizures alone to Dravet syndrome (Rogawski and 
Loscher, 2004). Inheritable mutations to the GABAAR α1 and γ2 subunits have been 
identified in family pedigrees with GGEs (Farrant and Nusser, 2005; Macdonald et al., 2010).  
Table 1-1 GABAARs epilepsy mutations and their related phenotypes. 
GABAARs epilepsy mutations Related epilepsy phenotype 
α1D192N Genetic generalised epilepsy with febrile seizures 
α1A295D Autosomal dominant juvenile myoclonic epilepsy 
α1T10’I Epileptic encephalopathy 
γ2R43Q Absence epilepsy with febrile seizures 
γ2P44S Genetic generalised epilepsy 
γ2N40S Generalised tonic-clonic seizures 
γ2R177G Febrile seizure 
γ2K289M Genetic generalised epilepsy with febrile seizures 
The α1D192N-containing GABAAR, which gives rise to GGE with febrile seizures 
(Lachance-Touchette et al., 2011), is located in the extracellular domain in a region that lines 
the base of the GABAAR binding pocket. This region has been shown to be critical for 
triggering activation in GABAARs (Zhang et al., 2009) and other pLGICs (Miller and Smart, 
2010). Whole cell recordings reveal 50% reduced surface expression levels compared to 
wild-type receptors, in addition to accelerated whole-cell deactivation and desensitisation 
(Lachance-Touchette et al., 2011). The α1A295D mutation, which causes autosomal dominant 
juvenile myoclonic epilepsy, results in receptor misfolding, internalisation and subsequent 
degradation via the endoplasmic reticulum degradation pathway (Gallagher et al., 2007). Its 
clinical presentation is not associated with febrile seizures. α1T10’I mutation was recently 
discovered as a de novo mutation in a child with epileptic encephalopathy ( Allen et al., 
2013). 
The γ2R43Q mutation gives rise to absence epilepsy with febrile seizures (Petrou and 
Reid, 2012). The γ2P44S mutant, which causes GGE, and the γ2N40S mutant, which causes 
generalised tonic-clonic seizures (Lachance-Touchette et al., 2011; Migita et al., 2013). The 
γ2R177G-containing GABAAR produces a febrile seizure phenotype (Audenaert et al., 2006). 
γ2K289M leads to generalised epilepsy including febrile seizures (Bouthour et al., 2012). 
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Anti-epileptic drugs target a1βγ2 GABAARs 
           The GABAAR is a major therapeutic target for the treatment of epilepsy and drugs 
that block GABAAR currents, such as bicuculline, can give rise to seizures (Rogawski and 
Loscher, 2004). Carbamazepine and phenytoin are common anti-epileptic drugs that 
classically inhibit voltage-gated sodium channels (Kuo et al., 1997). Both drugs also affect 
other ion channels that modulate neuronal firing, such as Ca2+ channels (phenytoin) 
(Rogawski and Porter, 1990) and N-methyl-Daspartate receptors (carbamazepine) 
(Lancaster and Davies, 1992). They also enhance whole-cell currents mediated by α1β2γ2 
GABAARs expressed in HEK293 cells or neurons. GABAARs that either lack the γ2 subunit 
or express α3 or α5 subunits instead of α1 are unaffected by either drug (Granger et al., 
1995). The modulatory effects require both α1 and γ2 subunits, implying a α1−γ2 subunit 
interface pharmacophore. However, the current-potentiating effects of both drugs are 
unaffected by the benzodiazepine competitive antagonist flumazenil, suggesting that the 
drugs act via sites other than the benzodiazepine site (Granger et al., 1995). 
Table 1-2 GABAAR modulators and their function. 
GABAAR modulators Function/disease relevance 
Bicuculline Gives rise to seizures 
Carbamazepine Common anti-epileptic drug 
Phenytoin Common anti-epileptic drug 
Midazolam Potent common anti-epileptic drug 
Lorazepam Potent common anti-epileptic drug 
α5-GABAAR modulators Function/disease relevance 
Isoflurane Causes post-operative amnesia 
Etomidate Causes post-operative amnesia 
TB-21007 Enhances cognitive performance without the anxiogenic 
MRK-016 Enhances cognitive performance without anxiogenic 
α5IA Used for Down syndrome, alcohol induced amnesia, nootropic 
L-655708 Reverses post-operative amnesia in rodents, nootropic 
In contrast, midazolam and lorazepam are benzodiazepine compounds that exert 
potentiation by binding in the benzodiazepine binding pocket. They have potent anti-epileptic 
activity and are generally used for the acute treatment of epilepsy (status epilepticus). 
However, their utility in the long-term treatment of epilepsy is limited by side effects, including 
sedation and muscle relaxation. Patients taking these drugs are also at risk of developing 
tolerance and dependence (Riss et al., 2008; Rogawski and Loscher, 2004). Recent studies 
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using structural homology models of the GABAAR docked with the classic benzodiazepine, 
diazepam, have identified new diazepam analogues that exhibit a high binding affinity for 
GABAARs expressed in Xenopus oocytes. Four compounds within these analogues exhibit 
anti-convulsant (anti-epileptic) activity in animal models (Richter et al., 2012). To summarize, 
the GABAAR is a major therapeutic target for the treatment of epilepsy and GABAARs 
modulators are potent anti-epileptic drugs. However, every GABAAR epilepsy mutation has 
a different effect on GABAergic synaptic signalling. The main aim of my thesis was to 
understand how synaptic signalling was affected and which drug may be most efficacious in 
reversing the effects. 
α5GABAARs 
GABAARs containing α5 subunits are highly sensitive to activation by GABA and do 
not desensitise. They are considered promising therapeutic targets for a range of clinical 
conditions including age-related dementia, stroke, schizophrenia, Down syndrome, 
anaesthetic-induced amnesia and anxiety (Soh and Lynch, 2015). α5GABAARs are found 
mainly in hippocampal pyramidal neurons and layer 5 cortical neurons where they are 
located both synaptically and extrasynaptically and comprise mainly α5β1γ2, α5β2γ2 and 
α5β3γ2 isoforms in vivo (Olsen and Sieghart, 2009). Although synaptic and extrasynaptic 
GABAARs are both important for inhibiting neurons, they differ in key respects. For example, 
their surface stability and subcellular positioning are under the control of different sets of 
proteins. Extrasynaptic GABAARs are also often activated by GABA from non-vesicular 
sources such as glia and dendritic GABA transporters working in reverse (Attwell et al., 
1993). These factors mean that synaptic and extrasynaptic GABAARs are regulated 
differently under physiological and pathological conditions. Synaptic and extrasynaptic 
α5GABAARs can also have very different pharmacological properties. This has significant 
clinical implications. 
Synaptic and extrasynaptic α5GABAARs 
Synaptic α5GABAARs contribute a small, slow phasic component to GABAergic 
IPSCs (Collinson et al., 2002, Caraiscos et al., 2004, Glykys et al., 2008, Vargas-Caballero 
et al., 2010, Hausrat et al., 2015). α5GABAARs contribute to the second main class of 
extrasynaptic GABAARs (Olsen and Sieghart, 2009). α5GABAARs are concentrated 
extrasynaptically via a direct interaction between α5 subunits and the cytoplasmic protein, 
radixin (Hausrat et al., 2015). GABAAR distribution is also controlled in a β subunit-specific 
manner. For example, β3-containing GABAARs are held away from the synapse by a binding 
interaction between β3 and the AP2 clathrin adaptor protein (Vien et al., 2015). α5 subunits 
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are incorporated into these β3-containing receptors and the main partner in the brain (Olsen 
and Sieghart, 2009).  
Other anchoring mechanisms with differential interactions with β subunit isoforms 
have also been identified. For example, only β2 and β3 subunits bind to the synapse 
clustering protein, gephyrin, and only β1 and β3 subunits bind to the anchoring protein, 
AKAP79/150 (Nakamura et al., 2015). Thus, it is highly likely that the synaptic versus 
extrasynaptic distributions of α5β1γ2, α5β2γ2 and α5β3γ2 GABAARs are differentially 
controlled via their β subunits. α5β3γ2 GABAARs might be the only α5GABAAR isoform that 
located extrasynaptically.  
Drugs target on α5GABAARs 
Therapeutic interest in α5GABAARs has extended to a variety of disorders including 
stroke, cognitive enhancement, schizophrenia and dementia-related conditions. Unlike other 
GABAAR subtypes, both positive and negative modulators for α5GABAARs have the 
potential to be clinically useful (Soh and Lynch, 2015). 
Isoflurane and etomidate are thought to cause post-operative amnesia by selectively 
potentiating extrasynaptic α5GABAARs (Cheng et al., 2006, Saab et al., 2010). TB-21007 
(sometimes referred to as compound 43) was first reported in 2003 as a selective inverse 
agonist of α5β3γ2 GABAARs and was shown to inhibit the steady-state current with an 
efficacy of -51 % (Chambers et al., 2003). When delivered intraperitoneally to rats, TB-21007 
enhanced cognitive performance without the anxiogenic or pro-convulsive effects usually 
associated with non-specific GABAAR inverse agonists (Chambers et al., 2003). 
MRK-016 was first described in 2009 where it was shown to selectively inhibit steady-
state currents mediated by α5β3γ2 GABAARs with an efficacy of -55 % (Atack et al., 2009). 
Similar to TB-21007, it enhanced cognitive performance in rats without evoking anxiogenic 
or convulsive side-effects. It has also been shown to exhibit anti-depressant activity in rats 
(Fischell et al., 2015). However, MRK-016 was poorly tolerated in elderly humans which 
precluded further clinical development (Atack et al., 2009). MRK-016 has been shown to 
work as a nootropic (Chambers et al., 2003; Atack et al., 2009). Some groups showed it 
could be used for postoperative cognitive dysfunction (Lecker et al., 2013). 
α5IA was first described in 2009 where it selectively inhibited steady-state currents 
mediated by α5β3γ2 GABAARs with an efficacy of -29 % (Dawson et al., 2006). It exhibited 
cognitive enhancing properties in rodents but not in elderly humans (Atack, 2010). As a 
negative α5GABAAR modulator, α5IA was proposed for use for Down syndrome (Braudeau 
et al., 2011; Atack, 2010; Braudeau et al., 2011), alcohol induced amnesia (Sternfeld et al., 
2004; Atack, 2010) and also works as nootropic (Nutt et al., 2007; Atack, 2010). 
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L-655708 was first reported as an α5-specific ligand  in 1996 (Quirk et al., 1996). It 
was subsequently shown to selectively inhibit steady-state currents mediated by α5β3γ2 
GABAARs with an efficacy of -17 % (Atack et al., 2006). In contrast to the three drugs 
described above, it achieves its selectivity via a higher binding affinity rather than by a 
greater inhibitory efficacy. Although it produced cognitive enhancement in rats, it was also 
anxiogenic, presumably due to off target effects on α2- and α3-containing isoforms (Atack 
et al., 2006). It reverses post-operative amnesia in rodents (Saab et al., 2010) and has been 
investigated as a nootropic (Navarro et al., 2002; Atack et al., 2006). Some groups also 
showed that it can help recover from stroke (Clarkson et al., 2010).  
 
Ⅳ: NMDARs and NMDAR epilepsy mutations 
NMDARs belong to one of three families of glutamate-gated, cation-selective ion 
channel receptors (GluRs), which mediate most of the excitatory neurotransmission in the 
mammalian brain. They form tetrameric oligomers of similar structure and are divided 
according to pharmacological criteria into AMPA, kainate and NMDA receptors (Traynelis et 
al., 2010). With the publication of crystal structures of mammalian and amphibian receptors, 
NMDARs typically comprise two GluN1 subunits with either two GluN2 subunits or a mixture 
of GluN2 and GluN3 subunits (Karakas and Furukawa, 2014; Lee et al., 2014). The most 
prevalent stoichiometries in native synapses are the diheteromeric GluN1/2A and GluN1/2B 
isoforms and the triheteromeric GluN1/2A/2B isoform (Traynelis et al., 2010). NMDARs are 
highly Ca2+ permeable and subject to voltage-dependent Mg2+ blockade, which is alleviated 
with membrane depolarisation (Traynelis et al., 2010). These properties are essential to 
NMDAR-dependent long term potentiation (LTP), which is critical to learning and memory 
(Bliss and Collingridge, 1993). 
NMDAR structure and isoforms 
The subunits are structurally homologous and divided into the following modular 
domains, which are connected by flexible linkers; a large extracellular domain, that divides 
into an amino terminal domain (ATD), a ligand binding domain (LBD), four transmembrane 
domain (TMD), and finally, an intracellular domain (Traynelis et al., 2010) (Fig. 1-5) (Karakas 
and Furukawa, 2014). The ATD is involved in receptor assembly and binds ligands that 
modulate receptor activity (Zhu and Gouaux, 2017), in addition to determining receptor 
desensitisation and open probability (Traynelis et al., 2010). The LBD forms a cleft where 
glutamate, glycine and other competitive antagonists bind (Traynelis et al., 2010; Zhu and 
Gouaux, 2017; Zhu et at., 2016) (Fig. 1-5). The TMDs are made of four helices (M1-M4). 
The M2, which is a re-entrant segment, lines the narrow permeation pathway, is the site of 
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Mg2+ block, and likely contributes the ion selectivity filter (Fig. 1-5). The M3 domain 
contributes most of the pore structure whereas the other helices girdle the M3 and M2 
segments (Karakas and Furukawa, 2014; Lee et al., 2014). The intracellular domain is 
involved with membrane trafficking, post-translational modification and interacts with 
scaffolding and anchoring proteins (Traynelis et al., 2010).  
The various isoforms of 
NMDARs exhibit distinct spatial 
and temporal expression 
patterns, kinetics and 
pharmacological profiles. For 
example, GluN1/2B-containing 
receptors predominate 
extrasynaptically in immature 
neurons where they exhibit 
longer channel open times and 
high sensitivity to the inhibitor, 
ifenprodil (Traynelis et al., 
2010). By adulthood, these 
receptors have largely been 
replaced by GluN1/2A-
containing receptors that are 
insensitive to ifenprodil and 
mediate fast-decaying EPSCs 
(Traynelis et al., 2010). The 
GluN2 subunits largely 
determine the kinetic 
properties of NMDARs. 
Receptors containing GluN2A 
deactivate and desensitise faster than those incorporating the GluN2B, GluN2C and/or 
GluN2D subunits. Triheteromeric GluN1/2A/2B receptors give rise to decay times that are 
intermediate between diheteromeric GluN1/2A and GluN1/2B receptors (Tovar and 
Westbrook, 2017; Tovar et al., 2013). Although there is no mutually exclusive demarcation 
in synaptic versus extrasynaptic localisation of subunits, GluN1/2B receptors are more 
abundant at extrasynaptic locations, whereas GluN1/2A and GluN1/2B are thought to 
relatively equally abundant at synapses (Hardingham and Bading, 2010; Traynelis et al., 
Figure 1-5 NMDAR structure. Schematic representation 
of an NMDAR and the binding sites of agonists, 
antagonists, and modulators (Karakas and Furukawa, 
2014). As indicated in the figure, the antagonists of 
ifenprodil, Zn2+ and spermine bind to the ATD. 
Glutamate and glycine bind to the LBD. Memantine and 
Mg2+ bind to the TMD. 
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2010). However, in the hippocampus and cortex GluN1/2A/2B receptors are believed 
contribute over half of the total number of synaptic NMDARs (Traynelis et al., 2010). 
NMDAR mediated EPSCs 
The various NMDAR isoforms exhibit distinct regional and developmental expression 
patterns, as well as differences in synaptic localization and EPSC kinetics (Traynelis et al., 
2010). Synaptic current activation is initiated by the release of presynaptic glutamate, which 
rises to low mM concentrations (∼1−3 mM) at the synaptic cleft and decays with a time 
constant of about 1 ms (Tovar and Westbrook, 2017). However, the time course of the 
NMDAR-mediated EPSCs is orders of magnitude slower (Tovar and Westbrook, 2017; 
Traynelis et al., 2010). The relatively long time course of these EPSCs is thought to play a 
role in the network activity that underlies working memory in prefrontal cortex. Slow NMDAR 
deactivation is also thought to produce overlap in synaptic responses that give rise to a 
steady-state NMDAR receptor tone in the hippocampus (Tovar and Westbrook, 2017). 
Unlike synaptic NMDARs, extrasynaptic NMDARs are not activated by low frequency 
pre-synaptic release of glutamate. Extrasynaptic receptors are located on cell bodies, the 
neck of dendritic spines and dendritic shafts, as well as at the periphery of the synapse (peri-
synaptic) (Hardingham and Bading, 2010). They are activated by low ambient 
concentrations of glutamate and mediate tonic excitation in the brain. Extrasynaptic NMDAR 
isoforms contribute to tonic excitation of neurons and can give rise to neuronal death when 
activated excessively (Hardingham and Bading, 2010).   
NMDAR pharmacology 
Unique amongst GluRs, NMDAR activation requires the simultaneous binding of 
glutamate and glycine. The GluN1 (and GluN3) subunits bind glycine, whereas the binding 
site for glutamate (and NMDA) is formed by the GluN2 subunit (Traynelis et al., 2010). The 
GluN2 subunits confer much of the functional and pharmacological variation that exists 
amongst NMDARs. Ligands that exhibit GluN2 isoform selectivity are highly desired 
because they have subunit-specific therapeutic potential (Traynelis et al., 2010). The 
subunits present binding sites for various drugs, including the GluN2B-selective antagonists 
phenylethanolamine, ifenprodil and its analogues (Traynelis et al., 2010; Regan et al., 2015), 
Zn2+ (Traynelis et al., 2010) and potentiating polyamines like spermine ( Regan et al., 2015). 
Zn2+ is co-released with glutamate at glutamatergic synapses where it binds at GluN2 
subunits to inhibit receptor activity with a nanomolar affinity at GluN1/2A and micromolar 
affinity at GluN1/2B receptors (Traynelis et al., 2010). In contrast, ifenprodil binds selectively 
to GluN1/2B receptors because its binding cavity at subunit interfaces is largely ablated in 
GluN1/2A receptors (Romero et al., 2016). GluN1/2A/2B receptors exhibit a Zn2+ sensitivity 
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similar to GluN1/2A and ifenprodil pharmacology in between for GluN1/2A and GluN1/2B 
receptors (Hansen et al., 2016). MPX-007 inhibits GluN1/2A receptors with greater potency 
than those containing the GluN2B subunit (Yi et al., 2016). 
Pore blocking agents include Mg2+ ions, MK-801, ketamine and memantine (Traynelis 
et al., 2010; Regan et al., 2015). Memantine has a moderate affinity for the pore of GluN1/2A 
and GluN1/2B receptors, where it interacts with homologous residues of the M3 domains of 
GluN1 and GluN2 subunits. It is strongly voltage-dependent, dissociates rapidly (Limapichat 
et al., 2013) and exhibits a preference for extrasynaptic NMDARs (Hardingham and Bading, 
2010; Henstridge et al., 2016). The drug is currently used to treat Alzheimer’s disease 
(Traynelis et al., 2010) and is effective in rodent models (Ghasemi and Schachter, 2011) 
and children (Pierson et al., 2014) with epilepsy and autistic spectrum disorders (Chez et 
al., 2007).  
NMDAR epilepsy mutations   
Individuals that harbour either de novo or inherited mutations in NMDAR subunits 
present with epilepsy that ranges in severity from benign focal epilepsy to epileptic 
encephalopathies (Lesca et al., 2013; Lemke et al., 2013), which are related to impaired 
speech development (Lesca et al., 2013), intellectual disability (Endele et al., 2010), 
psychiatric and autism spectrum disorders (Lesca et al., 2012; Kenny et al., 2014). Genetic 
screening of individuals that present with epilepsy has yielded an ever-increasing number 
of mutations to NMDAR subunits.  
Table 1-3 NMDAR mutations. 
NMDA subunits Mutations related to epilepsy 
GluN2A N615K, A243V, R518H, F652V, T531M and Q218X 
GluN2B C461F, N615I, V618G and R682C 
GluN1 R217T, S549R and G618R 
A variety of mutations in the GRIN2A and GRIN2B genes have been linked to 
epilepsy (Endele et al., 2010; Reutlinger et al., 2010; Lesca et al., 2012; Carvill et al., 2013; 
Lemke et al., 2013; Lesca et al., 2013; Fedele et al 2018). For instance, mutations in 
GRIN2A, which encodes the GluN2A subunit, are found in individuals with focal epilepsies 
ranging from mild benign epilepsy with centro-temporal spikes to severe epileptic 
encephalopathies (Lesca et al., 2013). These later epilepsies are accompanied by language 
and cognitive impairment (Endele et al., 2010; and Allen et al., 2013). Studies have identified 
the missense mutations, N615K (Endele et al., 2010), A243V (Lemke et al., 2013), R518H 
and F652V (Lesca et al., 2013), T531M (Carvill et al., 2013) and Q218X (Endele et al., 
2010), where epilepsy was co-morbid with developmental delay and intellectual disability. 
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The GluN2A-N615K mutation occurs in the pore lining M2 domain (Wollmuth et al., 1998a). 
This was shown to ablate voltage-dependent Mg2+ block and reduce Ca2+ permeability 
(Lemke et al., 2014; Marwick et al., 2015). 
Mutations in GRIN2B, which encodes the GluN2B subunit, have been identified in 
epileptic encephalopathy (C461F), a severe type of epilepsy, known as West syndrome 
(N615I and V618G) (Lemke et al., 2014), intellectual disability (R682C) (Endele et al., 2010) 
and autism spectrum disorder (Kenny et al., 2014). N615I and V618G mutations, which lie 
adjacent to the pore Mg2+ binding site (Wollmuth et al., 1998a) where they have been shown 
to reduce voltage-sensitive Mg2+ block (Lemke et al., 2014; Marwick et al., 2015; Fedele et 
al 2018). Finally, mutations in GRIN1, encoding GluN1, such as R217T, S549R and G618R 
are relatively poorly functionally characterised. GluN1 mutations are associated with severe 
ID, developmental delay, epilepsy and movement disorders ( Allen et al., 2013; Lemke et 
al., 2016).  
Models that are used to investigate mutated ion channels 
To investigate the effect of epilepsy mutations on the physiological and 
pharmacological properties of ion channels, there are several models used in vitro (oocytes, 
HEK293 cells and cultured neurons). The advantage of using recombinant expression 
systems lke oocytes or HEK293 cells is to establish the properties of relevant defined pure 
population of mutant channels (Lemke et al., 2014; Marwick et al., 2015; Mullier et al., 2017; 
Fedele et al., 2018; Vyklicky et al., 2018). The disadvantage is obviously that those 
properties are measured out of the synaptic context. To avoid this, some groups have 
overexpressed mutant subunits in neurons and characterised changes in IPSCs and EPSCs 
(Fedele et al., 2018), however, the disadvantage here is that the stoichiometries of resultant 
receptors cannot be verified or controlled. To avoid both problems, the artificial synapse 
preparation (Biederer and Scheiffele, 2007; Zhang et al., 2015) was used in this thesis to 
examine the effects of mutations on synaptic NMDARs of defined subunit composition. The 
main advantage is that it enables us to define the physiological and pharmacological 
properties of the pure population of channels activated under the same dynamic conditions 
as they would be within the synapse. 
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Summary 
Advances in clinical and basic science are increasing our understanding of epilepsy 
mechanisms. Molecular genetics, imaging techniques, and cellular physiology have shown 
that abnormal ionic channel function affects synaptic and network function, and influences 
behaviour and cognition. The challenge is to find the links between the different levels of 
pathophysiology in epilepsy, and translate these into beneficial therapies.  
As mentioned in last three sections, hereditary mutations to both inhibitory and 
excitatory receptors are important causes of epilepsy and major therapeutic targets for 
epilepsy medications. Our hypothesis is that mutations located in discrete functional regions 
on a specific subunit will correlate with an epileptic clinical phenotype. A corollary is that 
these regions will be targeted by classes of drugs including uncompetitive antagonists, 
competitive antagonists, and pore blockers. The aim of this thesis is to understand how the 
epilepsy mutations affect the physiological and pharmacological properties of GABAAR-
mediated IPSCs and NMDAR-mediated EPSCs, as a means of understanding their 
contribution to mechanisms of epileptogenesis.  
In Chapter 2, I examined the functional effects of three mutations to the α1 subunit 
(α1T10’I, α1D192N and α1A295D) mediated by the major synaptic GABAAR isoform, α1β2γ2L, by 
comparing the IPSCs mediated by pure populations of those mutant and wild type 
GABAARs. IPSCs were also recorded in the presence of the anticonvulsant drugs, 
carbamazepine and midazolam, and at elevated temperatures (22, 37 and 40 oC) to gain 
insight into the mechanisms of febrile seizures. In Chapter 3, I defined the basic biophysical 
and pharmacological properties of IPSCs mediated by α5β1γ2, α5β2γ2 and α5β3γ2 
isoforms. As a range of drugs has been developed to specifically modulate these receptors, 
I also quantified the effects of four α5-specific inverse agonists (TB-21007, MRK-016, α5IA 
and L-655708) and other three newly developed inverse agonists (RM68, RM69 and RM70) 
on IPSCs mediated by the three isoforms. In Chapter 4, I examined the physiological and 
pharmacological properties of WT di- and triheteromeric NMDA receptors and mutant 
receptors containing mutant (GluN2AN615K, GluN2BN615I or GluN2BV618G) subunits. All those 
results provide us with a better understanding of the links between epilepsy genotype to 
epilepsy pathophysiology and epilepsy phenotype to anti-epileptic drugs. 
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ABSTRACT 
 
Epilepsy is a spectrum of neurological disorders with many causal factors. The GABA 
type-A receptor (GABAAR) is a major genetic target for some forms of heritable human 
epilepsies. Here we examine the functional effects of three mutations to the α1 subunit 
(α1T10’I, α1D192N and α1A295D) on inhibitory postsynaptic currents (IPSCs) mediated by the 
major synaptic GABAAR isoform, α1β2γ2L. We employed a neuron - HEK293 cell 
heterosynapse preparation to record IPSCs mediated by mutant-containing GABAARs in 
isolation. IPSCs were recorded in the presence of the anticonvulsant drugs, carbamazepine 
and midazolam, and at elevated temperatures (22, 37 and 40 oC) to gain insight into 
mechanisms of febrile seizures. The mutant subunits were also transfected into cultured 
cortical neurons to investigate changes in synapse formation and neuronal morphology 
using fluorescence microscopy. We found that IPSCs mediated by α1T265Iβ2γ2L, 
α1D192Nβ2γ2L GABAARs decay faster than those mediated by α1β2γ2L receptors. IPSCs 
mediated by α1D192Nβ2γ2L and α1A295Dβ2γ2L receptors also exhibit a heightened 
temperature sensitivity. In addition, the α1T265Iβ2γ2L GABAARs were refractory to 
modulation by carbamazepine or midazolam. In agreement with previous studies, we found 
that α1A295Dβ2γ2L GABAARs expressed poorly in HEK293 cells and neurons. However, pre-
incubation with 100 nM suberanilohydroxamic acid (SAHA) resulted in α1A295Dβ2γ2L 
GABAARs mediating IPSCs that were indistinguishable in magnitude and waveform to those 
mediated by α1β2γ2L receptors. Finally, mutant-specific changes to synaptic bouton size, 
synapse number and neurite branching were also observed. These results provide new 
insights into the mechanisms of epileptogenesis of α1 epilepsy mutations and suggest 
possible leads for optimising treatment options for patients harbouring these mutations. 
 
Key words, epilepsy, GABA receptors, synaptic inhibition, anticonvulsant, febrile 
 
  
30 
 
INTRODUCTION 
 
Epilepsy is a serious neurological condition, affecting 2-3% of the world’s population 
(1). It is not a single neurological disorder, but a diverse set of disorders arising from multiple 
causes, many of which have a genetic component (2,3). The disorders have in common the 
recurrence of episodic seizures (4). Brain regions that have been identified as sites of 
epileptic activity include the neocortex, thalamus, hypothalamus and amygdala (5). The γ-
aminobutyric acid (type A) receptor (GABAAR) is emerging as a major causal agent in some 
forms of genetic epilepsy. Heritable mutations to the GABAAR α, β, γ and δ subunits have 
been identified in family pedigrees of epilepsy (6) and new mutations continue to be 
identified (7,8). Studies of thalamo-cortical connections of the brain have demonstrated that 
epileptic states are preceded by the synchronisation of excitatory activity in neuronal 
populations. This hypersynchronous firing can be a result of impaired GABAergic inhibitory 
input (9), and is consistent with the presence of epilepsy-like symptoms in animals in which 
thalamic GABAARs have been selectively knocked-out by genetic manipulation (10). The 
prevailing hypothesis is that GABAergic inhibitory input is critical in restraining the inherent 
tendency of recurrently connected excitatory neurons to transition, via positive feedback, 
into synchronous epileptiform firing (5). 
The GABAAR belongs to the pentameric ligand-gated ion channel (pLGICs) family (11). 
Each subunit comprises a large extracellular N-terminal domain that incorporates the 
neurotransmitter binding site and four α-helical transmembrane domains termed M1-M4 
(Fig. 2-1). Synaptic GABAARs mainly consist of α (α1-6), β (β1-3) and γ (γ1-3) subunits 
arranged in a pentameric ring as, β-α-β-α-γ (12). The most abundant synaptic subtype 
comprises α1, β2 and γ2 subunits (13). The GABAAR is a major therapeutic target for the 
treatment of epilepsy and drugs that block GABAAR currents, such as bicuculline and 
picrotoxin, can give rise to seizures (5). GABA binds at the two interfaces between β (+) and 
α (−) subunits in the extracellular domain of the receptor and benzodiazepines bind at the 
homologous, single α-γ subunit interface (11). Benzodiazepines, such as midazolam, have 
been used extensively in the treatment of epilepsy (14,15). Carbamazepine is another 
commonly prescribed anti-epileptic drug that inhibits voltage-gated sodium channels (16) 
and affects other ion channels that modulate neuronal firing, such as N-methyl-D-aspartate 
receptors (17). It also enhances whole-cell currents mediated by α1β2γ2 GABAARs 
expressed in HEK293 cells or neurons (18). 
In this study we sought to resolve the molecular mechanisms of epileptogenesis 
caused by three epilepsy-causing α1 mutations: α1T265I (or α1T10’I), α1D192N and α1A295D (Fig. 
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1), with the aim of identifying novel therapeutic strategies for these disorders. The α1A295D 
mutation, located in M3, gives rise to autosomal dominant juvenile myoclonic epilepsy. Its 
clinical presentation is not associated with febrile seizures. The alanine residue at position 
295 is highly conserved amongst α subunits. Previous studies of this mutation in 
recombinantly expressed α1A295D–containing GABAARs in HEK293 cells demonstrated 
reduced current amplitude (19,20) and reduced cell surface expression (21). It is reported 
to result in subunit misfolding, internalisation and subsequent degradation via the 
endoplasmic reticulum degradation pathway (21). The FDA-approved drug, 
suberanilohydroxamic acid (SAHA), was shown to modestly enhance the functional 
expression of α1A295D–containing GABAARs at the cell surface (22). However, the extent to 
which the mutation impairs synaptic signalling and the extent to which these effects are 
recovered by SAHA remain to be determined. The α1D192N mutation, which gives rise to 
idiopathic generalised epilepsy with febrile seizures (23), is located in the extracellular 
domain in a region that lines the base of the GABA binding pocket. This region has been 
shown to be critical for triggering activation in GABAARs (24) and other pLGICs (25). Whole-
cell current recordings revealed accelerated whole-cell deactivation and desensitisation 
(23), although it is unclear whether these changes alter the activation or deactivation time 
courses of GABAergic inhibitory postsynaptic currents (IPSCs). Little is known about the 
functional consequences of the α1T10’I mutation. The mutation is located in the middle of the 
pore-lining M2 domain, near the permeation ‘gate’ of the receptor (25) and other residues 
that are critical for channel conductance and gating (26-30). It was recently discovered as a 
de novo mutation in a child with epileptic encephalopathy (31). 
The effects of epilepsy mutations on the magnitudes, rise and decay times of IPSCs 
were investigated in α1β2γ2L GABAARs. Because it is not possible to control GABAAR 
subunit composition in neurons, we employed a heterosynapse preparation in which the 
postsynaptic GABAARs comprised only the subunits of interest (32). These recordings were 
also used to determine the effects of temperature (22, 37 and 40 oC) and anti-epileptic drugs 
(midazolam and carbamazepine) and on IPSC rise and decay kinetics. We also investigated 
the effects of SAHA on GABAARs incorporating the α1A295D mutation (22). Finally, 
fluorescence microscopy was employed to monitor the effects of mutations and SAHA on 
neuronal morphology and on GABAAR surface expression efficiency and synapse number. 
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Figure 2-1. Structural model of a pentameric GABAAR showing the positions of the three 
epilepsy mutant residues (red) in a single highlighted (yellow) subunit. The left panel shows 
a view of the complex from within the plane of the membrane. The right panel shows a view 
from the extracellular space along the central pore axis perpendicular to the membrane. The 
model was generated from the 3 Å crystal structure of the homomeric β3 GABAAR (33)(PDB 
access code: 4COF) and rendered in Visual Molecular Dynamics software. (This figure was 
done by Angelo Keramidas.) 
 
MATERIALS and METHODS 
HEK293 cell culture and transfection  
Methods for preparing neurons and HEK293 cells for heterosynapse recordings have 
previously been detailed (32). Briefly, euthanasia of timed-pregnant rats was performed via 
CO2 inhalation as approved by the University of Queensland Animal Ethics Committee 
(approval number: QBI/142/16/NHMRC/ARC). The cortices of e18 rat embryos were 
dissected out, triturated and plated on poly-D-lysine coated coverslips at a density of ~100 
x 103 cells per coverslip. The cells were bathed in DMEM medium with 10 % fetal bovine 
serum, then replaced after 24 h with Neurobasal medium, including 2 % B27 and 1 % 
glutamax. After one week, half of this medium was replaced with fresh medium. Neurons 
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were allowed to grow for 3-4 weeks before introducing the transfected HEK293 cells. 
HEK293 cells were transfected with cDNAs encoding human α1, β2, and γ2L GABAAR 
subunits (all in the pcDNA3.1 plasmid) and co-transfected with pEGFP and neuroligin 2A (in 
pNICE) at a ratio of 1:1:4:1:1, using Ca2+-phosphate co-precipitation. Synaptic currents in 
HEK293 cells were recorded by whole-cell patch clamp 1-3 days later. Mutations to the α1 
subunit were introduced by site-directed mutagenesis and confirmed by DNA sequencing of 
the entire plasmid. 
Preparation of neurons for imaging  
Primary cortical neurons were plated onto poly-D-lysine-coated glass-bottomed 
dishes at a density of 10-15 x 104 cells per 29 mm dish and transfected with the α1 subunit 
harbouring a superecliptic pHluorin (SEpH) (Addgene plasmid 49168)(34), near its N 
terminus. The transfection was performed 7-10 days after plating, using Lipofectamine 200 
and the neurons were typically imaged between DIV 25 and DIV 28. 
Electrophysiology  
All heterosynapse experiments were performed in the whole-cell configuration of the 
patch-clamp technique, at a holding potential of −70 mV. The intracellular solution was 
composed of (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, and 10 EGTA, adjusted to 
pH 7.4 with CsOH. Cells were perfused with extracellular solution, which contained (in mM): 
140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 D-glucose, adjusted to pH 7.4 with 
NaOH. Currents were filtered (−3dB, 4-pole Bessel) at 4 kHz and sampled at 10 kHz and 
recorded using a Multiclamp 700B amplifier and pClamp 10 software. Recordings with series 
resistances >20 MΩ were discarded and series resistance compensation was not applied to 
the recorded cell. In experiments where drugs were applied, the events from the wash phase 
were averaged with the pre-drug period to control for any run-down or run-up of current 
amplitude. The temperature of the bath was increased from room temperature 22 ± 2oC to 
40 ± 2oC using an in-line bath heater (Warner TC-324B). Single channel recordings were 
done using excised outside-out membrane patches from transfected HEK293 cells at a 
clamped potential of −70 mV. The recorded patches were continuously perfused with an 
extracellular solution containing 3 mM GABA. Currents were recorded using an Axopatch 
200B amplifier (Molecular Devices), filtered at 5 kHz and digitized at 20 kHz using Clampex 
(pClamp 10, Molecular Devices) via a Digidata 1440A digitizer. 
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Microscopy experiments  
All experiments were performed on an Elyra fluorescent microscope (Carl Zeiss 
Microscopy GmbH) equipped with 100x objective (α Plan-Apochromat 100x 1.46 NA oil-
immersion), a focus lock system and an EMCCD camera Andor iXon Ultra 897 (Andor 
Technologies). This system has significantly higher sensitivity than confocal microscopes 
and is better suited for detecting the presence of GABAARs that express poorly at the cell 
membrane. Presynaptic terminals were identified using Oyster 550 labelled anti-
synaptotagmin antibodies (Synaptic Systems Cat. No. 105 311). SEpH and Oyster 550 
fluorescence was recorded with a LF488/561-A-000 beam splitter and FF01-523/610-25 
emission filter (Semrock). Red and green channels were aligned with fluorescent 
microspheres (Molecular Probes) and the channel alignment module in Zen 2012 SP2 
(black) software (Carl Zeiss Microscopy GmbH).  
To access surface expression of GABAARs the HEK293 cells were fixed with 4 % 
paraformaldehyde in phosphate buffered saline for 5 min and then incubated with Atto-647N 
conjugated anti-GFP antibody (132 003AT1, Synaptic Systems) for 1 h. We also quantified 
surface expression of GABAARs using Atto 647N labelled antibodies against GFP in 
neurons. The images were taken immediately after washing with phosphate buffered saline. 
For comparative intensity analysis, the microscope settings were held constant for all 
measurements. The images were processed in Fiji (National Institutes of Health). GABAAR 
surface expression was quantified by measuring the fluorescence intensity of Atto-647N at 
the membrane surface.  
Synaptic contacts in neuronal cultures were defined as points of co-localisation 
between the green puncta found in neurons transfected with tagged wild-type (WT) or 
mutant α1 subunits and magenta synaptotagmin rich presynaptic contacts of surrounding 
neurons. A minimum of 12 neurons per mutation from 3 separate transfections were used 
for analysis. To determine the number synaptic contacts and the size of the presynaptic 
terminals, images were segmented by applying a threshold to create a binary mask that 
maximized the number of presynaptic terminals for analysis, while minimizing the 
coalescence of individual puncta (35). A particle detection algorithm was then applied only 
to regions previously found to co-localise with SEpH-labeled GABAAR clusters. A total of 
240-260 presynaptic terminals were measured for WT and each of the three mutant α1 
constructs. 
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Statistical analyses 
Data sets were first tested for normal distribution prior to using ANOVA tests to 
determine statistical significance, with p < 0.05 as the significant threshold. The tests were 
conducted with SigmaPlot software. All data are presented as mean ± SEM. 
 
RESULTS 
 
Epilepsy-causing α1 mutant subunits accelerate the IPSC decay rate.  
We recorded spontaneous IPSCs mediated by α1T10’Iβ2γ2L, α1D192Nβ2γ2L and 
α1A295Dβ2γ2L GABAARs and compared them with those mediated by wild-type (WT) 
α1β2γ2L GABAARs at room temperature (22 oC). All constructs with the exception of the 
α1A295Dβ2γ2L GABAARs mediated robust spontaneous IPSCs ranging in magnitude from 
∼10 to 900 pA (Fig. 2-2 A, Table 2-1). To quantify the effects of mutations on cell surface 
expression levels, we transfected HEK 293 cells with the mutant subunits containing pH 
sensitive GFP (SEpH) near extracellular N-terminus and used Atto647N-conjugated 
antibodies to label GABAARs expressed at the cell surface (Fig. 2-2 B). Quantification of the 
relative surface expression levels revealed the expression level of α1D192N-containing 
receptors to be similar to that of α1WT-containing receptors, whereas the α1T10’I mutation 
reduced surface expression (Fig. 2-2 C).  
In agreement with previous reports (20-22), spontaneous IPSCs were never 
observed in the heterosynapse preparations transfected with α1A295D-containing receptors 
(Fig. 2-2 B). Consistent with this, antibody labelling of cells transfected with α1A295Dβ2γ2L 
GABAARs showed no surface labelling (not shown). We repeated these experiments after 
exposing transfected cells to suberanilohydroxamic acid (SAHA) at concentrations of either 
2.5 µM or 100 nM for a period of 3 - 4 days post-transfection. After incubating with a clinically 
relevant (2.5 µM) concentration of SAHA (22), IPSCs of robust magnitude were apparent in 
heterosynapse recordings (Fig. 2-2 A). Given the effectiveness of 2.5 µM SAHA, we also 
tested the effectiveness of a lower (100 nM) SAHA concentration. This enhanced the surface 
expression of α1A295Dβ2γ2L GABAARs to a detectable level (Fig. 2-2 B, C) and resulted in 
spontaneous IPSCs of robust magnitude (Fig. 2-2 A, see also below). 
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Figure 2-2. Epilepsy-causing α1 mutations reduce surface expression but form functional 
synapses in heterosynaptic cultures. A. Sample recordings of spontaneous IPSCs mediated 
by GABAARs with the indicated subunit compositions. The α1A295Dβ2γ2 GABAAR did not 
mediate IPSCs unless it was pre-incubated with SAHA. Green traces represent sample 
recordings with no SAHA treatment (top green trace), 2.5 µM SAHA for 3 days (middle green 
trace) or 100 nM SAHA for 3 days (bottom green trace). B. Sample images of HEK293 cells 
expressing the following GABAARs (from top to bottom): α1β2γ2, α1T10’Iβ2γ2, α1D192Nβ2γ2 
and α1A295Dβ2γ2. Cells expressing α1A295Dβ2γ2 GABAARs were treated with 2.5 µM SAHA 
for 3 days. C. Quantification of surface expression for the experiment in C. The α1T10’Iβ2γ2 
and α1A295Dβ2γ2 receptors exhibited significantly reduced expression levels (***p<0.001). 
 
As the α1T10’I mutation occurs within the pore-forming M2 transmembrane domain, 
we also explored the possibility that the mutation may affect the ability of the pore to flux 
current. Thus, single channel recordings were carried out by exposing membrane patches 
excised from HEK293 cells expressing either α1β2γ2L or α1T10’Iβ2γ2L GABAARs to 3 mM 
GABA (Fig. 2-3 A). Single channel amplitudes for each receptor were determined by plotting 
frequency histograms of current magnitudes and fitting these to Gaussians (Fig. 2-3 B). The 
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fitted histograms revealed that WT single channel amplitude was 1.94 pA, whereas that for 
the mutant was 1.83 pA. These measurements demonstrate that the α1T10’I mutation does 
not change the unitary conductance to an appreciable degree and suggests that mutation 
affects other aspects of receptor function. 
 
Figure 2-3. Comparison of the 
single channel conductances for 
α1β2γ2L and α1T10’Iβ2γ2L 
GABAARs (This figure was done 
by Angelo Keramidas) A. Sample 
single channel recordings for the 
α1β2γ2L GABAARs (above) and 
the α1T10’Iβ2γ2L GABAARs 
(below) in response to a 
saturating (3 mM) GABA 
concentration. B. Amplitude 
histograms for the α1β2γ2L 
GABAARs (left) and the 
α1T10’Iβ2γ2L GABAARs (right) 
fitted to single Gaussians. The 
corresponding peaks are at 1.94 
pA for WT and 1.83 pA for the 
mutant. 
 
 
We next proceeded to quantify the decay time constants, 10 - 90 % rise times and 
peak current amplitudes of spontaneous IPSCs activated by the WT and mutant GABAARs. 
Examples of digitally averaged, normalised and overlayed IPSCs for the WT and all three 
α1 mutant-containing GABAARs are shown in Fig. 2-4 A, and the averaged decay time 
constants, 10 - 90 % rise times and peak current amplitudes are presented in Fig. 2-4 B-D 
and summarized in Table 1. The IPSC decay rates for α1β2γ2L and α1A295Dβ2γ2L GABAARs 
were similar to each other (19 - 26 ms), whereas those for the α1T10’I- and α1D192N-containing 
GABAARs were significantly faster, at 12 - 14 ms (Fig. 2-4 A, B; Table 2-1). A previous study 
on α1A295D-containing GABAARs expressed in HEK293 cells reported that this mutation 
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accelerated the current decay rate in macropatch experiments without altering the single 
channel conductance (20). Our measurement of the IPSC decay rates of this mutant, 
although tending towards faster times, were not significantly different compared to WT 
controls (Fig. 2-4 B). 
The IPSC rise times for all four receptors ranged between 2.5 and 1.5 ms (Fig. 2-4 
C). Only the α1D192N- and α1A295D-containing GABAARs mediated IPSCs that rose to peak 
at significantly slower rates (Table 2-1). Peak IPSC amplitudes for all four receptors were 
variable, reflecting cell-to-cell variation in receptor expression and synapse number, but 
averaged to similar levels (Fig. 2-4 D). 
 
Figure 2-4. Effects of 
epilepsy mutations on the 
properties of 
spontaneous 
heterosynaptic IPSCs at 
22 oC. A. Digitally 
averaged, superimposed, 
normalised IPSCs 
mediated by α1β2γ2L 
(black), α1T10’Iβ2γ2L (red), 
α1D192Nβ2γ2L (blue) and 
α1A295Dβ2γ2L (green) 
GABAARs revealing 
faster decay times for the 
α1T10’Iβ2γ2L and 
α1D192Nβ2γ2L receptors. 
B. Mean IPSC decay time 
constants for the four 
constructs. C. Mean 10 – 
90 % IPSC rise times for the four constructs. D. Mean IPSC amplitudes for the four 
constructs. * p < 0.05.  
 
The functional phenotypes underlying GABAergic impairment that emerge from the 
data are, first, the spontaneous IPSCs mediated by α1T10’I and α1D192N-containing GABAARs 
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decay significantly faster than WT receptors, the α1T10’I -containing GABAARs also express 
at lower levels than WT, and finally, the α1A295D mutation precludes the surface expression 
of functional GABAARs. Surprisingly, the magnitudes of IPSCs mediated by α1A295D-
containing GABAARs were completely rescued by a 3 - 4 day pre-incubation with 100 nM 
SAHA. Throughout the remainder of this study all data for α1A295D-containing GABAARs were 
recorded following the same 100 nM SAHA pre-incubation. 
 
The effects of elevated temperature on IPSCs mediated by epilepsy-causing mutant 
receptors.  
As noted above, the α1D192N mutation gives rise to febrile seizures. Heterosynapse 
recordings were carried out at 22, 37 and 40 oC to determine whether febrile seizures may 
be caused by differential temperature-dependence of the kinetic parameters of IPSCs by 
WT and mutant GABAARs. At 40 oC, IPSCs mediated by all receptors were more frequent 
(Fig. 2-5 A). Examples of digitally averaged, superimposed and normalised IPSCs (Fig. 2-5 
B) suggest that IPSCs mediated by α1β2γ2L and α1T10’Iβ2γ2L GABAARs decayed more 
slowly than those mediated by α1D192Nβ2γ2L and α1A295Dβ2γ2L GABAARs at 40 oC.  
Fig. 2-5 C shows the mean IPSC decay time constants recorded at 22 and 40 oC for 
each receptor. As expected, the decay time constants in each case were dramatically 
reduced at 40 oC. However, the decay time constants for the α1D192Nβ2γ2L and α1A295Dβ2γ2L 
GABAARs were reduced further than those mediated by α1β2γ2L or α1T10’Iβ2γ2L GABAARs 
(Fig. 2-5 C, Table 2-1). Fig. 2-5 D and E compare rise times and peak amplitudes, 
respectively, at 22 and 40 oC. It is evident that α1T10’Iβ2γ2L GABAARs activated at a faster 
rate than the others at 40 oC (Fig. 2-5 D). Although we observed a trend to higher amplitude 
IPSCs in response to the elevated temperature, only the α1T10’Iβ2γ2L GABAARs showed a 
significant increase (Fig. 2-5 E). 
We also sought to quantify changes in IPSC properties under simulated febrile 
seizure conditions, i.e., as temperature increased from 37 to 40 oC. Although there was no 
significant change in IPSC decay time constant for any of the receptors (Fig. 2-5 F), IPSCs 
mediated by α1T10’Iβ2γ2L and α1A295Dβ2γ2L GABAARs activated more rapidly at 40 oC (Fig. 
2-5 G). IPSCs mediated by α1T10’Iβ2γ2L GABAARs also exhibited significantly greater 
amplitudes at 40 oC (Fig. 2-4 G). 
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Figure 2-5. Effects of elevated temperature on IPSC properties. A. Sample recordings of 
IPSCs mediated by the indicated GABAARs at 40 oC. B. Digitally averaged, superimposed, 
normalised IPSCs mediated by α1β2γ2L (black), α1T10’Iβ2γ2L (red), α1D192Nβ2γ2L (blue) and 
α1A295Dβ2γ2L (green) GABAARs. C. Comparison of mean IPSC decay time constants for the 
four constructs at 22 and 40 oC. D. Comparison of mean 10 – 90 % IPSC rise times for the 
four constructs at 22 and 40 oC. E. Comparison of mean IPSC magnitudes for the four 
constructs at 22 and 40 oC. F-H. Effect of increasing temperature from 37 - 40 oC on IPSC 
decay time constant, rise time and amplitude * p < 0.05. 
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Table 2-1. Summary of rise and decay time constants and peak amplitude for the 
indicated GABAARs at 22oC and 40oC. 
 
# Significance WAS TESTED within TEMPERATURE groupS. Significance was tested using 
ANOVA with p < 0.05 as the threshold. $ measurements after SAHA incubation for 3-4 days, 
* p < 0.05, ** p < 0.001.  
 
Effects of anti-epileptic drugs on IPSCs mediated by epilepsy mutant receptors. 
Midazolam and carbamazepine are widely used to treat epilepsy, and both are 
known to act at GABAARs (15,18). In an attempt to establish whether drug efficacy varied 
according to the mutation, we tested these drugs on IPSCs mediated by WT and the two α1 
mutated receptors in heterosynapse preparations. Each drug-test recording was paired to a 
drug-free control recording in the same cell. The results of these experiments are 
summarised in Figure 2-6 A-D and Table 2-2. Neither drug affected the rise times nor peak 
amplitude of IPSCs mediated any of the receptors (Table 2-2), suggesting that receptor open 
probability was unaffected. In contrast, both drugs significantly slowed the decay rate of 
IPSCs mediated by α1β2γ2L and α1D192Nβ2γ2L GABAARs (Fig. 2-6 D, Table 2-2). This effect 
was not observed at α1T10’Iβ2γ2L GABAARs, which exhibited decay time constants of 15 -18 
ms in both the absence and presence of midazolam and carbamazepine (Fig. 2-6 D, Table 
2-2). This latter result suggests that the α1T10’I mutation ablated the potentiating effect of the 
drugs. 
Receptor Decay time (ms) Rise time (ms) Amplitude (pA) n 
22 oC 
α1β2γ2L 26 ± 2 1.5 ± 0.1 112 ± 14 30 
α1T10’Iβ2γ2L 14 ± 0.8#* 1.8 ± 0.1 114 ± 18 13 
α1D192Nβ2γ2L 12 ± 1#* 2.2 ± 0.1#* 149 ± 30 12 
α1A295Dβ2γ2L$ 19 ± 1 2.5 ± 0.1#* 155 ± 23 12 
40 oC 
α1β2γ2L 7.3 ± 0.6 1.2 ± 0.1 371 ± 53 17 
α1T10’Iβ2γ2L 5.9 ± 0.7 1.4 ± 0.1 313 ± 121*# 15 
α1D192Nβ2γ2L 5.3 ± 0.6*# 1.4 ± 0.1*# 121 ± 20*# 17 
α1A295Dβ2γ2L$ 5.0 ± 0.3 1.3 ± 0.1 168 ± 45*# 14 
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Figure 2-6. Effects of the anti-epileptic drugs, midazolam and carbamazepine, on IPSC 
decay time constants. A. Examples of IPSC recordings mediated by α1β2γ2L GABAARs 
before the application of drugs (above), and during the application of 100 nM midazolam 
(middle) and 100 nM carbamazepine (below). B. Sample IPSCs mediated by α1T10’Iβ2γ2L 
GABAARs before the application of drug (above), and during the application of midazolam 
(middle) and carbamazepine (below). C. Sample IPSCs currents mediated by α1D192Nβ2γ2L 
GABAARs before the application of drug (above), and during the application of midazolam 
(middle) and carbamazepine (below). D. Summary of the effects of the drugs on IPSC decay 
time constants. * p < 0.05. 
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Table 2-2. Summary of rise and decay time constants and peak amplitude for the 
indicated GABAARs in the presence of midazolam and carbamazepine. 
Receptor Decay time (ms) Rise time (ms) Amplitude (pA) n 
Control 
α1β2γ2L 28 ± 3 1.4 ± 0.1 146 ± 21 15 
α1T10’Iβ2γ2L 15 ± 1 1.7 ± 0.2 116 ± 19 11 
α1D192Nβ2γ2L 14 ± 2 1.8 ± 0.2 167 ± 46 6 
Midazolam (100 nM) 
α1β2γ2L 47 ± 8* 1.4 ± 0.2 149 ± 28 9 
α1T10’Iβ2γ2L 18 ± 2 1.5 ± 0.2 95 ± 16 8 
α1D192Nβ2γ2L 23 ± 3* 1.8 ± 0.2 167 ± 49 6 
Carbamazepine (100 nM) 
α1β2γ2L 46 ± 7* 1.2 ± 0.1 125 ± 35 7 
α1T10’Iβ2γ2L 18 ± 1 1.7 ± 0.2 107 ± 16 10 
α1D192Nβ2γ2L 21 ± 3* 1.4 ± 0.1 129 ± 37 6 
 
Significance was tested using ANOVA with p < 0.05 as the threshold 
 
Epilepsy-causing α1 mutations reduce surface expression and induce morphological 
changes in neurons 
In addition to affecting the kinetic properties of GABAergic IPSCs, the epilepsy 
mutations may exert other effects on GABAergic neurons. For example, a recent study 
showed that two of the mutations investigated here, α1D192N and α1A295D, affect GABAergic 
bouton and dendritic spine formation in a mutation-specific manner, potentially leading to 
changes in excitatory/inhibitory balance (36). In addition, an epilepsy-causing mutation in 
the gene coding for the γ2 subunit (GBRG2) gives rise to an increase in GABAergic neurons 
in specific cortical layers (37). Here we transfected WT and mutant α1 subunits into cultured 
cortical neurons to investigate how the mutations affected the surface expression of 
GABAARs, as well as neuronal morphology and synaptic contact formation. 
Neurons transfected with SEpH-labeled α1WT subunits showed strong surface 
expression in neurites as previously observed (36,37) (Fig. 2-7 A, green). Also visible were 
synaptotagmin rich presynaptic boutons of surrounding neurons (Fig. 2-7 A, magenta). 
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Clusters of GABAARs could be observed on neuronal processes. These were either co-
localised with synaptotagmin and thus considered to be synaptic, or were otherwise 
considered to be extrasynaptic (38,39). Diffuse labelling was also present, likely reflecting 
the existence of a mobile extrasynaptic GABAAR population (40). Transfecting neurons with 
mutant subunits also produced synaptic and extrasynaptic clusters of GABAARs with some 
diffuse labelling, but clear morphological differences were also observed (Fig. 2-7 B-E). 
Neurons expressing the α1D192N subunit showed lower levels of surface fluorescence and 
reduced neurite branching relative to α1WT-transfected neurons (Fig. 2-7 B, F and G). On 
the other hand, the total number of synapses was not significantly affected (Fig. 2-7 H).  
Surprisingly, α1D192N-expressing cells exhibited a significant number of presynaptic 
terminals that appeared to be enlarged (Fig. 2-7 B, right panel). We measured the size of 
presynaptic terminals formed between GABAAR clusters containing the α1D192N subunit and 
compared it to neurons that had been transfected with α1WT subunits. The mean size of 
presynaptic terminals in α1WT-expressing neurons was adequately fitted by a single 
Gaussian with a mean diameter of 0.68 ± 0.08 µm (Fig 2-7 I). In contrast, neurons expressing 
the α1D192N subunit required two Gaussians to adequately describe presynaptic terminal 
sizes associated with surface expressed GABAARs. Approximately 60% of the presynaptic 
terminals were of comparable diameter to those of the α1WT controls, 0.65 ± 0.05 µm, 
whereas the remaining 40% were enlarged, 1.48 ± 0.22 µm (Fig 2-7 J). The enlarged 
presynaptic terminals covered multiple postsynaptic contacts (Fig. 2-7 B, magnified), helping 
to explain why the total synapse number remained high in α1D192N-transfected neurons 
despite reduced surface expression. No change in presynaptic terminal size was observed 
in neurons transfected with the other two α1 mutants, indicating that this morphological 
change was specific to α1D192N. A previous study showed that introduction of the α1D192N 
subunit had no significant effect on synaptic bouton density (36), although bouton size was 
not quantified. 
Neurons expressing α1A295D subunits exhibited intracellular fluorescence in the soma 
but not in the neurites (Fig. 2-7 E) consistent with the retention of this mutant in the 
endoplasmic reticulum (22). Incubation with 100 nM SAHA resulted in detectable but low 
levels of surface expression (Fig. 2-7 C, F) similar to that observed in HEK293 cells (Fig. 2-
2 D). There was, however, no impairment in neurite branching relative to α1WT-transfected 
neurons (Fig. 2-7 G). Consistent with the overall reduced level of surface expression, the 
total number of synapses was significantly reduced relative to α1WT-transfected neurons 
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(Fig. 2-7 H). The effects of SAHA on surface expression of α1A295D subunits are consistent 
with electrophysiological data from the heterosynaptic cultures (Figs. 2-2 and 2-4).  
Neurons expressing the α1T10’I subunit showed reduced expression levels compared 
to those expressing the α1WT subunit (Fig. 2-7 D, F). The reduced surface expression 
observed in neurons was similar to that in HEK293 cells (Fig. 2-2 D). A reduced number of 
synapses was also observed in α1T10’I- expressing neurons, and neurite branching 
morphology was also significantly impaired (Fig. 2-7 G, H).  
 
 
Figure 2-7. Effects of epilepsy mutations on primary neuronal cultures (This figure was done 
by Nela Durisic). A. Sample images of neurons transfected with the SEpH-tagged α1WT 
subunit (green). Synaptotagmin labeling is shown in magenta. The magnified image (right) 
shows clusters of synaptic GABAARs associated with synaptotagmin (white arrows) and 
clusters of extrasynaptic GABAARs (yellow arrows). B. Images of neurons transfected with 
the SEpH-tagged α1D192N subunit. Neurons showed reduced neurite branching and enlarged 
presynaptic formations. The magnified image (right) shows clusters of GABAARs associated 
with synaptotagmin immunofluorescence (white arrows). C. Images of neurons transfected 
with the SEpH-tagged α1A295D mutant after exposure to 100 nM SAHA. Note the reduction 
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in number of GABAAR clusters associated with synaptotagmin. D. Images of neurons 
transfected with the SEpH-tagged α1T10’I mutant subunit, which exhibits similar features to 
the SEpH-tagged α1WT subunit, but with reduced surface expression levels. E. Sample 
neuron transfected with SEpH-tagged α1A295D mutant without SAHA treatment. Note 
receptor internalisation in the soma. F. Comparison of the relative surface expression levels 
of each subunit. G. Comparison of the number of neurite branching points per 100 µm in 
neurons expressing each subunit. H. comparison of the number of GABAAR clusters 
associated with synaptotagmin. I. Gaussian distribution of the size of presynaptic boutons 
obtained from neurons expressing the α1WT subunit. J. Gaussian distribution of the size of 
presynaptic boutons obtained from neurons expressing the α1D192N mutant subunit. Two 
Gaussians were required to fit the data, indicating a WT-like and an enlarged population of 
boutons. p < 0.05 
 
DISCUSSION 
 
Effects of epilepsy mutations on heterosynaptic IPSCs 
The main advantage of engineered heterosynapses is that they permit us to 
investigate the synaptic properties of defined GABAAR isoforms in isolation from the 
multitude of other undefined GABAAR isoforms that are likely to exist in any neuron (41). 
Thus far, the function and pharmacology of GABAARs incorporating epilepsy mutations have 
been investigated using conventional whole-cell recordings of GABA-activated currents in 
heterologous expression systems such as oocytes or HEK293 cells (1,19,21). To date, little 
is known about how epilepsy mutations affect GABAergic IPSCs. 
The heterosynapse preparation enabled us to determine that the α1T10’Iβ2γ2L and 
α1D192Nβ2γ2L GABAARs compromise effective neuronal inhibition by accelerating the decay 
rate of IPSCs. However, data from both neurons and HEK293 cells indicates that both 
mutations also impaired the cell surface expression of these GABAARs. Our data also 
confirm that the α1A295Dβ2γ2L GABAAR is not expressed at all at the cell surface. It is well 
established that a reduction or ablation of functional GABAAR expression in the synapse will 
lead to epilepsy. For example, this mechanism of impairment has also been demonstrated 
for the nonsense GABAAR epilepsy mutations, γ2Q1X, γ2R97X, γ2Q351X and γ2W390X, all of which 
completely ablate γ2 expression (42,43). This is likely to induce epilepsy by several 
mechanisms, one of which would presumably be via the de-clustering of GABAARs from the 
synapse (44). Gentamicin, which rescues full length expression of nonsense truncated 
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subunits by aminoglycoside-induced stop codon read-through, has recently been shown to 
partially rescue the expression of GABAARs incorporating the γ2Q1X subunit (45), suggesting 
a possible new direction for epilepsy therapy. 
SAHA (also known as Vorinostat) is an orally-available histone deacetylase inhibitor 
that crosses the blood brain barrier and is FDA-approved for human clinical use. It was 
previously shown to correct the protein folding and thereby enhance the surface expression 
of α1A295D-containing GABAARs in HEK293 cells (22). Using cell surface biotinylation 
experiments, these authors demonstrated that SAHA (2.5 µM for 24 hr) increased the 
surface expression of α1A295D subunits from ~10 to 49 % of the level of α1WT subunits. Using 
whole-cell electrophysiological recordings, they showed that the same SAHA treatment 
produced saturating GABA-gated currents that were 10 % of those mediated by WT 
receptors (22). Here we demonstrate that SAHA (100 nM for 3 days) restored the functional 
expression of α1A295Dβ2γ2L GABAARs in HEK293 cells to the extent that the peak 
magnitudes and decay time constants of spontaneous IPSCs mediated by these receptors 
were not significantly different to those mediated by α1β2γ2L GABAARs. This dramatic effect 
suggests SAHA may be worth investigating as a treatment for epilepsies caused by this 
mutation.  
Mutation-specific changes in neuronal morphology and GABAAR expression levels 
Epilepsy can also result from morphological alterations to GABAergic neurons (46). 
A recent study reported that overexpression of α1A295D subunits on the background of 
GLRA1 gene knock-down resulted in increased peri-somatic bouton density and enhanced 
innervation fields in cultured GABAergic neurons (22). Another study employing GABAergic 
basket interneurons and glutamatergic pyramidal neurons in which the GABRA1 gene had 
been knocked down, also found morphological changes upon transfection with α1A295D 
subunits (36). That study reported that the transfection of the mutant α1A295D subunit in 
GABAergic basket interneurons increased the number of GABAergic boutons onto target 
cells and restored the innervation field after GABRA1 knock-down. In pyramidal neurons, 
transfection of the α1A295D subunit also increased the formation of dendritic spines, which 
are sites of glutamatergic synapses (36). As SAHA was not present in the experiments of 
these other studies, the results cannot be compared with ours. Consistent with our results 
from HEK293 cells, we found that SAHA enhanced the surface expression of α1A295D 
subunits in cultured cortical neurons. This in turn reduced the number of GABAergic 
synapses without affecting neurite branching. In contrast, transfection of α1T10’I subunits 
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reduced both the number of synapses and the neurite branching rate, whereas transfection 
of α1D192N subunits reduced the neurite branching rate and produced a population of 
enlarged presynaptic terminals. Although it is unclear how changes in the presynaptic 
terminal size and neurite branching morphology would affect neuronal excitability, we can 
be confident that reductions in GABAAR surface expression and number of synapses would 
alter the excitatory/inhibitory balance in neurons expressing GABAergic synapses. Together 
with more rapid IPSC decay rates, this could certainly lead to an epilepsy phenotype. 
Although we did not investigate the molecular basis by which GABAAR mutations 
affect neuronal morphology, we note that the N-terminal domains of GABAAR α1, β2 and γ2 
subunits play a direct structural role in synaptic contact formation (47). In such a model, it 
seems reasonable to infer that mutations to, or alterations in the surface expression of, α1 
subunits could interfere in this process. We are not aware of any studies that have reported 
a link between GABAAR receptor expression and presynaptic terminal size.  
 
Effects of high body temperature 
Epilepsy with thermal seizures is a common form of epilepsy and is mostly associated 
with mutations in the γ2 subunit of the GABAAR (48). One proposed mechanism by which 
an elevated temperature could lead to impaired GABAergic inhibition is by triggering the 
escape of mutant receptors from the synapse (49). Our data reveal another mechanism. By 
raising the temperature from 22 - 40 oC we observed that the IPSC decay times mediated 
by α1D192Nβ2γ2L and α1A295Dβ2γ2L GABAARs were reduced to a greater extent than 
α1β2γ2L and the α1T10’Iβ2γ2L GABAARs. One of these mutant receptors (α1D192Nβ2γ2L) is 
associated with febrile seizures (23), whereas the other (αT10’Iβγ2L) is not.  
Similarly, our IPSC data show that the magnitude of the decay time decrease is 
similar for the α1D192Nβ2γ2L and α1A295Dβ2γ2L GABAARs, implying that the later receptors 
might also induce febrile seizures if they expressed efficiently in synapses. However, when 
we increased temperature from 37 – 40 oC, to more realistically mimic a febrile seizure 
temperature excursion, we observed no significant effect on IPSC decay time constant for 
any of the mutants (Fig. 2-4 F). We speculate that the rapid decay rate of IPSCs mediated 
by α1D192Nβ2γ2L GABAARs at 37 oC renders them more susceptible to the effects of elevated 
temperature. We further speculate that this does not pertain to α1T10’Iβγ2L GABAARs 
because any effect of elevated temperature on the IPSC decay rate would be counteracted 
by the significant increase in IPSC magnitude that would occur simultaneously (Fig. 2-4 G). 
49 
 
The effectiveness of common anti-epileptic drugs 
It is currently estimated that over 30% of people with epilepsy do not respond to 
currently available medications (50,51). Midazolam and carbamazepine are commonly used 
to treat symptoms of epilepsy and both drugs potentiated α1β2γ2L and α1D192Nβ2γL 
GABAARs by slowing the IPSC decay rates, but surprisingly, neither drug affected the 
α1T10’Iβ2γL GABAARs. This result is similar to that of a benzodiazepine-resistant epilepsy-
causing mutation in the γ2 subunit (1) and suggests that benzodiazepine administration for 
some epilepsy-causing GABAARs may be an ineffective treatment. 
The α1D192N mutation occurs on the complementary (−) side of the GABA binding 
pocket (Fig. 1A), whereas the β2 subunit contributes the principal (+) side. Hence, our 
observation that currents mediated by the α1D192Nβ2γL GABAARs are enhanced by 
midazolam is not surprising given that the benzodiazepine binding site is formed at the 
interface of the α1 (+) and γ2 (-) subunits. Carbamazepine potentiates α1D192Nβ2γL 
GABAARs to a similar extent as midazolam. Two lines of evidence suggest that this 
compound binds to a site other than the benzodiazepine site. First, the current-potentiating 
effects of carbamazepine are unaffected by the benzodiazepine competitive antagonist, 
flumazenil, and second, GABAARs that either lack the γ2 subunit or express α3 or α5 
subunits instead of α1 are not modulated by carbamazepine (18).  
Although our experiments do not provide information regarding the location of the 
carbamazepine pharmacophore, we can infer that the mutation does not affect the binding 
or the signal transduction mechanism of the drug. The situation is evidently different for 
α1T10’Iβ2γL GABAARs. Here both drugs failed to have any modulatory effect on IPSCs. This 
suggests that, irrespective of where on the receptor the two tested drugs bind, the signal 
transduction for both drugs is ablated by the α1T10’I mutation. As carbamazepine and 
midazolam are routinely used to treat epilepsy, our data suggest that neither would be 
effective in treating individuals harbouring the α1T10’I mutation. 
 
CONCLUSION 
In this study, we investigated three separate hereditary epilepsy mutations in the α1 
subunit of the GABAAR and made new findings regarding their mechanisms of 
epileptogenesis and its possible reversal. All three mutations significantly reduced surface 
expression of GABAARs in neurons and the α1A295D and α1T10’I mutations reduces 
expression in HEK293 cells. In addition, the α1D192N and α1T10’I mutations significantly 
accelerated the decay rate of GABAergic IPSCs. The α1T10’I mutation also reduced the 
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number of GABAergic synaptic contacts in neurons. The resulting loss of inhibitory input 
would enhance the tendency of recurrently connected excitatory neurons to transition, via 
positive feedback, into synchronous hyperactivity and could thus explain the epileptogenic 
mechanism for these mutations. We showed that SAHA at clinically relevant concentrations 
restores surface expression of α1A295Dβ2γ2L GABAARs to the point where they mediate 
IPSCs with waveforms and magnitudes comparable to those mediated by α1β2γ2L 
GABAARs. This implies SAHA may be worthy of investigation as a treatment for epilepsies 
caused by this mutation. The newly discovered de novo mutation, α1T10’I, was found to 
render GABAARs insensitive to the standard anti-epileptic drugs, midazolam and 
carbamazepine. The three mutant subunits also caused morphological changes in neurons, 
demonstrating that multiple factors combine to impair GABAergic inhibition in these 
epilepsies. 
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• Their IPSC decay rates are slow and dominated by intrinsic channel closing rates 
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Abstract 
α5-containing GABAARs are potential therapeutic targets for clinical conditions 
including age-related dementia, stroke, schizophrenia, Down syndrome, anaesthetic-
induced amnesia, anxiety and pain. α5-containing GABAARs are expressed in layer 5 
cortical neurons and hippocampal pyramidal neurons where they mediate both tonic 
currents and slow inhibitory postsynaptic currents (IPSCs). A range of drugs has been 
developed to specifically modulate these receptors. The main α5-containing GABAARs that 
are likely to exist in vivo are the α5β1γ2, α5β2γ2 and α5β3γ2 isoforms. We currently have 
few clues as to how these isoforms are distributed between synaptic and extrasynaptic 
compartments or their relative roles in controlling neuronal excitability. Accordingly, the aim 
of this study was to define the basic biophysical and pharmacological properties of IPSCs 
mediated by the three isoforms in a hippocampal neuron-HEK293 cell co-culture assay. The 
IPSC decay rates were slow (α5β1γ2L: 45 ms; α5β1γ2L: 80 ms; α5β3γ2L: 184 ms) and were 
largely dominated by the intrinsic channel deactivation rates. By comparing IPSC rise times, 
we inferred that α5β1γ2L GABAARs are located post-synaptically whereas the other two are 
predominantly peri-synaptic. α5β3γ2L GABAARs alone mediated tonic currents. We 
quantified the effects of four α5-specific inverse agonists (TB-21007, MRK-016, α5IA and L-
655708) on IPSCs mediated by the three isoforms. All compounds selectively inhibited IPSC 
amplitudes and accelerated IPSC decay rates, albeit with distinct isoform specificities. MRK-
016 also significantly accelerated IPSC rise times. These results provide a reference for 
future studies seeking to identify and characterize the properties of IPSCs mediated by α5-
containing GABAAR isoforms in neurons. 
 
 
Keywords 
GABAergic, IPSC, tonic inhibition, synaptic inhibition, TB-21007, MRK-016, α5IA, L-655708 
 
Chemical compounds studied in this article 
TB-21007: PubChem CID: 6918633 
MRK-016: PubChem CID: 6918583 
α5IA: PubChem CID: 6918451 
L-655708: PubChem CID: 5311203 
  
57 
 
Introduction 
 
GABAA receptors (GABAARs) are ligand-gated Cl- channels that mediate synaptic 
and extra-synaptic inhibition in the brain. As GABAARs are pentameric oligomers 
constructed from a family of 19 different subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ and ρ1-3), the 
number of possible stoichiometries is enormous. As with many other types of ion channel, 
their biophysical and pharmacological properties and their cellular and subcellular 
distribution patterns vary according to their subunit stoichiometry (D'Hulst et al., 2009; Mele 
et al., 2016; Sieghart and Sperk, 2002; Vithlani et al., 2011). α5-containing GABAARs are 
found mainly in layer 5 cortical neurons and hippocampal pyramidal neurons where they are 
located both extra-synaptically and synaptically (Caraiscos et al., 2004; Collinson et al., 
2002; Sieghart, 1995; Sieghart and Sperk, 2002; Yamada et al., 2007). Because extra-
synaptic α5-containing GABAARs can be activated by the low ambient GABA concentrations 
that exist outside of the synapse, they generate a persistent Cl- ‘leak’ current that tonically 
inhibits neurons (Farrant and Nusser, 2005; Lee and Maguire, 2014). Synaptic α5-containing 
GABAARs contribute a slow component to the GABAergic inhibitory postsynaptic currents 
(IPSCs) (Caraiscos et al., 2004; Collinson et al., 2002; Glykys et al., 2008; Hausrat et al., 
2015; Prenosil et al., 2006; Vargas-Caballero et al., 2010; Zarnowska et al., 2009). α5-
containing GABAARs are considered promising therapeutic targets for a range of clinical 
conditions including age-related dementia, stroke, schizophrenia, Down syndrome, 
anaesthetic-induced amnesia, anxiety and pain (Botta et al., 2015; Brickley and Mody, 2012; 
Clayton et al., 2015; Perez-Sanchez et al., 2017; Rudolph and Mohler, 2014; Soh and Lynch, 
2015), and indeed a wide range of drugs has been developed to specifically modulate them 
(Clayton et al., 2015; Soh and Lynch, 2015).  
The main α5-containing GABAARs that are likely to exist in vivo are the α5β1γ2, 
α5β2γ2 and α5β3γ2 isoforms (Olsen and Sieghart, 2009). We currently have few clues as 
to how these isoforms are distributed between synaptic and extra-synaptic compartments 
or their relative contributions to controlling neuronal excitability. A first step towards 
addressing this would be to define the basic biophysical and pharmacological properties of 
IPSCs mediated by individual α5-containing GABAAR isoforms. To date, the 
pharmacological profiles of α5-specific drugs have been evaluated under equilibrium 
conditions, whereby the drug and a low (e.g., EC20) concentration of GABA have been co-
applied for an extended period (typically several seconds) (Ballard et al., 2009; Chambers 
et al., 2002; Chambers et al., 2003; Quirk et al., 1996; Sternfeld et al., 2004). These 
conditions are relevant to quantifying drug effects on tonically-activated GABAARs. 
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However, they are not relevant to IPSCs because the kinetics of the synaptic agonist 
transient plays a crucial role in determining the susceptibility of IPSCs to pharmacological 
modulation (Barberis et al., 2011). 
The aim of this study was to characterize the physiological and pharmacological 
properties of IPSCs mediated by the α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs to improve 
our understanding of their individual roles in controlling neuronal excitability and the 
mechanisms by which α5-modulating drugs influence neuronal activity. When taken in 
conjunction with human clinical, animal behavioral and cell biological studies, this 
information should help provide new insights into which isoform should be preferentially 
targeted (and how it should be targeted) when seeking to treat the various disorders for 
which α5-containing GABAAR modulation has been implicated.  
The study of individual GABAAR isoforms in neurons is confounded by the large 
number of GABAAR isoforms present and the unknown or poor selectivity profiles of 
available pharmacological blockers. This problem can be circumvented via the use of a 
neuron-HEK293 cell co-culture system, whereby functional ‘hetero-synapses’ can be 
induced to form between neuronal presynaptic terminals and HEK293 cells that re-
combinantly express the GABAAR isoform of interest (Brown et al., 2014; Dixon et al., 2015; 
Dong et al., 2007). Using such a system, we investigated the biophysical properties of IPSCs 
mediated by recombinant α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs and characterized 
their sensitivity to four widely-used α5-specific inverse agonists: TB-21007, MRK-016, α5IA 
and L-655708. 
 
Methods 
Drugs  
TB-21007 and MRK-016 were obtained from Tocris Bioscience. Bicuculline 
methiodide, α5IA, L-655708, 6-cyano-7-nitroquinoxaline-23-dione (CNQX), AP5, 
tetrodotoxin (TTX) and GABA were obtained from Sigma-Aldrich. TB-21007, MRK-016, 
bicuculline methiodide, α5IA and L-655708 were dissolved in DMSO as 10 mM stock 
solutions. CNQX and AP5 stocks were dissolved in DMSO at 1 mM and 20 mM, respectively. 
The TTX and GABA stocks were dissolved in H2O at 1 and 500 mM, respectively.  RM 68, 
RM 69 and RM 70 provided by our collaborators, Professor Rob Capon and Pritesh Prasad 
(Institute of Molecular Bioscience). The three compounds were also dissolved in DMSO as 
100 mM stock. All stocks were stored at -20 oC until use. 
 
 
59 
 
Primary culture of cortical neurons and hippocampal neurons  
Cortical neurons and hippocampal neurons were prepared using methods as recently 
described (Dixon et al., 2015). Briefly, E18 timed-pregnant rats were euthanized via CO2 
inhalation in accordance with procedures approved by the University of Queensland Animal 
Ethics Committee. The cortices and hippocampi were rapidly removed, triturated and plated 
onto poly-D-lysine-coated coverslips in a 4-well plate at a density of 8-10 x 104 cells/well, 
and cultured for 3-4 weeks until spontaneous IPSCs could be detected. The cells were 
initially cultured in Dulbecco’s Modified Eagles Medium supplemented with 10 % fetal bovine 
serum (DMEM-FBS). After 24 h the entire DMEM-FBS medium was replaced with 
Neurobasal medium including 2 % B27 and 1 % GlutaMAX supplements. A second (and 
final) feed 1 week later replaced half of this medium with fresh Neurobasal medium. Neurons 
were used in co-culture experiments between 3-5 weeks later. 
 
HEK 293 cell culture, transfection and heterosynapse formation 
HEK293 cells were cultured in DMEM-FBS until approximately 90% confluent. One 
day prior to transfection, they were trypsinized and plated onto glass coverslips in 35 mm 
culture dishes at a density of 5 x 103 cells/dish.  
This study employed the following plasmid DNAs: human GABAAR α5 
(pcDNA3.1Zeo), human GABAAR β1 (pcDNA3.1Zeo), human GABAAR β2 (pcDNA3.1Zeo), 
human GABAAR β3 (pcDNA Zeo), human GABAAR γ2L (pcDNA3.1), mouse neuroligin 2A 
(pNice) and GFP (pEGFP). GABAAR clones were obtained from Prof. Neil Harrison 
(Columbia University), whereas neuroligin 2A was obtained from Addgene (plasmid 15259) 
and pEGFP from Clontech. Each 35 mm dish of HEK293 cells was transfected with GFP, 
α5, β and γ2L GABAAR plasmid DNAs in a ratio of 1:1:1:5. Neuroligin 2A (100 ng) was also 
transfected, with the total plasmid DNA amount totalling around 0.5 µg per dish.  
Transfection was performed via a Ca2+ phosphate-DNA co-precipitation method for 
5-20 h in a 3% CO2 incubator and terminated by washing cells twice with divalent cation-
free phosphate buffered saline. Cells were trypsinized the next day, centrifuged and re-
suspended in Neurobasal medium (including 2% B27 and 1% GlutaMAX supplements) then 
seeded onto the neurons. One 35 mm dish of HEK293 cells was typically sufficient to seed 
four coverslips of neurons. Once seeded with HEK293 cells, the co-cultures were returned 
to the incubator overnight to allow synapses to form. Cultures were used for patch clamp 
recording over the following 2-3 days. 
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Electrophysiology 
Patch clamp recordings were performed at room temperature (22 ± 1°C) at a clamped 
potential of −70 mV, in whole-cell or outside-out configurations. All recordings were 
performed using a Multiclamp 700B amplifier and pClamp10 software (Molecular Devices), 
filtered at 4 kHz and sampled at 10 kHz. Patch pipettes (4 – 8 MΩ resistance) were fabricated 
from borosilicate glass (GC150F-7.5, Harvard Apparatus) and filled with an internal solution 
comprising (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES and 10 EGTA, adjusted to pH 
7.4 with CsOH. The extracellular solution comprised (in mM) 140 NaCl, 5 KCl, 2 CaCl2, 1 
MgCl2, 10 HEPES and 10 D-glucose, adjusted to pH 7.4 with NaOH.  
  For macropatch recordings, pipettes were fire-polished to a resistance of ~10 MΩ 
and filled with the same internal solution. Outside-out patches pulled from transfected 
HEK293 cells were activated by brief (<1 ms) exposure to agonists using a piezo-electric 
translator (Siskiyou). The speed of the solution exchange system was regularly calibrated 
by rapidly switching the solution perfusing an open patch pipette between standard 
extracellular solution and an extracellular solution that had been diluted by 50% with distilled 
water. By monitoring the resulting pipette current, we were able to ensure that the solution 
perfusing the macropatch was completely exchanged within 200 μs (Dixon et al., 2014).  
 
Data analysis  
Analyses of IPSC amplitude, 10−90% rise time, and decay time constant were 
performed using Axograph X (Axograph Scientific). Only cells with a stable series resistance 
of <25 MΩ throughout the recording period were selected for analysis. IPSCs were detected 
using a semi-automated sliding template. Each detected event was visually inspected and 
only those with no inflections in the rising or decay phases were included. All selected events 
from a single cell were digitally averaged. Parameters derived from these digitally averaged 
waveforms were then pooled with those form other cells to obtain group data. 
To calculate macroscopic current decay time constants, digitally averaged 
macroscopic recordings were fitted with double-exponential functions in Axograph X, and a 
weighted time constant was calculated from individual time constants (τ1, τ2) and their 
relative amplitude (A1, A2) as follows: τweighted = (τ1×A1+τ2×A2)/(A1+A2).  
Displayed averaged data represent group means ± SEMs. The Hill equation was 
used to calculate the saturating current magnitude (Imax), half-maximal concentration (EC50) 
and Hill coefficient (nH) values for GABA activation. Individual concentration-response 
relationships were fitted using a nonlinear least squares algorithm (SigmaPlot 11.0; Jandel 
Scientific, San Rafael, CA, USA). Statistical analysis and graphing were performed with 
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SigmaPlot 11.0. Group data were tested for normal probability distribution and for significant 
differences between groups using one-way ANOVA. Pair-wise comparisons were 
determined using Tukey’s test, where P ≤ 0.05 was taken as the significance threshold.  
 
Results  
GABA concentration-response relationships for α5β1γ2L, α5β2γ2L and α5β3γ2L 
GABAARs 
Previously published GABA EC50 values for α5-containing GABAARs expressed in 
HEK293 cells vary widely. For example, reported EC50 values for α5β3γ2 GABAARs range 
from 1.4 μM (Mortensen et al., 2011), to 10.8 μM (Burkat et al., 2014) and 19.4 μM 
(Caraiscos et al., 2004). Similarly, EC50 values for α5β2γ2 GABAARs range from 0.8 μM 
(Kumar and Dillon, 2016) to 10.2 μM (Petroski et al., 2006). GABA EC50 values for the three 
isoforms expressed in HEK293 cells have never been compared in a single study, although 
a single study performed on Xenopus oocyte-expressed receptors reported remarkably 
consistent EC50 values (31 – 41 μM) for the three isoforms (Karim et al., 2013). We quantified 
the GABA concentration-response relationships for α5β1γ2L, α5β2γ2L and α5β3γ2L 
GABAARs expressed in HEK293 cells. Sample currents recorded in response to increasing 
GABA concentrations for each isoform are shown in Fig. 3-1 A. The mean concentration-
response relationships are shown in Fig. 3-1 B with mean parameters of best fit to the Hill 
equation summarized in Table 3-1. The threshold concentrations for GABA activation were 
in the 1-3 μM range and EC50 values were reasonably consistent among the isoforms, 
ranging between 9.6 and 15.4 μM.  
 
Figure 3-1. GABA sensitivity of α5-containing GABAARs (This figure was done by Joseph 
Lynch). In this and all subsequent figures, data corresponding to α5β1γ2L, α5β2γ2L and 
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α5β3γ2L receptors are coloured green, orange and blue, respectively. (A) Examples of 
currents recorded in response to indicated GABA concentrations in HEK293 cells 
expressing each isoform. (B) Averaged GABA concentration-response relationships for the 
three isoforms. Mean parameters of best fit to the Hill equation are summarized in Table 3-
1. 
Table 3-1. GABA activation properties of α5-containing isoforms. 
Isoform EC50 (µM) nH Imax (pA) n 
α5β1γ2L 13.2 ± 2.6 2.0 ± 0.4 3209 ± 638 4 
α5β2γ2L 15.4 ± 0.5 3.2 ± 0.2 1704 ± 265 4 
α5β3γ2L 9.6 ± 2.4 2.0 ± 0.4 3890 ± 553 5 
 
Properties of IPSCs mediated by α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs  
Whole cell recordings from transfected HEK293 cells in co-culture with cortical 
neurons exhibited robust, spontaneous IPSCs with amplitudes up to 1000 pA for each of the 
three isoforms (Fig. 3-2 A). Fig. 3-2 B shows digitally averaged and normalized IPSCs from 
single HEK293 cells expressing each isoform. Mean IPSC 10-90 % rise times, decay time 
constants and amplitudes, measured from 14 or 15 digitally averaged IPSCs, are presented 
in Figs. 3-2 C-E. IPSCs mediated by α5β1γ2L GABAARs activated rapidly with a mean 10-
90 % rise time of 0.96 ± 0.07 ms and decayed rapidly with a mean decay time constant of 
45 ± 3 ms (both n = 15 cells). IPSCs mediated by α5β2γ2L GABAARs activated and decayed 
significantly more slowly, with a mean 10–90% rise time of 3.5 ± 0.2 ms and a mean decay 
time constant of 80 ± 4 ms (both p < 0.01 by two-way ANOVA, n = 14 cells). The α5β3γ2L 
GABAARs mediated IPSCs with much longer decay time constants (184 ± 14 ms, p < 0.01, 
n =15 cells) than either the α5β1γ2L or α5β2γ2L isoforms (Fig. 3-2 D). This isoform also 
exhibited slow IPSC rise times (Fig. 3-2 C). Thus, the β subunit has a strong influence on 
the rise and decay kinetics of IPSCs mediated by α5-containing GABAARs.  
 
Identification of the isoform responsible for tonic GABA currents in heterosynapses  
Tonic chloride flux in hippocampal neurons is thought to be mediated exclusively by 
α5β3γ2 GABAARs (Zarnowska et al., 2009). We thought to verify this in heterosynapses by 
assessing the relative contributions of the three α5-containing isoforms to the net leak 
current. Using 100 µM bicuculline to block both GABAergic IPSCs and tonic currents, we 
found the mean tonic current magnitude in synaptically-connected HEK293 cells expressing 
α5β3γ2L GABAARs to be 93 ± 20 pA (n = 8 cells) (Fig. 3-3 A, E). In contrast, 100 µM 
bicuculline had no effect on the baseline current in more than 30 synaptically-connected 
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HEK293 cells expressing α5β1γ2L or α5β2γ2L GABAARs (Fig. 3-3 B, C, E). By comparison, 
we found the mean bicuculline-sensitive tonic current magnitude in cultured rat hippocampal 
neurons to be 102 ± 15 pA (n = 8 cells) (Fig. 3-2 D, E). From these data we infer that the 
tonic extrasynaptic GABA current in our heterosynaptic system is mediated primarily by 
α5β3γ2L GABAARs.  
Figure 3-2. Properties of 
spontaneous IPSCs recorded from 
heterosynapses incorporating 
α5β1γ2L, α5β2γ2L and α5β3γ2L 
GABAARs. (A) Representative 
recordings of IPSCs from HEK293 
cells expressing each isoform. Grey 
traces are magnified from indicated 
sections of colored traces to show 
individual events. (B) Averaged 
(from 20-100 events), normalized 
IPSCs from individual cells 
expressing each isoform. (C) Mean 
10-90 % rise times from cells 
expressing the indicated isoform. 
(D) Mean IPSC decay time 
constants from cells expressing the 
indicated isoform. (E) Mean IPSC 
amplitudes from cells expressing the 
indicated isoform. All n values are 
provided in the text.  Group means 
were tested for significance using 
one-way ANOVA and pair-wise 
comparisons were determined using 
Tukey’s test, where * p ≤ 0.05 and ** 
p ≤ 0.01 relative to each other 
isoform. 
 
To determine whether this current was due to spontaneous channel activity 
(Wlodarczyk et al., 2013) or to activation by ambient GABA released from local neurons or 
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glia (Attwell et al., 1993; Lee et al., 2010; Semyanov et al., 2004), we applied 100 µM 
bicuculline to isolated (i.e., not co-cultured) HEK293 cells expressing α5β3γ2L GABAARs. 
In each of 7 cells, we found that 100 µM bicuculline had no detectable effect on the baseline 
current level (not shown), implying that the bicuculline-sensitive tonic current in our 
heterosynaptic preparation is mediated by ambient GABA. 
Figure 3-3. Quantification 
of tonic GABAergic 
currents from 
heterosynaptically 
connected HEK293 cells 
and from cultured rat 
hippocampal neurons. In 
all panels the purple bar 
indicates the duration of 
application of 100 µM 
bicuculline, a non-specific 
GABAAR blocker. (A-C) 
Sample recordings from 
cells incorporating 
α5β1γ2L, α5β2γ2L or 
α5β3γ2L GABAARs as indicated. Only α5β3γ2L GABAARs supported tonic currents. (D) A 
sample recording of phasic and tonic GABAergic currents from a cultured rat hippocampal 
neuron in the presence of TTX (200 nM), CNQX (10 µM) and AP5 (50 µM). (E) Mean 
amplitudes of tonic currents averaged from at least 8 cells expressing each recombinant 
GABAAR isoform and from hippocampal neurons. 
 
Table 3-2. Individual time constants and relative areas for macropatch currents. 
Isoform τ1 (ms) A1 (%) τ2 (ms) A2 (%) τweighted (ms) n 
α5β1γ2L 108 ± 9 21 ± 1* 11.0 ± 0.8 73 ± 2* 23 ± 6 6 
α5β2γ2L 78 ± 2 57 ± 3 11.1 ± 0.8 31 ± 4 56 ± 7 11 
α5β3γ2L 285 ± 27*** 53 ± 1 20.4 ± 0.8 47 ± 2 160 ± 13 7 
Data represent mean ± SEM. *p < 0.05 **p ≤ 0.05 and ***p ≤ 0.001 relative to both non-
asterisked values.  
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Macropatch currents mediated by α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs  
To determine whether the β subunit-dependent variation in IPSC kinetics was due to 
variations in the intrinsic receptor gating properties or to differential interactions with 
synapse-specific molecules (Barberis et al., 2011; Dixon et al., 2017), we recorded 
ensemble currents from outside-out patches excised from HEK293 cells that expressed 
either α5β1γ2L, α5β2γ2L or α5β3γ2L GABAARs. To mimic synaptic activation conditions, 
we applied a saturating (5 mM) GABA concentration for 1 ms via a piezoelectric translation 
device.  Two standard exponentials functions were required to fit the deactivation phase of 
macropatch currents for the three receptor subtypes. The individual time constants (and 
areas) are tabulated in Table 3-2. Examples of ensemble currents activated under these 
conditions for the three receptor isoforms are shown in Fig. 3-4 A with mean weighted 
deactivation time constants and 10-90 % rise times summarized in Fig. 3-4 B and C.  
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Figure 3-4. Outside-out macropatch recordings of currents mediated by each of the three 
α5-containing GABAAR isoforms. (A) Sample recordings from macropatches expressing the 
indicated isoforms in response to ≤ 1 ms applications of saturating (5 mM) GABA. (B) Group 
averages of macropatch current deactivation time constants reveal a significant difference 
between the three isoforms. The time constants have been weighted. The individual time 
constants and their relative magnitudes are summarized in Table 2. (C) Group averages of 
10-90 % activation times reveal no significant difference between isoforms. (D) Comparison 
of decay time constants for macropatch and IPSC recordings, showing that the macropatch 
current decay rates are significantly faster than the corresponding IPSC decay rates. (E) 
Comparison of 10-90 % activation times for macropatch and IPSC recordings, showing that 
the macropatch current rise times are much faster than IPSC rise times. Mean results were 
averaged from 7 macropatches (α5β1γ2L), 11 macropatches (α5β2γ2L) and 6 
macropatches (α5β3γ2L). *p < 0.05, **p < 0.01, ***p < 0.001. 
 
A two-way ANOVA revealed no statistically significant differences in rise times among 
receptor isoforms (Fig. 3-4 C). However, the mean deactivation time constant for α5β2γ2L 
GABAARs (56 ± 7 ms, n =11 patches) was significantly slower than for α5β1γ2L GABAARs 
(23 ± 6 ms, n = 7 patches; p < 0.01). The presence of the β3 subunit slowed the current 
deactivation time constant further to 160 ± 13 ms (n = 6; p < 0.05 relative to α5β1γ2L and 
α5β2γ2L GABAARs). A one-way ANOVA revealed a highly significant correlation between 
the β subunit and the ensemble current decay of α5-containing GABAARs (p ≤ 0.001). Fig. 
3-4 D demonstrates that the macropatch current decay time constants correlated reasonably 
well with the IPSC decay time constants, although in each case the macropatch currents 
decayed significantly faster. In contrast, the macropatch current rise times were dramatically 
faster than the IPSC rise times for all three isoforms (Fig. 3-4 E). Possible explanations for 
these results are provided below. 
 
Effects of TB-21007, MRK-016, α5IA and L-655708 on IPSCs mediated by α5β1γ2L, 
α5β2γ2L and α5β3γ2L GABAARs 
A structurally diverse range of drugs specific for α5-containing GABAARs has been 
developed (Clayton et al., 2015; Soh and Lynch, 2015). These drugs have generally been 
tested on only a single α5-containing isoform, most commonly α5β3γ2, under equilibrium 
conditions in the presence of a low (typically EC20) GABA concentration (Ballard et al., 2009; 
Chambers et al., 2002; Chambers et al., 2003; Quirk et al., 1996; Sternfeld et al., 2004). 
These conditions are relevant to evaluating drug effects on tonically-activated receptors. 
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However, synaptically- and tonically-activated GABAARs may have very different 
pharmacological properties because the potency of ion channel modulators is dominated by 
two factors, agonist concentration and channel open time, which vary drastically between 
synaptic- and extrasynaptically-expressed receptors (Barberis et al., 2011). An investigation 
of the efficacy of α5-specific modulators on IPSCs mediated by the major α5-containing 
isoforms is thus warranted. Here we compared the effects of saturating (1 µM) 
concentrations of four α5-GABAAR specific inverse agonists, TB-21007, MRK-016, α5IA and 
L-655708, on IPSCs mediated by α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs. The results 
are presented in Figs. 3-5 and 3-6 with all results summarized in Table 3-3.  
 
Table 3-3. Effects of 1 µM TB-21007, MRK-016, α5IA and L-655708IPSC on IPSC 
parameters expressed as a percentage of pre-drug control values.  
 
Drug  Isoform Rise time  
(% of control) 
Decay time constant 
(% of control) 
Amplitude 
(% of control) 
TB-21007 α5β1γ2L 111 ± 2   n=13 92 ± 2      n=12 124 ± 5      n=13 
 α5β2γ2L 106 ± 2   n=15 95 ± 1      n=14 78 ± 1*      n=11 
 α5β3γ2L 103 ± 1   n=11 81 ± 1*    n=10 62 ± 3**    n=8 
 
  
 
 
MRK-016 α5β1γ2L 90 ± 2*    n=7 97 ± 3        n=7 68 ± 1**    n=6 
 α5β2γ2L 81 ± 3*    n=7 91 ± 4        n=7 71 ± 4%*   n=7 
 α5β3γ2L 80 ± 3*    n=6 73 ± 2**    n=6 99 ± 5%     n=7 
 
  
 
 
α5IA α5β1γ2L 108 ± 2   n=12 110 ± 2      n=13 63 ± 3**    n=10 
 α5β2γ2L 96 ± 3     n=8 76 ± 2*      n=7  82 ± 2*      n=7 
 α5β3γ2L 97 ± 3     n=8 77 ± 2**    n=8 103 ± 4      n=9 
 
  
 
 
L-655708 α5β1γ2L 103 ± 2   n=12 103 ± 2      n=12 118 ± 4      n=12 
 α5β2γ2L 100 ± 2   n=13 116 ± 3      n=13 82 ± 2*      n=10 
 α5β3γ2L 111 ± 2   n=11 89 ± 2*      n=10 102 ± 4      n=11 
Group means were tested for significance using one-way ANOVA. Pair-wise comparisons 
were made relative to corresponding pre-drug control values and were determined using 
Tukey’s test, where *p ≤ 0.05 and *p ≤ 0.01 relative to corresponding pre-drug control. 
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Figure 3-5. Effect of 1 µM TB-21007 on IPSCs recorded from heterosynaptically connected 
HEK293 expressing α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs. (A) A sample recording of 
IPSCs from a cell expressing α5β1γ2L GABAARs in the absence (left) and presence (right) 
of TB-21007. In all panels, grey traces are magnified from indicated sections of colored 
traces to show individual IPSCs. Digitally averaged and normalized IPSCs from the 
displayed cell (inset right) suggest that TB-21007 did not affect the IPSC decay rate. (B) A 
similar recording of IPSCs from a cell expressing α5β2γ2L GABAARs suggest that TB-21007 
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decreased the amplitude but not the decay time constant of α5β2γ2L-mediated IPSCs. (C) 
A similar recording of IPSCs from a cell expressing α5β3γ2L GABAARs suggest that TB-
21007 decreased the amplitude and decay time constant of α5β3γ2L-mediated IPSCs. (D) 
TB-21007 had no significant effect on IPSC rise times. (E) TB-21007 significantly reduced 
the decay time constant of IPSCs mediated by α5β2γ2L and α5β3γ2L GABAARs. (F) TB-
21007 significantly reduced the peak amplitude of IPSCs mediated by α5β2γ2L and 
α5β3γ2L GABAARs.  Group means were tested for significance using one-way ANOVA and 
pair-wise comparisons were determined using Tukey’s test, where *p ≤ 0.05 and **p ≤ 0.01 
relative to the pre-drug control.  
 
Examples of the effect of TB-21007 on IPSCs mediated by the three isoforms are 
shown in Fig. 3-5 A-C. Digitally-averaged, normalised IPSCs from the corresponding cells 
are shown to the right of each panel. The mean effects of TB-21007 on mean IPSC 10-90 
% rise times, decay time constants and amplitudes are presented in Fig. 3-5 D-F. TB-21007 
had no effect on the activation rate of IPSCs mediated by any isoform. Similarly, TB-21007 
did not affect α5β1γ2L- and α5β2γ2L-mediated IPSC decay time constants although it 
significantly slowed the decay time constant of IPSCs mediated by α5β3γ2L GABAARs. The 
amplitude of IPSCs mediated by α5β2γ2L and α5β3γ2L GABAARs were also significantly 
reduced, whereas those mediated by α5β1γ2L GABAARs were not affected.  These results 
indicate that TB-21007 exerts a differential effect on the major α5-containing isoforms.  
MRK-016 significantly decreased the 10-90 % activation times of IPSC mediated by 
all three isoforms (Fig. 3-6 A). It also significantly reduced the amplitude of α5β1γ2L and 
α5β2γ2L-mediated IPSCs and significantly reduced the decay time constant for α5β3γ2L-
expressing GABAARs to 73 ± 2% of control (Fig. 3-6 A).   
As for TB-21007, α5IA had no effect on the activation rate of any isoform (Fig. 3-6 B). 
However, it significantly inhibited the peak magnitude of IPSCs mediated by α5β1γ2L and 
α5β2γ2L GABAARs but not of α5β3γ2L GABAARs. α5IA also significantly shortened the 
decay time constant of IPSCs mediated by α5β2γ2L GABAARs and α5β3γ2L GABAARs but 
not of α5β1γ2L GABAARs (Fig. 3-6 B).  
L-655708 exerted relatively weak effects on IPSCs (Fig. 3-6 C). It significantly 
reduced the peak IPSC magnitude of α5β2γ2L GABAARs and the decay time constant of 
IPSCs mediated by α5β3γ2L GABAARs. 
70 
 
 
Figure 3-6. Effects of MRK-016, α5IA and L-655708 on the amplitudes, rise times and decay 
time constants of IPSCs mediated by α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs. The n 
values for all experiments are presented in Table 3-3. (A) Averaged effects of saturating (1 
µM) MRK-016 reveal a significant reduction in IPSC rise times for all three isoforms, a 
significant acceleration in IPSC decay time constant for α5β3γ2L GABAARs and a significant 
reduction in magnitude of IPSCs mediated by α5β1γ2L and α5β2γ2L GABAARs. (B) 
Averaged effects of saturating (1 µM) α5IA reveal no effect on IPSC rise times, but a 
significant acceleration in decay time constant for α5β2γ2L and α5β3γ2L GABAARs and a 
significant reduction in magnitude of IPSCs mediated by α5β1γ2L and α5β2γ2L GABAARs. 
(C) Averaged effects of saturating (1 µM) L-655708 reveal no effect on IPSC rise times, but 
a significant acceleration in decay time constant for α5β3γ2L GABAARs and a significant 
reduction in magnitude of IPSCs mediated by α5β2γ2L GABAARs. Group means were 
tested for significance using one-way ANOVA and pair-wise comparisons were determined 
using Tukey’s test, where *p ≤ 0.05 and **p ≤ 0.01 relative to the pre-drug control values. 
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Effects of RM68, RM69 and RM70 on IPSCs mediated by α5β1γ2L, α5β2γ2L and 
α5β3γ2L GABAARs 
In collaboration with AI McGeary (UQ), the lab developed three new drug, RM68, 
RM69 and RM70. The previous measurements performed by other member in Lynch lab, 
which had revealed that RM 68, RM 69 and RM 70 are all potent GABAAR modulators. More 
interestingly, these isomers, except RM 69, demonstrate bidirectional modulation, 
selectively potentiating α5GABAARs in the nM (sometimes pM) range, but inhibiting 
GABAARs non-selectively at higher, μM concentrations. Given the good results got before, 
I quantified the effects of drugs on spontaneous IPSCs and tonic currents mediated by each 
isoform to confirm the effectiveness on synaptic level. 
As shown in Figure 3-7 A, B and D, RM68 (10 µM) significantly decreased (71 ± 4% 
of control, n =8, p <0.001) the deactivation time of IPSC and inhibit tonic currents (as good 
as 100 µM bicuculline) mediated by α5β3γ2L isoform, meanwhile RM70 had no effect on 
the decay times of IPSCs mediated by this isoform. In addition, application of RM68 (10 µM) 
significantly decreased α5β3γ2L mediated IPSC decay times without affecting α5β1γ2L, 
α5β2γ2L or α1β2γ2L GABAARs (Figure 3-7 C, results representative of n≥6 cells expressing 
each isoform). In Figure 3-7 A, RM69 significantly decreased the deactivation times (74 ± 
4% of control, n =6, p ≤0.05), while had no tonic inhibition for currents mediated by α5β3γ2L 
GABAARs. To confirm the results, RM69 (10 µM) also be exposed to α5β2γ2L and α1β2γ2L 
GABAARs, none of them be effected (Data did not show here, results representative of n≥6 
cells expressing each isoform). In Figure 3-7 B and D, RM 68 blocked tonic current mediated 
by both α5β3γ2L and Hippocampal neurons, which suggesting RM68 is phasic and tonic 
current blocker for α5β3γ2L. However, RM69 is only effect phasic current mediated by 
α5β3γ2L. 
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 Figure 3-7. Effect of 10 µM RM 68 on IPSCs mediated by α5β1γ2L, α5β2γ2L, α5β3γ2L and 
α1β2γ2L GABAARs. (A) Averaged effects of saturating (10 µM) RM 68, RM69 and RM70 on 
the decay time constant mediated by α5β3γ2L GABAARs. (B) Sample recording for tonic 
currents with RM68 from cells incorporating α5β3γ2L GABAARs. (C) Averaged effects of 
saturating (10 µM) RM 68 reveal no effect on IPSC decay time constant for α1β2γ2L, 
α5β2γ2L and α5β1γ2L GABAARs, but a significant reduction for α5β3γ2L GABAARs. (D) 
Mean amplitudes of tonic currents averaged from cells expressing each recombinant 
GABAAR isoform and from hippocampal neurons with RM 68.  Group means were tested for 
significance using one-way ANOVA and pair-wise comparisons were determined using 
Tukey’s test, where *p ≤ 0.05 and **p ≤ 0.01 relative to the pre-drug control.  
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Discussion 
Comparison of the physiological properties of the three isoforms 
The unique advantage of heterosynapses is that they permit the investigation of the 
physiological and pharmacological properties of IPSCs mediated by defined GABAAR 
isoforms. However, as HEK293 cells do not express all necessary postsynaptic clustering 
proteins at appropriate levels for synaptogenesis, it is possible that the synaptic cleft 
geometry and the GABAAR receptor clustering mechanisms in our heterosynapses may not 
be identical to those of native neuronal synapses. This could result in aberrant 
neurotransmitter concentration profiles that could affect IPSC kinetics. This uncertainty is 
the main limitation of the technique. Moreover, cytoplasmic proteins such as radixin or AP2 
clathrin adaptor protein that trap α5β3γ2L GABAARs in extrasynaptic compartments 
(Hausrat et al., 2015; Vien et al., 2015) may not be functional in HEK293 cells. Irrespective 
of these potential limitations, a range of recombinant GABAAR isoforms has been found to 
mediate heterosynaptic IPSCs with kinetics similar to those mediated by the same isoforms 
in neurons (Dixon et al., 2014; Dixon et al., 2015; Dixon et al., 2017; Fuchs et al., 2013; Wu 
et al., 2012). Because the kinetics of IPSCs mediated by defined α5-containing GABAARs 
in vivo are not known, this comparison is not possible. However, α5-containing GABAARs in 
neuronal synapses mediate a slowly-decaying IPSC component consistent with our results 
(Caraiscos et al., 2004; Collinson et al., 2002; Glykys et al., 2008; Hausrat et al., 2015; 
Prenosil et al., 2006; Vargas-Caballero et al., 2010; Zarnowska et al., 2009). 
  Fast IPSC rise times imply expression within the postsynaptic density whereas slow 
rise times suggest perisynaptic expression (Farrant and Nusser, 2005; Wu et al., 2012). Of 
the receptors investigated here, the α5β1γ2L GABAAR exhibited the fastest rise times (~1 
ms). Notably, the major synaptically-expressed α1β2γ2 isoform also exhibits a rise time of 
~1 ms irrespective of whether it is expressed in heterosynapses (Dixon et al., 2014) or 
neurons (Eyre et al., 2012; Okada et al., 2000). From this we infer that α5β1γ2L GABAARs 
are also located in postsynaptic densities of heterosynapses close to transmitter release 
sites. 
In contrast, the α5β2γ2L and α5β3γ2L isoforms exhibited IPSC rise times of ~3 ms. 
As both receptors were activated rapidly upon GABA application (rise times < 0.4 ms, Fig. 
3-4 C), the slow IPSC rise times were most likely dominated by the neurotransmitter access 
time. In a previous heterosynapse study, IPSC rise times of 3-5 ms were shown to be 
associated with perisynaptic GABAARs (Wu et al., 2012).  We thus infer that the α5β2γ2L 
and α5β3γ2L GABAARs have a reduced propensity to cluster at postsynaptic densities, and 
may thus be predominantly located in the perisynaptic region.  
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The decay time constants for all three isoforms correlated well with the intrinsic 
channel closing rates as determined by fast GABA application (Fig. 3-4 C). This fits well with 
our recent Monte Carlo simulations that demonstrated GABAergic IPSC decay time 
constants are not affected by changes in a variety of synapse parameters, including GABA 
diffusion coefficient, synaptic cleft width, postsynaptic density size or GABAAR clustering 
density (Dixon et al., 2017). 
Extrasynaptic GABAergic leak currents can be mediated either by a low concentration 
of extrasynaptic GABA activating high affinity, non-desensitizing receptors (Lee and 
Maguire, 2014) or by spontaneously-activating receptors in the absence of GABA 
(Wlodarczyk et al., 2013). In our heterosynapse preparation, we found that tonic inhibition 
was it mediated only by α5β3γ2L GABAARs (Fig. 3-3). As α5β3γ2L GABAARs exhibited no 
spontaneous activity when expressed in HEK293 cells in the absence of neurons and glia, 
we infer that the extrasynaptic α5β3γ2L GABAARs in heterosyaptic preparation are activated 
by GABA released from local neurons or glia. Although all three α5-containing receptors 
exhibited comparable sensitivities to low (3 µM) concentrations of GABA (Fig. 3-1), only the 
α5β3γ2L isoform was tonically active, suggesting it is located in the appropriate 
extrasynaptic locations so as to sense extrasynaptically-released GABA.  
Putting these observations together, we infer that α5β1γ2L GABAARs are located 
mainly within postsynaptic densities, α5β2γ2L GABAARs tend to be located perisynaptically 
and α5β3γ2L GABAARs tend to be located both perisynaptically and in extrasynaptic regions 
close to tonic GABA release sites. Of course, it remains to be determined whether these 
locations also pertain to neurons. Finally, the decay time constants of the three isoforms 
varied over a wide range (i.e., α5β1γ2L: 45 ms; α5β1γ2L: 80 ms; α5β3γ2L: 184 ms) and we 
infer that these were largely dominated by the respective intrinsic channel closing rates and 
not their synaptic versus perisynaptic locations. 
 
Pharmacological properties of the three isoforms 
TB-21007 (sometimes referred to as compound 43) was first reported in 2003 as a 
selective inverse agonist of α5β3γ2 GABAARs and was shown to inhibit the steady-state 
current with an efficacy of -51 % and a Ki of 1.6 nM (Chambers et al., 2003).  When delivered 
intraperitoneally to rats, TB-21007 enhanced cognitive performance without the anxiogenic 
or pro-convulsive effects usually associated with non-specific GABAAR inverse agonists 
(Chambers et al., 2003). Here we showed that a saturating (1 µM) concentration of TB-
21007 preferentially inhibited IPSCs mediated by α5β3γ2L GABAARs with an efficacy of -38 
%. It exhibited a weaker inhibitory effect on IPSCs mediated by α5β2γ2L GABAARs and did 
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not affect those mediated by α5β1γ2L GABAARs at all. Of the compounds tested here, TB-
21007 exhibited the highest selectivity for α5β3γ2L GABAARs over other α5-containing 
isoforms.  
MRK-016 was first described in 2009 where it was shown to selectively inhibit steady-
state currents mediated by α5β3γ2 GABAARs with an efficacy of -55 % and a Ki of 1.4 nM  
(Atack et al., 2009). Similar to TB-21007, it enhanced cognitive performance in rats without 
evoking anxiogenic or convulsive side-effects. It has also been shown to exhibit anti-
depressant activity in rats (Fischell et al., 2015). However, MRK-016 was poorly tolerated in 
elderly humans which precluded further clinical development (Atack et al., 2009). We found 
that although MRK-016 selectively reduced the IPSC decay time constant in α5β3γ2L 
GABAARs, it also reduced the magnitude of IPSCs mediated by α5β1γ2L and α5β2γ2L 
GABAARs. It thus appears to have minimal utility for distinguishing among α5-containing 
isoforms.  
α5IA was first described in 2009 where it selectively inhibited steady-state currents 
mediated by α5β3γ2 GABAARs with an efficacy of -29 % and a Ki of 1.4 nM  (Dawson et al., 
2006). It exhibited cognitive enhancing properties in rodents but not in elderly humans 
(Atack, 2010). We found that a saturating concentration of α5IA modestly but significantly 
reduced the decay time constant of IPSCs mediated by α5β2γ2L and α5β3γ2L GABAARs 
and reduced the magnitude of IPSCs mediated by α5β1γ2L and α5β2γ2L GABAARs. Thus, 
similar to MRK-016, it appears to have minimal utility for discriminating among α5-containing 
isoforms.   
L-655708 was first reported as an α5-specific ligand  in 1996 (Quirk et al., 1996). It 
was subsequently shown to selectively inhibit steady-state currents mediated by α5β3γ2 
GABAARs with an efficacy of -17 % and a Ki of 1.0 nM (Atack et al., 2006). In contrast to the 
three drugs described above, it achieves its selectivity via a higher binding affinity rather 
than by a greater inhibitory efficacy. Although it produced cognitive enhancement in rats, it 
was also anxiogenic, presumably due to off target effects on α2- and α3-containing isoforms 
(Atack et al., 2006). It presumably works most effectively on tonic currents in vivo as it 
exerted only minor effects on IPSCs mediated by α5-containing isoforms investigated here.    
These results indicate that, with the possible exception of TB-21007, these drugs 
have weak and non-selective effects on IPSCs mediated by the major α5-containing 
GABAAR isoforms. These results suggest they cannot be used reliably as probes to 
pharmacologically define α5-mediated IPSC components in neurons.  
RM 68 had a selective effect on α5β3γ2L GABAARs other than its isomers RM69 and 
RM70. Although the three isomers share the same chemical formula, their characteristics 
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somewhat vary from one another. RM 68, with a nitro on the ortho- position of the phenyl 
group, dissolves in DMSO to form a light yellow solution, while RM 69 with a meta-nitro on 
its phenyl group forms a colourless solution in DMSO. Placing the nitro group to in the para- 
position on the phenyl in RM 70 results in a bright sunshine yellow solution when dissolved 
in DMSO. The selective effect of RM 68 on α5β3γ2L GABAARs sugguests that the nitro on 
the ortho- position of the phenyl group formed a critical steric configuration relates to the 
bonding site. The selectivity profile of RM68 is unprecedented and is certain to be of great 
interest to the field. 
 
Conclusions 
The IPSC decay time constants of the three isoforms varied over a wide range (45 - 
184 ms) and were largely dominated by the respective intrinsic channel deactivation rates. 
As IPSC duration is an important determinant of neuronal network functions including signal 
integration, oscillations and output firing rates, our results suggest that IPSCs mediated by 
the three major α5-containing isoforms may exert dramatically different effects on network 
activity. We also quantified the effects of four α5-specific inverse agonists on IPSCs 
mediated by the three isoforms. Each of the four compounds inhibited IPSC amplitudes and 
durations, although with unique isoform-specific efficacies. MRK-016 also significantly 
accelerated IPSC rise times. The results may help provide a basis for understanding how 
the drugs are likely to differentially affect network activity. By comparing IPSC rise times, we 
infer that α5β1γ2L GABAARs are mainly located in the postsynaptic density whereas the 
other two isoforms are predominantly perisynaptic. We also present evidence that the 
α5β3γ2L GABAAR is tonically active, whereas α5β1γ2L and α5β2γ2L GABAARs are not. 
The physiological and pharmacological characterisation we present here provides a 
reference for future studies seeking to identify and characterize the synaptic properties of 
α5-containing GABAAR isoforms in neurons. 
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ABSTRACT 
 
Mutations in synaptic NMDA receptors (NMDARs) are associated with epilepsy and 
neurodevelopmental disorders. The effects of NMDAR mutations have been investigated on 
recombinantly-expressed NMDARs activated under steady-state conditions. However, 
because synaptic NMDARs are exposed to glutamate for extremely brief periods, the 
steady-state experiments have provided limited insight into how mutations affect 
synaptically-activated NMDARs. It is important to define the effects of mutations on synaptic 
currents mediated by defined NMDAR isoforms to both understand epileptogenic 
mechanisms and design optimal therapies for particular epilepsy genotypes. Here we 
evaluated the effects of the GluN2AN615K, GluN2BN615I and GluN2BV618G gain-of-function 
epilepsy mutations on synaptic currents mediated by diheteromeric GluN1/2A, GluN1/2B or 
triheteromeric GluN1/2A/2B receptors. These are most abundant NMDAR isoforms in vivo, 
and no mutation has yet been tested on triheteromers. Subunit composition was controlled 
by recording from ‘artificial’ synapses formed between primary cultured neurons (which 
provide presynaptic terminals) and HEK293 cells that express the NMDAR subunits of 
interest plus neuroligin-1B. When incorporated into diheteromeric receptors, the mutations 
ablated voltage-dependent Mg2+ block. Indeed, contrary to the normal physiological 
response, increasing external Mg2+ from 0 to 1 mM strongly enhanced synaptic current 
magnitude. By enhancing neuronal excitability, these effects would contribute directly to 
epilepsy phenotypes. The mutations also diminished the potency of the anti-epileptic pore-
blocker, memantine, thus providing a molecular explanation for the lack of memantine 
efficacy in patients with GluN2BN615I or GluN2BV618G mutations. These findings provide a 
comprehensive account of the unusual effects of these mutations on the major synaptic 
NMDAR isoforms. 
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INTRODUCTION 
 
Epilepsy is a spectrum of neurological disorders that involves recurrent seizures 
(Fisher et al., 2014). Around 30 % of patients are refractory to pharmacological treatments 
(Regesta and Tanganelli, 1999; Luciano and Shorvon, 2007) partly because the underlying 
causes of many epilepsies are unknown (Berg et al., 2010; Merwick et al., 2012). With the 
development of next-generation DNA sequencing, the rate of identification epilepsy 
susceptibility genes has increased considerably (Merwick et al., 2012). Many of these genes 
encode synaptic proteins, including excitatory N-methyl-D-aspartic acid receptor (NMDAR) 
subunits (Endele et al., 2010; Lemke et al., 2013; Lesca et al., 2013). Individuals who harbor 
mutations in NMDAR subunits present with epilepsies ranging in severity from benign focal 
epilepsy to epileptic encephalopathies, with the latter often associated with impaired speech 
development, intellectual disability, autism and psychiatric disorders (Endele et al., 2010; 
Lesca et al., 2012; Lemke et al., 2013; Lesca et al., 2013; Kenny et al., 2014). It is essential 
to resolve the mechanisms by which these mutations affect NMDAR-mediated excitatory 
postsynaptic currents (EPSCs) to both understand epileptogenic mechanisms and design 
optimal therapies for particular epilepsy genotypes.  
NMDARs are glutamate-gated cation channels that mediate excitatory 
neurotransmission in the brain. Seven NMDAR subunits have been identified: GluN1, 
GluN2A-D, GluN3A-B. NMDARs are tetrameric oligomers that typically comprise two GluN1 
subunits with either two GluN2 subunits or a mixture of GluN2 and GluN3 subunits. The 
most prevalent stoichiometries in native synapses are the diheteromeric GluN1-GluN2A 
(GluN1/2A) and GluN1-GluN2B (GluN1/2B) isoforms and the triheteromeric GluN1-GluN2A-
GluN2B (GluN1/2A/2B) isoform (Traynelis et al., 2010). These isoforms exhibit distinct 
spatial and temporal expression patterns, kinetics and pharmacological profiles. For 
example, GluN1/2B-containing receptors predominate extrasynaptically in immature 
neurons where they exhibit longer channel open times and high sensitivity to the inhibitor, 
ifenprodil (Traynelis et al., 2010). By adulthood these receptors have largely been replaced 
by GluN1/2A-containing receptors that are insensitive to ifenprodil and mediate fast-
decaying EPSCs.  
A variety of mutations in the GRIN2A and GRIN2B genes have been linked to 
epilepsy (Endele et al., 2010; Reutlinger et al., 2010; Lesca et al., 2012; Carvill et al., 2013; 
Lemke et al., 2013; Lesca et al., 2013). Although most mutations characterised to date are 
loss-of-function, three mutations in the pore-lining M2 domain have been characterised as 
gain-of-function. These include N615K in GRIN2A (Endele et al., 2010) and N615I and 
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V618G in GRIN2B (Lemke et al., 2014). All three mutations lie adjacent to the pore Mg2+ 
binding site (Wollmuth et al., 1998a) where they have been shown to reduce voltage-
sensitive Mg2+ block (Lemke et al., 2014; Marwick et al., 2015).  
Here we sought to understand how the GluN2AN615K, GluN2BN615I and GluN2BV618G 
mutations affect the physiological and pharmacological properties of NMDAR-mediated 
EPSCs. Although expressing the relevant NMAR subunits in recombinant expression 
systems permit the study of defined NMDAR isoforms, it is difficult to replicate the fast 
glutamate dynamics that exist in the synapse. Hence, to date recombinantly-expressed 
NMDARs have only been investigated under steady-state glutamate activation conditions 
(Lemke et al., 2014; Marwick et al., 2015; Mullier et al., 2017; Fedele et al., 2018; Vyklicky 
et al., 2018). An alternate method is to overexpress GluN2BN615I and GluN2BV618G mutant 
subunits in neurons and characterise changes in NMDAR-mediated EPSCs (Fedele et al., 
2018). The problem with this approach is that the stoichiometries of the investigated synaptic 
NMDARs may be variable and cannot be ascertained. We circumvented both problems by 
using an engineered ‘artificial’ synapse preparation (Biederer and Scheiffele, 2007; Zhang 
et al., 2015). This technique involves co-culturing cortical neurons with HEK293 cells that 
recombinantly express the NMDA subunits of interest plus neuroligin-1B, a synapse-
promoting molecule. The cortical neurons efficiently form presynaptic contacts onto the 
HEK293 cells. EPSCs mediated by defined NMDAR isoforms can then be recorded from 
HEK293 cells. Here we use this approach in combination to evaluate the effects of the three 
mutations on EPSCs mediated by diheteromeric and triheteromeric NMDARs comprising 
GluN1, GluN2A and GluN2B subunits. 
 
MATERIALS AND METHODS 
 
Primary neuronal cultures 
Cortical neurons were harvested from Wistar rat embryos of both sexes at embryonic 
day 18 (University of Queensland, Institutional Breeding Colony). Euthanasia of timed-
pregnant rats was performed via CO2 inhalation as approved by the University of 
Queensland Animal Ethics Committee (approval number: QBI/142/16/NHMRC/ARC).  
 
HEK293 cell culture 
HEK293 cells were obtained from ATCC (#CRL-1573). Cells were cultured at 37°C 
with 5% CO2, in Dulbecco’s modified Eagles medium (DMEM) with 10 % fetal bovine serum. 
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Cells were transiently transfected via a calcium phosphate precipitation protocol. Cells were 
passaged once or twice a week and were used until the 30th passage. 
 
cDNA site-directed mutagenesis, cell culture and transfection 
The human NMDAR GluN1 (isoform GluN1-4b), GluN2A and GluN2B cDNAs were 
cloned into the pRK5 expression vector (with CMV promoter) with optimised Kozak 
sequences. Site-directed mutagenesis using the QuikChange Lightning kit (Stratagene, 
Agilent Technologies) was used to generate GluN2A and GluN2B mutants, which were 
confirmed by Sanger DNA sequencing. Methods for preparing neurons and HEK293 cells 
for artificial synapse recordings have previously been described in detail (Dixon et al., 2015). 
Briefly, HEK293 cells were transfected with cDNAs encoding human GluN1, GluN2A, 
GluN2B subunits (all in the pRK5 expression vector) plus empty pEGFP and mouse 
neuroligin 1B (Addgene #15261; in the pCAAGS expression vector) in a ratio of 1:1:1:0.5:1, 
using a calcium-phosphate co-precipitation protocol. Euthanasia of timed-pregnant rats was 
performed via CO2 inhalation as approved by the University of Queensland Animal Ethics 
Committee (approval number: QBI/142/16/NHMRC/ARC). The cerebral cortices of e18 rat 
embryos were dissected out, triturated and plated on poly-D-lysine coated coverslips at a 
density of ~100 x 103 cells per coverslip. The cells were plated into Dulbecco’s modified 
Eagles medium with 10 % fetal bovine serum and this was replaced after 24 h with 
Neurobasal medium, including 2 % B27 and 1 % glutamax. After one week, half of this 
medium was replaced with fresh medium. Neurons were allowed to grow for 3-4 wk before 
freshly transfected HEK293 cells were plated onto the neurons. Artificial synaptic 
connections typically formed spontaneously within 24 h and EPSCs in HEK293 cells were 
recorded by whole-cell patch clamp between 2-5 d later. Spontaneous EPSCs were 
recorded from transfected HEK293 cells identified by their strong green fluorescence. The 
voltage-step experiments described in Figure 4-1 were performed on isolated HEK293 cells 
that were not in co-culture with neurons. 
 
Electrophysiology 
All electrophysiological experiments were performed at room temperature (22 ± 2 °C). 
Artificial synapse recordings were performed in the whole-cell patch clamp recording 
configuration at a holding potential of −70 mV unless otherwise stated. Patch pipettes were 
fabricated from borosilicate hematocrit tubing (Harvard Apparatus, Germany) and had tip 
resistances of 2-5 MΩ when filled with the intracellular solution which contained (in mM): 
145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, and 10 EGTA, adjusted to pH 7.4 with CsOH. Cells 
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were perfused with extracellular solution, which contained (in mM): 140 NaCl, 5 KCl, 2 
CaCl2, 10 HEPES and 10 D-glucose, adjusted to pH 7.4 with NaOH. Synaptic currents were 
filtered (−3dB, 4-pole Bessel) at 4 kHz and sampled at 10 kHz and recorded using a 
Multiclamp 700B amplifier and pClamp 10 software (Molecular Devices, Sunnyvale, CA, 
USA). Recordings with series resistance above 20 MΩ were discarded. Capacitance of the 
HEK293 cells was typically 20 pF, resulting in a typical corner frequency of 398 Hz. Because 
this was satisfactory for our experiments, series resistance compensation was not applied. 
Where drugs were applied, the events from the wash phase were averaged with the pre-
drug period to control for any run-down or run-up. Solutions containing defined 
concentrations of glutamate, glycine, Mg2+, ifenprodil or memantine were applied to cells via 
gravity induced perfusion via parallel microtubules. Ifenprodil (+)-tartrate salt was dissolved 
in water as a 10 mM stock solution. Memantine hydrochloride dissolved in dimethylsulfoxide 
as a 100 mM stock solution. All the chemicals employed in the study were obtained from 
Sigma-Aldrich. Sliding templates in Axograph X were used to identify synaptic events. 10-
90% rise times were recorded and mono-exponential simplex fits applied to the decay period 
of individual events, which were then averaged for each cell. 
Conventional whole-cell recordings of glutamate- and glycine-gated currents in 
transfected HEK293 cells were performed using intracellular and extracellular solutions as 
described in the previous paragraph. In these experients, currents were filtered at 1 kHz and 
digitised at 2 kHz. Solutions containing defined concentrations of glutamate, glycine, Mg2+ 
were applied to cells via gravity induced perfusion through parallel microtubules. Whole-cell 
current-voltage (I-V) experiments were performed by holding the membrane potential at 0 
mV, then stepping the voltage from −100 to +100 mV for 500 ms in 20 mV increments. Leak 
currents recorded in the absence of both glutamate and glycine were digitally subtracted to 
produce the resultant I-V relationship. All currents were normalized to the +40 mV current in 
0 Mg2+ recorded from the same cell. 
 
Statistical analysis  
Data sets were first tested for normal distribution prior to using one-way ANOVA 
(followed by Bonferroni post-hoc test) or paired t-test as indicated below to determine 
statistical significance. In all experimental analyses, p < 0.01 was taken as the significance 
threshold, with ** and *** representing significance levels of p ≤ 0.01 and p ≤ 0.001, 
respectively. The tests were conducted with SigmaPlot s14.0 software. All data are 
presented as mean ± SEM, with n values (representing the total number of cells or patches) 
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presented within the bars of bar plots. Graphs were rendered in Sigmaplot 14.0 and figures 
were assembled using Adobe Illustrator. 
 
RESULTS 
 
Effects of mutations on the Mg2+ sensitivity of NMDARs 
GluN2AN615K, GluN2BN615I and GluN2BV618G mutations lie close to the pore-lining Mg2+ 
binding site and previous studies have demonstrated that they reduce voltage-dependent 
Mg2+ block in diheteromeric NMDAR isoforms (Lemke et al., 2014; Marwick et al., 2015; 
Fedele et al., 2018). We sought to repeat these experiments: to 1) quantify Mg2+ potentiation 
by recording current-voltage (I-V) relations in both the absence and presence of Mg2+ in the 
same cell, and 2) to ensure the ionic conditions of these experiments were identical to the 
synaptic current experiments described below. Thus, we analysed Mg2+ block and 
potentiation on the two wild-type (WT) and three mutant diheteromeric NMDAR isoforms.  
Currents were activated by applying saturating concentrations of glutamate (300 µM) 
and glycine (100 µM) to HEK293 cells expressing GluN1/2A, GluN1/2AN615K, GluN1/2B, 
GluN1/2BN615I and GluN1/2BV618G receptors, in both 0 and 1 mM Mg2+. Note that the ‘0 Mg2+’ 
solution was nominally Mg2+-free (i.e., it contained no divalent cation chelator). In Figure 4-
1 A-E, we show sample currents in response to voltage-step experiments recorded 
sequentially in 1 and 0 mM extracellular Mg2+ from the same cell. Averaged I-V relationships, 
measured from n ≥ 7 cells each, are presented in the right-hand panels of Figures 4-1 A-E. 
All data points recorded from a given cell have been normalised to the +40 mV value 
recorded in 0 Mg2+ in that cell. 
As expected, GluN1/2A receptors exhibited voltage-dependent Mg2+ block at 
negative potentials that was abolished in 0 Mg2+ (Figure 4-1 A). In addition, 1 mM Mg2+ also 
potentiated the saturating current. This effect was evident at positive potentials where it was 
not confounded by voltage-dependent Mg2+ block. This potentiating action of Mg2+ has 
previously been described (Paoletti et al., 1995; Wang and MacDonald, 1995). By contrast, 
GluN1/2AN615K receptors exhibited a linear I-V relationship in 0 Mg2+, which was enhanced 
in a voltage-independent manner by 1 mM Mg2+ (Figure 4-1 B). Thus, the N615K mutation 
ablates voltage-dependent Mg2+ block but not the potentiating effect of Mg2+. This lack of 
voltage-dependence implies a discrete positive modulatory Mg2+ site lying outside the 
membrane electrical field. The linearized I-V was not surprising: it has been previously 
shown that mutations to N615 in the GluN2A subunit pore-lining domain eliminate voltage-
dependent Mg2+ block (Wollmuth et al., 1998a). 
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Figure 4-1. 
Effects of Mg2+ on 
I-V relationships 
of whole cell 
currents 
mediated by WT 
and mutant 
diheteromeric 
receptors in 
HEK293 cells. In 
all experiments, 
currents were 
activated by 300 
µM glutamate 
plus 100 µM 
glycine. The ‘0 
Mg2+’ solution 
was nominally 
Mg2+-free. A. Left 
panel: Examples 
of glutamate-
gated currents 
mediated by 
GluN1/2A 
receptors in the 
absence and 
presence of 1 mM 
Mg2+. Center 
panel: I-V 
relationships 
recorded in the 
absence and 
presence of 1 mM 
Mg2+. The holding voltage was -70 mV. Cells were initially stepped to 0 mV and then to 
voltages from -100 to +100 mV for 500 ms in 20 mV increments. Leak currents recorded in 
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the absence of glutamate and glycine were digitally subtracted to produce the displayed 
recordings. Right panel: averaged, leak-subtracted I-V relationships in the absence and 
presence of 1 mM Mg2+. The 0 Mg2+ and 1 Mg2+ I-Vs were recorded from the same 6 cells 
and all data points are normalised to the +40 mV data point in 0 Mg2+. In this and all 
subsequent panels, error bars are shown when larger than symbol size. All data points were 
averaged from at least 6 cells. B-E. As for A but with currents recorded from HEK293 cells 
expressing the diheteromeric receptors as indicated. 
 
GluN1/2B receptors also exhibited the expected voltage-dependent Mg2+ block at 
negative potentials (Figure 4-1 C). However, 1 mM Mg2+ did not elicit the potentiating effect 
that was observed with GluN1/2A receptors (compare Figure 4-1 A, C). The GluN1/2BN615I 
and GluN1/2BV618G receptors also exhibited near linear I-V relationships in 0 Mg2+, which 
were both enhanced in a voltage-independent manner by 1 mM Mg2+ (Figure 4-1 D, E). This 
potentiating effect of extracellular Mg2+ on mutant GluN1/2A receptors is surprising given it 
was not observed in the corresponding WT receptor (Figure 4-1 C). Thus, we conclude that 
the three epilepsy mutations abolish voltage-dependent Mg2+ block but also reveal a 
voltage-independent potentiating effect of Mg2+ that is particularly evident at positive 
potentials.  
 
Properties of EPSCs mediated by WT NMDARs 
We next sought to determine the physiological and pharmacological properties of 
spontaneous EPSCs mediated by WT diheteromeric GluN1/2A and GluN1/2B NMDARs and 
WT triheteromeric GluN1/2A/2B NMDARs in artificial synapses. Sample recordings of 
spontaneous EPSCs mediated by each receptor isoform, revealing Mg2+ block at -70 mV, 
are presented in Figure 4-2 A-C. From each cell we collected and digitally averaged all well-
isolated EPSCs recorded in the absence and presence of 1 mM Mg2+, separately. These 
averaged currents were normalised to peak amplitude and overlayed (Figure 4-2 A-C, right 
panels). The results suggest that the EPSCs mediated by each isoform were not greatly 
affected by changes in external Mg2+ concentration. Figure 4-2 D, which displays the same 
six waveforms grouped according whether they were recorded in 0 or 1 mM Mg2+, suggests 
that the EPSCs in cells transfected with GluN1, GluN2A and GluN2B subunits decayed with 
a mean time constant that was intermediate between those mediated by GluN1/2A and 
GluN1/2B receptors. The mean amplitudes, 10 – 90 % rise times and decay time constants 
of EPSCs derived from the analysis of these digitally averaged waveforms in these and all 
mutant constructs are summarised in Table 4-1 and presented as bar plots in subsequent 
figures.  
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The respective mean amplitudes of EPSCs recorded from cells expressing GluN1/2A, 
GluN1/2B and presumptive triheteromeric GluN1/2A/2B receptors in the absence and 
presence of 1 mM Mg2+ are displayed in Figure 4-2 E, confirming strong block by Mg2+  at -
70 mV in each case. Mean rise times of EPSCs mediated by GluN1/2B and presumptive 
GluN1/2B/2A receptors were found to be significantly slower than those mediated by 
GluN1/2A receptors (Figure 4-2 F), but were not significantly Mg2+-dependent. The EPSC 
decay time constants were not significantly Mg2+-dependent for GluN1/2A and GluN1/2B 
receptors although 1 mM Mg2+ induced a significant slowing in the EPSC decay rate for 
presumptive GluN1/2A/2B receptors (Figure 4-2 G). Furthermore, as suggested by the 
sample traces in Figure 4-2 D, the mean decay time constant of EPSCs mediated by 
presumptive GluN1/2A/2B receptors (89 ± 8 ms in 0 Mg2+) was intermediate between those 
mediated by GluN1/2A receptors (43 ± 5 ms in 0 Mg2+) and GluN1/2B receptors (204 ± 11 
ms in 0 Mg2+) (Figure 4-2 G). The decay rates for GluN1/2A and GluN1/2B receptors 
correspond well with those reported in a previous artificial synapse study (50 and 340 ms, 
respectively) (Fu et al., 2003).  
These results are also in close agreement with data from native hippocampal 
neurons. For example, Rauner and Kohr reported that EPSCs mediated by GluN2A- and 
GluN2B-containing receptors decayed with time constants of 34 and 306 ms, respectively 
(Rauner and Kohr, 2011), whereas Tovar et al. observed respective decay time constants 
of 23 and 315 ms (Tovar et al., 2013). The mean decay time constants of EPSCs mediated 
by triheteromeric GluN1/2A/2B receptors have previously been found to lie between those 
mediated by GluN1/2A and GluN1/2B receptors in hippocampal neurons (Rauner and Kohr, 
2011; Tovar et al., 2013). A similar observation applies to the rank order of deactivation rates 
of the three receptors when expressed in recombinant expression systems (Hansen et al., 
2014; Stroebel et al., 2014). However, as with previous studies investigating the properties 
of triheteromeric NMDARs (Rauner and Kohr, 2011; Tovar et al., 2013; Hansen et al., 2014; 
Stroebel et al., 2014; Bhattacharya et al., 2018), we sought to strengthen the case for the 
existence of triheteromeric GluN1/2A/2B receptors via a pharmacological analysis. 
We first investigated the effects of the GluN2B-specific inhibitor, ifenprodil on WT 
triheteromers. As a control, we first applied 1 µM ifenprodil to EPSCs mediated by WT 
GluN1/2B NMDARs and observed marked inhibition (57 ± 6 %, n = 10, p < 0.001 by paired 
t-test; Figure 4-2 H). In contrast, EPSCs mediated by cells transfected simultaneously with 
GluN1, GluN2A and GluN2B subunits were not significantly affected by 1 µM ifenprodil 
(Figure 4-2 I).  
93 
 
  
Figure 4-2. Properties of EPSCs mediated by diheteromeric GluN1/2A, GluN1/2B and 
triheteromeric GluN1/2A/2B receptors in artificial synapses. A. An example recording of 
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spontaneous EPSCs recorded from HEK293 cells expressing GluN1/2A receptors in 0 and 
1 mM Mg2+-containing external solution. Digitally averaged EPSC waveforms averaged from 
50-500 events in 0 and 1 Mg2+ are shown normalized and superimposed in the right-hand 
panel. B. As for A, except HEK293 cells expressed GluN1/2B receptors. C. As for A, except 
HEK293 cells expressed GluN1/2A/2B receptors. D. Examples of normalised, digitally-
averaged EPSC waveforms from the three isoforms superimposed separately according to 
whether they were recorded in 0 Mg2+ (left panel) or 1 mM Mg2+ (right panel). E. Mean 
amplitude of EPSCs recorded in both 0 and 1 mM Mg2+ from cells expressing the indicated 
subunit combinations. In this and all subsequent bar plots, n values for each observation are 
provided within bars. *** p ≤ 0.001 by one way ANOVA. F. Mean 10-90 % rise times of 
EPSCs recorded in both 0 and 1 mM Mg2+ from cells expressing the indicated subunit 
combinations. *** p  ≤ 0.001 by one way ANOVA (n = 6) between 0 mM GluN1/2A and 0 mM 
GluN1/2B, 1 mM GluN1/2B, 0 mM GluN1/2A/2B or 1 mM GluN1/2A/2B.  G. Mean decay 
time constants of EPSCs recorded in both 0 and 1 mM Mg2+ from cells expressing the 
indicated subunit combinations. ** p  ≤ 0.01, *** p  ≤ 0.001 by one way ANOVA. H.  Sample 
recording showing the inhibitory effect of 1 µM ifenprodil on EPSCs mediated by GluN1/2B 
receptors. J. Sample recording showing the lack of inhibitory effect of 1 µM ifenprodil on 
EPSCs mediated by GluN1/2A/2B receptors. K. The mean effect of ifenprodil on the 
amplitudes (left panel), 10-90 % rise times (middle panel) and decay time constants (right 
panel) of EPSCs recorded in 0 mM Mg2+ from cells expressing GluN1/2B and GluN1/2A/2B 
receptors. *** p ≤ 0.001 by paired t-test. Displayed results have been normalised to the pre-
ifenprodil control values from the same cell. 
 
The mean effects of 1 µM ifenprodil, normalised to the pre-ifenprodil control values 
from the same cell, are presented in Figure 4-2 J and confirm that the amplitude of EPSCs 
mediated by GluN1/2B diheteromers were significantly inhibited by ifenprodil whereas those 
mediated by presumptive GluN1/2A/2B triheteromers were not affected (Figure 4-2 J, left 
panel). However, ifenprodil had no significant effects on EPSC rise or decay times at either 
receptor isoform (Figure 4-2 J, middle and right panels). The lack of effect of ifenprodil on 
presumptive GluN1/2A/2B triheteromers is consistent with previous studies showing that it 
exerted only a weak inhibitory effect on tonically-activated recombinant GluN1/2A/2B 
receptors (Hansen et al., 2014; Stroebel et al., 2014). Thus, three lines of evidence (i.e., the 
intermediate decay rate of EPSCs, the Mg2+-sensitivity of EPSC decay and the lack of 
ifenprodil inhibition) strongly suggest that when the three subunits are co-transfected, the 
predominant synaptic isoform formed is the triheteromeric GluN1/2A/2B receptor. 
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Properties of EPSCs mediated by NMDARs containing the GluN2AN615K mutation 
A similar set of experiments was carried out on cells transfected with the GluN1, 
GluN2B and mutant GluN2AN615K subunits in diheteromeric and triheteromeric combinations. 
A sample recording of EPSCs from cells expressing diheteromeric GluN1/2AN615K receptors 
is shown in Figure 4-3 A. A surprising result is that these EPSCs exhibited a reverse Mg2+ 
sensitivity compared to WT receptors. The averaged data confirmed that 1 mM Mg2+ strongly 
enhanced rather than reduced EPSC peak amplitudes (Figure 4-3 B). We next compared 
the amplitudes, rise times and decay time constants of EPSCs mediated by diheteromeric 
GluN1/2AN615K receptors with those mediated by WT GluN1/2A receptors. In 1 mM Mg2+, 
the GluN1/2AN615K receptor mediated EPSCs with significantly larger mean peak amplitudes 
than to the corresponding WT receptor (Figure 4-3 C, left panel), as expected given its 
reverse Mg2+ sensitivity. The EPSC rise times in the presence of 1 mM Mg2+ were 
significantly slower for GluN1/2AN615K versus GluN1/2A receptors, but no difference was 
observed in the EPSC decay rates (Figure 4-3 C, middle and right panels). 
We next investigated the effects of Mg2+ and ifenprodil on EPSCs mediated by 
triheteromeric receptors formed following the transfection of GluN1, GluN2AN615K and 
GluN2B subunits and compared these to WT triheteromers.  A sample recording of EPSCs 
mediated by GluN1/2AN615K/2B receptors (Figure 4-3 D) suggests strong block by 1 mM 
Mg2+. Figure 3E shows an overlay of normalised, digitally averaged EPSCs from WT 
GluN1/2A/2B and GluN1/2AN615K/2B receptors in both 0 and 1 mM Mg2+, suggesting strong 
Mg2+-dependence of the mutant triheteromeric receptor EPSC decay rate. Mean data from 
many averaged traces are presented in Figure 4-3 F and G. Figure 3F provides a 
comparison of EPSC amplitudes in 1 mM Mg2+ and rise times and decay rates for 
GluN1/2A/2B and GluN1/2AN615K/2B receptors in 0 mM Mg2+. The amplitudes and rise times 
were not significantly different, although the decay rates of GluN1/2AN615K/2B receptors were 
dramatically slower in 1 mM Mg2+ (see also Figure 4-3 E). In Figure 3G we demonstrate that 
1 mM Mg2+ inhibited the amplitudes and accelerated the decay rates of EPSCs mediated by 
the two receptors to a similar extent. A full comparison of EPSC amplitudes, rise times and 
decay time constants for all WT and mutant triheteromeric receptors in 0 and 1 mM Mg2+ is 
provided in Figure 4-4.  
 
96 
 
Figure 4-3. Properties of EPSCs mediated by diheteromeric GluN1/2A(N615K) and 
triheteromeric GluN1/2AN615K/2B receptors. A. Sample recording of spontaneous EPSCs 
recorded from HEK293 cells transfected with GluN1/2AN615K subunits in both 0 and 1 mM 
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Mg2+-containing external solution. B. Comparison of mean EPSC amplitudes recorded in 
both 0 and 1 mM Mg2+. *** p ≤ 0.001 by one way ANOVA.  C. Comparison of mean EPSC 
amplitudes (left panel), rise times (middle panel) and decay time constants (right panel) 
mediated by GluN1/2A and GluN1/2AN615K receptors in 1 mM Mg2+. *** p ≤ 0.001 by one way 
ANOVA between receptor types.  See Table 1 for full EPSC datasets in 0 and 1 mM Mg2+.  
D.  Sample recording showing the inhibitory effect of 1 mM Mg2+ on EPSCs mediated by 
triheteromeric GluN1/2AN615K/2B receptors. E. Examples of superimposed, normalised and 
digitally-averaged EPSCs in 0 and 1 mM Mg2+ for the triheteromeric GluN1/2A/2B and 
GluN1/2AN615K/2B receptors. F. Comparison of mean amplitudes (left panel), rise times 
(middle panel) and decay time constants (right panel) of EPSCs mediated by triheteromeric 
GluN1/2A/2B and GluN1/2AN615K/2B receptors. *** p ≤ 0.001 by one way ANOVA between 
receptor types. G. Comparison of the effect of 1 mM Mg2+ on the amplitudes (left panel) and 
decay time constants (right panel) of EPSCs recorded from cells expressing triheteromeric 
GluN1/2A/2B and GluN1/2AN615K/2B receptors. All data were normalised to the 
corresponding 0 Mg2+ control values in the same cell. ** p ≤ 0.01 by paired t-test. H. 
Comparison of the effect of 1 mM ifenprodil on the amplitudes of EPSCs recorded in 0 mM 
Mg2+ from cells expressing GluN1/2B, GluN1/2A/2B and GluN1/2AN615K/2B receptors. All 
data were normalised to the corresponding pre-ifenprodil control values in the same cell. *** 
p ≤ 0.001 by paired t-test. 
 
Finally, we observed no detectable ifenprodil block in cells transfected with GluN1, 
GluN2AN615K and GluN2B subunits (Figure 4-3 H). The pronounced inhibitory effect of Mg2+ 
on the GluN1/2AN615K/2B receptors indicates the virtual complete absence of diheteromeric 
GluN1/2AN615K receptors, and the complete absence of ifenprodil inhibition indicates the 
virtual complete absence of GluN1/2B receptors. It is notable that 1 mM Mg2+ caused a 
significant acceleration of the decay rate of EPSCs mediated by WT and GluN2AN615K-
containing triheteromeric receptors (Figure 4-3 G, middle panel), because this effect does 
not pertain to EPSCs mediated by either GluN1/2A or GluN1/2B diheteromeric receptors 
(Figure 4-2). Together, these observations provide strong evidence for the predominant 
expression of the triheteromeric GluN1/2AN615K/2B receptor in artificial synapses following 
transfection with the three component subunits.  
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Figure 4-4. Comparison of the 
properties of EPSCs mediated by 
WT and triheteromeric NMDARs in 
0 and 1 mM Mg2+. A.  Comparison 
of EPSC amplitudes. B. 
Comparison of EPSC rise times. C. 
Comparison of EPSC decay time 
constants. ** p ≤ 0.01, *** p ≤ 0.001 
by one way ANOVA between 
receptor types. ** p ≤ 0.01 and *** p 
≤ 0.001 by paired t-test within 
receptor types. 
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Properties of EPSCs mediated by NMDARs containing the GluN2BN615I and 
GluN2BV618G mutations 
We next investigated EPSCs mediated by NMDARs containing the GluN2BN615I and 
GluN2BV618G mutations in diheteromeric and triheteromeric subunit combinations. Sample 
recordings of EPSCs from cells expressing diheteromeric GluN1/2BN615I (Figure 4-5 A) and 
GluN1/2BV618G (Figure 4-5 B) receptors suggest that these GluN2B mutations also reverse 
the sensitivity to extracellular Mg2+ when compared to the WT GluN1/2B receptors. The 
averaged results confirm that 1 mM Mg2+ strongly increased the mean EPSC current 
amplitude in both mutant NMDARs (Figure 4-5 C). We next compared the amplitudes, rise 
and decay times of EPSCs mediated by the GluN1/2BN615I and GluN1/2BV618G receptors with 
those mediated by WT GluN1/2B receptors. In 1 mM Mg2+, both mutant diheteromers 
mediated EPSCs with significantly larger amplitudes relative to WT diheteromers (Figure 4-
5 D), as expected due to their reverse Mg2+ sensitivity. The EPSC rise times in the presence 
of 1 mM Mg2+ were not significantly different from WT diheteromer values (Figure 4-5 E). 
However, the GluN1/2BV618G receptor mediated EPSCs with a significantly accelerated 
decay rate relative to those mediated by GluN1/2B and GluN1/2BN615I receptors (Figure 4-5 
F). 
Next, we analysed EPSCs recorded from HEK293 cells transfected with GluN1, 
GluN2A and GluN2BN615I or GluN2BV618G subunits. Sample artificial synapse recordings 
suggest strong block by 1 mM Mg2+ of GluN1/2A/2BN615I receptors but no apparent block of 
GluN1/2A/2BV618G receptors (Figure 4-5 G, H). This effect, quantified in Figure 6I, confirms 
the Mg2+-resistance of GluN1/2A/2BV618G receptors. We next compared the amplitudes, rise 
times and decay time constants of EPSCs mediated by all three triheteromers in 0 and 1 
mM Mg2+. Both datasets are displayed in Table 1 although only the 0 Mg2+ data are plotted 
in Figure 4-5 J-L. We found that EPSC decay time constants did not vary significantly among 
the three triheteromeric receptors in either 0 or 1 mM Mg2+. However, amplitudes of EPSCs 
in 0 Mg2+ were significantly larger for GluN1/2A/2BN615I receptors than for either 
GluN1/2A/2B or GluN1/2A/2BV618G receptors (Figure 4-5 J). Rise times of EPSCs in 0 Mg2+ 
were significantly slower for GluN1/2A/2BV618G receptors than for either GluN1/2A/2B or 
GluN1/2A/2BN615I receptors (Figure 4-5 K). 
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Figure 4-5. Properties of EPSCs mediated by diheteromeric and triheteromeric receptors 
incorporating GluN2BN615I or GluN2BV618G mutant subunits. A, B. Sample recordings of 
spontaneous EPSCs recorded from HEK293 cells transfected with GluN1/2BN615I or 
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GluN1/2BV618G subunits, respectively, in 0 and 1 mM Mg2+-containing external solutions. C. 
Mean amplitude of EPSCs mediated by both mutant diheteromers in 0 and 1 mM Mg2+. *** 
p ≤ 0.001 by paired t-test.  D - F. Comparison of mean EPSC amplitudes (D), rise times (E) 
and decay time constants (F) for diheteromeric GluN1/2B, GluN1/2BN615I and GluN1/2BV618G 
receptors in 1 mM Mg2+. *** p ≤ 0.001 by one way ANOVA between receptor types. G, H. 
Sample recordings of spontaneous EPSCs recorded from HEK293 cells transfected with 
triheteromeric GluN1/2A/2BN615I or GluN1/2A/2BV618G receptors, respectively, in 0 and 1 mM 
Mg2+-containing external solutions. I. Comparison of the effect of 1 mM Mg2+ on the 
amplitudes of EPSCs recorded from cells expressing triheteromeric GluN1/2A/2B, 
GluN1/2A/2BN615I and GluN1/2A/2BV618G receptors. All data were normalised to the 
corresponding 0 Mg2+ control values in the same cell. ** p ≤ 0.01, *** p ≤ 0.001 by paired t-
test. J-L. Comparison of mean EPSC amplitudes (J), rise times (K) and decay time 
constants (L) for EPSCs mediated by triheteromeric GluN1/2A/2B, GluN1/2A/2BN615I and 
GluN1/2A/2BV618G receptors in 0 mM Mg2+. ** p ≤ 0.01, *** p ≤ 0.001 by one way ANOVA 
between receptor types. 
 
In conclusion, if HEK293 cells transfected with GluN1, GluN2A and GluN2BN615I 
subunits formed predominantly diheteromeric GluN1/2A and GluN1/2BN615I NMDARs then 
we would expect little net effect of 1 mM Mg2+ given that the mean amplitudes of EPSCs 
mediated by these receptors should be inhibited and enhanced by 1 mM Mg2+, respectively. 
Thus, our finding that 1 mM Mg2+ produced strong inhibition implies the dominant expression 
of triheteromeric GluN1/2A/2BN615I receptors. Similarly, the Mg2+-resistance of EPSCs in 
cells transfected with GluN1, GluN2A and GluN2BV618G subunits also implies predominant 
expression of GluN1/2A/2BV618G receptors because the otherwise substantial expression of 
GluN1/2A receptors should have resulted in detectable Mg2+ block. 
 
Effects of memantine on EPSCs mediated by WT and mutant NMDARs 
Memantine exhibits anticonvulsant properties in animal models of epilepsy (Ghasemi 
and Schachter, 2011), and is employed as an adjunct therapy in some human forms of 
epilepsy, notably those caused by gain-of-function NMDAR mutations (Pierson et al., 2014; 
Li et al., 2016). Memantine has been shown to bind in the NMDAR channel pore where it 
interacts directly with GluN1N616, with H-bonding between GluN1N616 and GluN2BN615 
stabilising memantine coordination (Limapichat et al., 2013; Fedele et al., 2018). It has also 
recently been demonstrated that the GluN2BV618G mutation reduces, whereas GluN2BN615I 
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enhances memantine block of steady-state whole-cell currents activated by saturating 
glutamate and glycine concentrations in Mg2+-free solution (Fedele et al., 2018). Here we 
sought to investigate the inhibitory potency of 10 µM memantine on EPSCs mediated by the 
WT and three mutant subunits in diheteromers and triheteromers. To maximise EPSC 
magnitudes, we employed 0 Mg2+-containing external solution for WT receptors and 1 mM 
Mg2+-containing external solution for mutant receptors. Figure 4-6 A-E displays sample 
recordings of EPSCs mediated by diheteromeric NMDAR combinations suggesting strong 
inhibition by memantine of all isoforms except GluN1/2BV618G. The averaged data (Figure 4-
6 F) confirm this effect and show that the other mutant diheteromers exhibit a similar 
memantine sensitivity to GluN1/2A or GluN1/2B receptors.  
 
 
Figure 4-6. Effects of 10 µM memantine on EPSCs mediated by WT and mutant 
diheteromeric and triheteromeric receptors.  A-E. Examples of the effects of 10 µM 
memantine of spontaneous EPSCs mediated by the indicated WT and mutant diheteromeric 
receptors. WT and mutant diheteromeric experiments were performed in 0 and 1 mM Mg2+ 
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external solution, respectively. F. Mean inhibitory effect of 10 µM memantine on indicated 
diheteromeric receptors expressed as a fraction of the control EPSC magnitude. *** p ≤ 
0.001 by paired t-test. G-I. Effect of 10 µM memantine on the amplitudes (G), rise times (H) 
and decay time constants (I) of EPSCs mediated by WT and the three mutant triheteromeric 
receptors. * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001 by paired t-test. 
 
 
Table 4-1. Properties of EPSCs mediated by all tested NMDAR isoforms in the 
absence and presence of 1 mM Mg2+ 
 
NMDAR isoform 
0 Mg2+ 1  Mg2+ 
Imax 
(pA) 
rise time 
(ms) 
decay time 
constant 
(ms) 
n Imax 
(pA) 
rise time 
(ms) 
decay time 
constant 
(ms) 
n 
GluN1/2A 225 ± 45 4.7 ± 0.6 43 ± 5 18 48 ± 3 6 ± 2 38 ± 8 6 
GluN1/2B 205 ± 63 13 ± 1 204 ± 11 22 61 ± 6 17 ± 3 195 ± 36 6 
GluN1/2AN615K 59 ± 5 n.d. n.d. 10 255 ± 38 10 ± 1 38 ± 2 12 
GluN1/2BN615I 42 ± 6 n.d. n.d. 20 232 ± 17 15 ± 1 217 ± 15 24 
GluN1/2BV618G 53 ± 8 n.d. n.d. 18 188 ± 19 17 ± 1 95 ± 6 23 
GluN1/2A/2B 189 ± 41 14 ± 2 89 ± 8 8 70 ± 28 14 ± 1 72 ± 8 8 
GluN1/2AN615K/2B 178 ± 32 15 ± 1 223 ± 34 18 77 ± 12 12 ± 1 158 ± 25 18 
GluN1/2A/2BN615I 319 ± 57 16 ± 0.3 104 ± 7 8 158 ± 32 15 ± 1 95 ± 11 8 
GluN1/2A/2BV618G 178 ± 48 19 ± 1 100 ± 8 15 189 ± 50 19 ± 2 101 ± 7 15 
 
n.d. – not determined as EPSC magnitudes were too small to permit accurate analysis. 
Statistical comparisons performed on subsets of this dataset are presented in Figures 2-5 and 6-8. 
 
Since the effects of memantine on mutant triheteromeric receptors have not 
previously been investigated, we examined the effect of 10 µM memantine on the mean 
amplitudes, rise times and decay time constants of EPSCs mediated by WT and three 
mutant triheteromeric NMDARs (containing GluN2AN615K, GluN2BN615I or GluN2BV618G; 
Figure 4-6 G-H). EPSC amplitudes mediated by all four triheteromeric receptors were 
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significantly inhibited by memantine (Figure 4-6 G). However, with the exception of 
GluN2BV618G-containing receptors, the mean inhibitory efficacy of memantine at each 
triheteromeric receptor was significantly less than for the corresponding diheteromeric 
receptor (Figure 4-7). In contrast, the EPSC rise times were not affected by memantine 
(Figure 4-6 H). However, the decay time constants of EPSCs mediated by GluN1/2A/2B 
receptors, but not by mutant receptors, were significantly accelerated by memantine (Figure 
4-6 I).  
 
 
 
 
Figure 4-7. Comparison of the effects of 10 µM memantine on EPSCs mediated by WT and 
mutant diheteromeric and triheteromeric receptors.  In each panel, the mean inhibitory effect 
of 10 µM memantine is compared for indicated diheteromeric and triheteromeric receptors 
expressed as a fraction of the control EPSC magnitude. ** p ≤ 0.01 and *** p ≤ 0.001 by one 
way ANOVA between receptor types. 
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DISCUSSION 
 
Validation of artificial synapses for the study of NMDAR epilepsy mutants 
A unique advantage of the artificial synapse system is that it permits the investigation 
of EPSCs mediated by defined NMDAR isoforms. It has long been known (Fu et al., 2003) 
that the decay time constants of GluN1/2A- and GluN1/2B-mediated EPSCs in artificial 
synapses correspond closely to those mediated by the same isoforms in neurons (Rauner, 
2011;Tovar, 2013;Traynelis, 2010) and the results of the present study are consistent with 
this. The present study also provides the first characterisation of triheteromeric GluN1/2A/2B 
NMDARs in artificial synapses. Similar to previous studies conducted in neurons (Rauner, 
2011; Tovar, 2013) or recombinant expression systems (Hansen, 2014; Stroebel, 2014), we 
found that the decay rate of EPSCs mediated by GluN1/2A/2B receptors was intermediate 
between those mediated by GluN1/2A and GluN1/2B receptors. We also found that 
GluN1/2A/2B receptor-mediated EPSCs were resistant to ifenprodil inhibition. This fits well 
with recent studies showing that ifenprodil exhibits only low efficacy inhibition of steady-state 
glutamate-gated currents mediated by recombinant GluN1/2A/2B receptors (Hansen, 2014; 
Stroebel, 2014). We also found that only GluN1/2A/2B receptors mediated EPSCs that 
decayed more slowly when Mg2+ was removed (Figure 4-2 G), consistent with a study that 
reported a similar effect on EPSCs mediated by GluN1/2A/2B receptors in neurons (Rauner 
and Kohr, 2011). Taken together, these results indicate that the artificial synapse faithfully 
recapitulates EPSC properties as mediated by the same NMDAR isoforms in neurons. 
 
Functional properties of NMDARs containing GluN2AN615K  
The GluN2AN615K variant is associated with early-onset epileptic encephalopathy and 
severe developmental delay (Endele et al., 2010). This mutation was shown to reduce Mg2+ 
block of steady-state activated GluN1/2A receptors expressed in oocytes (Marwick et al., 
2015), although its effect on NMDAR-mediated EPSCs has not previously been 
characterised. Here we demonstrated that GluN1/2AN615K-mediated EPSCs recorded at −70 
mV exhibit a novel characteristic whereby increasing Mg2+ from 0 to 1 mM greatly enhances 
EPSC magnitude. The GluN2A N615 residue is adjacent to the GluN2B N615 residue which, 
together with GluN1-N616, forms the Mg2+ coordination site (Fedele et al., 2018). The 
GluN2AN615K substitution is therefore likely to directly disrupt Mg2+ blockade. This would 
enhance neuronal excitability under physiological conditions by increasing the net cation 
influx per synaptic event.  
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EPSCs mediated by triheteromeric GluN1/2AN615K/2B receptors exhibited WT-like 
voltage-dependent Mg2+ block at −70 mV (Figure 4-3 D, G), although the EPSC decay time 
constants were dramatically slower than those mediated by WT GluN1/2A/2B receptors 
(Figure 4-3 F). This effect will also enhance neuronal excitability by increasing the amount 
of cation influx during each synaptic event.  
A preliminary study, conducted on NMDARs activated under steady-state conditions 
in Xenopus oocytes, reported reduced block by 10 µM memantine of GluN1/2AN615K relative 
to GluN1/2A receptors (Marwick et al., 2015). However, we found no significant impairment 
in memantine block of EPSCs mediated by mutant GluN1/2AN615K receptors relative to their 
WT counterparts (Figure 4-6). On the other hand, whereas 10 µM memantine significantly 
enhanced the EPSC decay rate of GluN1/2A/2B receptors, it had no effect on mutant 
GluN1/2AN615K/2B receptors (Figure 4-6 H). The GluN2AN615K mutation thus produces a 
degree of memantine resistance when incorporated into triheteromeric receptors.  
 
Functional properties of NMDARs containing GluN2BN615I  
This mutation is associated with West syndrome and severe developmental delay 
(Lemke et al., 2014) and was originally shown to reduce Mg2+ block of GluN1/2BN615I 
receptors activated under steady-state conditions in Xenopus oocytes (Lemke et al., 2014). 
A subsequent study confirmed the loss of Mg2+ block but also demonstrated that the 
mutation reduced the Ca2+ influx rate and enhanced memantine block of steady-state 
activated GluN1/2BN615I relative to GluN1/2B receptors (Fedele et al., 2018). Here we 
demonstrated that GluN1/2BN615I-mediated EPSCs also exhibit an unusual characteristic 
whereby increasing Mg2+ from 0 to 1 mM greatly enhances EPSC magnitudes. Again, even 
allowing for a reduced Ca2+ influx rate, this effect will increase the amount of cation influx 
during each synaptic event and thus increase neuronal excitability. The mutation did not 
affect rise or decay times of EPSCs mediated by diheteromeric receptors. EPSCs mediated 
by triheteromeric GluN1/2A/2BN615I receptors exhibited WT-like voltage-dependent Mg2+ 
block at -70 mV (Figure 4-5 G, I).  
In addition, the peak magnitudes of EPSCs mediated by GluN1/2A/2BN615I receptors 
were significantly larger than those mediated by GluN1/2A/2B receptors in 1 mM Mg2+ 
(Figure 4-5 J). This will also enhance neuronal excitability by increasing the amount of cation 
influx during each synaptic event. Despite a previous study reporting enhanced block by 10 
µM memantine of steady-state glutamate-activated currents in GluN1/2BN615I receptors 
(Fedele et al., 2018), we found no significant change in memantine block of EPSCs 
mediated by synaptic mutant GluN1/2BN615I receptors relative to WT diheteromers (Figure 
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4-6). On the other hand, whereas 10 µM memantine significantly enhanced the EPSC decay 
rate of GluN1/2A/2B receptors, it had no effect on mutant GluN1/2A/2BN615I receptors (Figure 
4-6 H). Thus, GluN2BN615I produces a degree of memantine resistance when incorporated 
into triheteromeric NMDARs.  
In contrast to our results, when the GluN2AN615K mutant subunit was overexpressed 
in hippocampal neurons, the resulting EPSCs exhibited an accelerated decay rate, a 
modestly reduced sensitivity to block by 1.2 mM Mg2+, and an unchanged memantine 
sensitivity (Fedele et al., 2018). One possible explanation is that the EPSCs were largely 
mediated by NMDAR isoforms not investigated here. 
 
Functional properties of NMDARs containing GluN2BV618G  
This mutation also results in West syndrome and severe developmental delay (Lemke 
et al., 2014) and eliminates Mg2+ block of steady-state activated GluN1/2BV618G receptors 
(Lemke et al., 2014); (Fedele et al., 2018). Although GluN2BV618G has little effect on the Ca2+ 
influx rate, it does render steady-state activated GluN1/2B receptors highly permeant to 
Mg2+ while dramatically impairing memantine block (Fedele et al., 2018). Here, we 
demonstrated that GluN1/2BV618G-mediated EPSCs at −70 mV are also increased in 
amplitude by increasing Mg2+ from 0 to 1 mM. EPSCs mediated by GluN1/2BV618G receptors 
also exhibited dramatically faster decay rates than those mediated by GluN1/2B receptors.  
As with the other mutations investigated here, EPSCs mediated by triheteromeric 
GluN1/2A/2BV618G receptors exhibited WT-like voltage-dependent Mg2+ block at −70 mV 
(Figure 4-5 G, I), although their respective EPSC decay time constants were not significantly 
different (Figure 4-5 L). This will enhance neuronal excitability by increasing the amount of 
cation influx during each synaptic event. Lastly, we found that memantine did not 
significantly block EPSCs mediated by GluN1/2BV618G receptors (Figure 4-6 F). Whilst 10 
µM memantine significantly enhanced the EPSC decay rate of GluN1/2A/2B receptors, it 
had no effect on mutant GluN1/2A/2BV618G receptors (Figure 4-6 H). The GluN2BV618G 
mutation therefore results in a relatively high degree of memantine resistance.  
When overexpressed in hippocampal neurons, the GluN2AV618G mutant subunit 
resulted in EPSCs that exhibited no change in the decay rate, a modestly reduced sensitivity 
to block by 1.2 mM Mg2+, and an unchanged memantine sensitivity (Fedele et al., 2018). 
These results would be expected if the dominant synaptic subtype were the triheteromeric 
GluN1/2A/2B receptors. 
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Conclusion 
 
This study provides a characterisation of EPSCs mediated by pure populations of 
GluN1/2A, GluN1/2B and GluN1/2A/2B receptors. The results conform well with previous 
studies on the same receptors expressed in neuronal synapses and thus validate artificial 
synapses as a model system for evaluating the effects of mutations on synaptically-activated 
NMDARs.  
When incorporated into diheteromeric receptors, each of the three mutations ablated 
voltage-dependent Mg2+ block. We demonstrated that increasing external Mg2+ from 0 to 1 
mM strongly enhanced EPSC magnitude, predominantly via a voltage-independent 
potentiating effect of Mg2+. The GluN2AN615K mutation resulted in a higher rate of cation 
influx at negative potentials by enhancing the magnitude of GluN1/2A-mediated EPSCs and 
slowing the decay rate of GluN1/2A/2B-mediated EPSCs. The GluN2BN615I mutation 
enhanced the magnitude of both GluN1/2B-mediated and GluN1/2A/2B-mediated EPSCs. 
The GluN2BV618G mutation also enhanced the magnitude of both GluN1/2B-mediated and 
GluN1/2A/2B-mediated EPSCs, although these effects were partly compensated by a faster 
EPSC decay rate. The mutations thereby each resulted in an enhanced cation influx rate 
which would dramatically increase neuronal excitability and contribute directly to the 
epilepsy phenotype. Importantly, the mutations also reduced the potency of the use-
dependent blocker, memantine, with the GluN2BV618G mutation having the largest 
deleterious effect by virtue of its complete ablation of memantine inhibitory efficacy in the 
GluN1/2BV618G receptor. Our data also explain the lack of beneficial treatment response in 
patients with GluN2BN615I or GluN2BV618G mutations where memantine was added to the 
anti-epileptic drug regimen (Platzer et al., 2017). Our findings explain the effects of three 
epilepsy mutations on the major synaptic NMDAR isoforms, and suggest that other subtype-
selective NMDAR antagonists that bind outside the channel pore should be explored as 
candidates for personalised therapeutics.  
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General discussion 
 
At present, there are crucial experimental limitations in studying the physiology and 
pharmacology of epilepsy mutant GABAARs or NMDARs in their native neuronal context. 
Conventional whole-cell electrophysiology using heterologous expression systems removes 
mutant receptor from their synaptic context. It is also not possible to easily investigate the 
mutations of interest in neuronal cultures or transgenic animal models, given that the effects 
of mutations to a particular isoform may be diluted by many other multiple isoforms that do 
not incorporate mutant subunits. To solve those problems, I investigated the pathological 
mechanisms of mutant GABAARs and NMDARs using the artificial synapse preparation. 
This preparation enables us to investigate the physiology and pharmacology of IPSCs or 
EPSCs mediated by defined postsynaptic GABAARs or NMDARs isoforms to infer how those 
mutations disturb neuronal inhibition and excitation. The results dramatically revise our 
understanding of genotype-phenotype correlations in GABAAR- and NMDAR-linked 
epilepsies, leading to new insights into how to therapeutically target these two important 
ligand-gated ion channels. Ultimately, this study provides a framework for devising 
personalised pharmacological interventions for patients with epilepsy.  
 
 
Ⅰ: Physiological properties of defined GABAARs and NMDARs in artificial synapses 
The unique advantage of artificial synapses is that it permits the investigation of the 
physiological and pharmacological properties of IPSCs and EPSCs mediated by defined 
GABAAR and NMDAR isoforms. However, as HEK293 cells do not express all necessary 
postsynaptic clustering proteins at appropriate levels for synaptogenesis, it is possible that 
the synaptic cleft geometry and the receptor clustering mechanisms in our artificial synapses 
not be identical to those of native neuronal synapses. This could result in aberrant 
neurotransmitter concentration profiles that could affect IPSC kinetics.  
Physiological properties of α1β2γ2 GABAARs  
Irrespective of these potential limitations, a range of recombinant GABAAR isoforms 
including α1β2γ2 has been found to mediate IPSCs with kinetics similar to those mediated 
by the same isoforms in neurons (Dixon et al., 2014; Dixon et al., 2015; Dixon et al., 2017; 
Fuchs et al., 2013; Wu et al., 2012). For instance, the major synaptically-expressed α1β2γ2 
isoform exhibits a rise time of ~1 ms irrespective of whether it is expressed in 
heterosynapses (Dixon et al., 2014) or neurons (Eyre et al., 2012; Okada et al., 2000). 
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Physiological properties and localizations of α5GABAARs 
α5-containing GABAARs in neuronal synapses mediate a slowly-decaying IPSC 
component consistent with our results (Caraiscos et al., 2004; Collinson et al., 2002; Glykys 
et al., 2008; Hausrat et al., 2015; Prenosil et al., 2006; Vargas-Caballero et al., 2010; 
Zarnowska et al., 2009). Of the receptors investigated here, the α5β1γ2L GABAAR exhibited 
the fastest rise times (~1 ms) and fastest decay times. Fast IPSC rise times imply expression 
within the postsynaptic density whereas slow rise times suggest perisynaptic expression 
(Farrant and Nusser, 2005; Wu et al., 2012). This implies that α5β1γ2L GABAARs are 
located in postsynaptic densities of artificial synapses close to transmitter release sites. In 
contrast, α5β2γ2L and α5β3γ2L exhibited IPSC rise times of ~3 ms, which suggests 
perisynaptic localization (Wu et al., 2012). α5β3γ2L receptors mediated the slowest 
deactivation times and were tonically active, suggesting the only extrasynaptic localization 
among α5GABAARs so as to sense extrasynaptically-released GABA. This consistent with 
the finding that α5GABAARs are concentrated extrasynaptically via a direct interaction 
between α5 subunits and the cytoplasmic protein, radixin (Hausrat et al., 2015) and the help 
of a binding interaction between β3 and the AP2 clathrin adaptor protein (Vien et al., 2015). 
Finally, the decay time constants of the three isoforms varied over a wide range and 
these were largely dominated by the respective intrinsic channel closing rates and not their 
synaptic versus perisynaptic locations. As synaptic current duration is an important 
determinant of neuronal network functions including signal integration, oscillations and 
output firing rates, these results suggest that IPSCs mediated by the three major α5-
containing isoforms may exert dramatically different effects on network activity. 
Physiological properties of GluN1/2A, GluN1/2B and GluN1/2A/2B NMDARs 
Like many previous studies, the present study showed that the decay time constants 
of GluN1/2A-mediated EPSCs is much faster than GluN1/2B-mediated EPSCs in artificial 
synapses, which correspond closely to those mediated by the same isoforms in neurons (Fu 
et al., 2003; Rauner and Kohr, 2011;Tovar, 2013;Traynelis, 2010). The present study also 
provides the first characterisation of triheteromeric GluN1/2A/2B NMDARs in artificial 
synapses. These EPSCs were found to have a decay time constant intermediate between 
those mediated by GluN1/2A and GluN1/2B, similar to previous studies conducted in 
neurons (Rauner, 2011;Tovar, 2013) or recombinant expression systems (Hansen, 2014; 
Stroebel, 2014).  
GluN1/2A/2B receptor-mediated EPSCs in artificial synapses were resistant to 
ifenprodil inhibition. This fits well with recent studies showing that ifenprodil exhibits only low 
efficacy inhibition of steady-state glutamate-gated currents mediated by recombinant 
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GluN1/2A/2B receptors (Hansen, 2014; Stroebel, 2014). Only GluN1/2A/2B receptors 
mediated EPSCs that decayed more slowly when Mg2+ was removed, consistent with a 
study that reported a similar effect on EPSCs mediated by GluN1/2A/2B receptors in 
neurons (Rauner and Kohr, 2011). Taken together, these results indicate that the artificial 
synapse faithfully recapitulates EPSC properties as mediated by the same NMDAR isoforms 
in neurons.  
 
Ⅱ: Epilepsy mutations effect neuronal inhibition and excitation 
In this study, I investigated six GABAAR or NMDAR epilepsy-causing mutations: 
α1T265I (or α1T10’I), α1D192N, α1A295D, GluN2AN615K, GluN2BN615I and GluN2BV618G with the aim 
of identifying the mechanisms of epileptogenesis and novel therapeutic strategies for these 
disorders.  
The α1A295D mutation, located in M3, gives rise to autosomal dominant juvenile 
myoclonic epilepsy (Cossette et al., 2002; Fisher, 2004). The α1D192N mutation, which gives 
rise to idiopathic generalised epilepsy with febrile seizures (Lachance-Touchette et al., 
2011), is located in the extracellular domain in a region that lines the base of the GABA 
binding pocket. This region has been shown to be critical for triggering activation in 
GABAARs (Zhang et al., 2009) and other pLGICs (Miller and Smart, 2010). α1T10’I mutation 
is located in the middle of the pore-lining M2 domain, near the permeation ‘gate’ of the 
receptor (Miller and Smart, 2010) and other residues that are critical for channel 
conductance and gating (Miko et al., 2004; Shan et al. 2002;  Bianchi and Macdonald, 2001; 
Keramidas et al., 2004; Moorhouse et al., 2002). It was recently discovered as a de novo 
mutation in a child with epileptic encephalopathy (Allen et al., 2013). 
The GluN2AN615K variant is associated with early-onset epileptic encephalopathy and 
severe developmental delay (Endele et al., 2010). Both GluN2BN615I and GluN2BV618G are 
associated with West syndrome and severe developmental delay (Lemke et al., 2014).  
Here, I found those mutations reduce neural inhibition, enhance neural excitation and thus 
contribute to epilepsy through multiple ways.  
Reduction in GABAAR expression levels 
In the artificial synapse preparation, the α1A295Dβ2γ2L GABAAR is not expressed at 
all up to the cell membrane. It was previously reported to result in subunit misfolding, 
internalisation and subsequent degradation via the endoplasmic reticulum degradation 
pathway (Gallagher et al., 2007) and reduced cell surface expression (Gallagher et al., 
2007). α1T10’I and α1D192N also impaired the cell surface expression of these mutant 
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GABAARs in both neurons and HEK293 cells. This mechanism of impairment has also been 
demonstrated for the nonsense GABAAR epilepsy mutations, which completely ablate γ2 
expression (Johnston et al., 2014; Kang et al., 2013). It is well established that a reduction 
or ablation of functional GABAAR expression in the synapse will lead to epilepsy (Schweizer 
et al., 2002). 
Change neuronal morphology  
N-terminal domains of GABAAR α1, β2 and γ2 subunits play a direct structural role in 
synaptic contact formation (Brown et al., 2016). In artificial synapse model, it seems 
reasonable to infer that mutations to, or alterations in the surface expression of, α1 subunits 
could interfere in this process. Transfection of α1T10’I subunits reduced both the number of 
synapses and the neurite branching rate, whereas transfection of α1D192N subunits reduced 
the neurite branching rate and produced a population of enlarged presynaptic terminals. 
α1A295D subunits reduced the number of GABAergic synapses without affecting neurite 
branching in cultured cortical neurons even with the help of SAHA. Other groups showed 
that overexpression of α1A295D subunits resulted in increased peri-somatic bouton density 
and enhanced innervation fields and other morphological changes in cultured GABAergic 
neurons (Di et al., 2013, Lachance-Touchette et al., 2014). In pyramidal neurons, 
transfection of the α1A295D subunit also increased the formation of dendritic spines, which 
are sites of glutamatergic synapses (Lachance-Touchette et al., 2014). Those alterations 
result in morphological changes to GABAergic neurons (Houser, 2014).  
Receptors incorporating mutations associated with febrile seizures are more 
sensitive at high temperature 
One proposed mechanism by which an elevated temperature could lead to impaired 
GABAergic inhibition is by triggering the escape of mutant receptors from the synapse 
(Bouthour et al., 2012). Our study reveal another mechanism. When temperature was 
increased from 37 – 40 oC, to mimic a febrile seizure temperature excursion, no observed 
significant effect on IPSC decay time constant for any of the mutants. The rapid activation 
rate of IPSCs mediated by α1D192Nβ2γ2L GABAARs from 37 to 40 oC renders them more 
susceptible to the effects of elevated temperature and this does not pertain to α1T10’Iβγ2L 
GABAARs.  
Disruption of Mg2+ blockade of NMDAR  
As the GluN2AN615 residue is adjacent to the GluN2BN615 residue, which together with 
GluN1-N616, forms the Mg2+ coordination site (Fedele et al., 2018), the GluN2AN615K, 
GluN2BN615I and GluN2BV618G substitutions are therefore likely to directly disrupt Mg2+ 
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blockade. GluN1/2AN615K,GluN1/2BN615I and GluN1/2BN615I-mediated EPSCs recorded at 
−70 mV exhibit a novel characteristic whereby increasing Mg2+ from 0 to 1 mM greatly 
enhanced EPSC magnitude and thus enhanced neuronal excitability under physiological 
conditions by increasing the net cation influx per synaptic event.  GluN1/2AN615K was 
previously shown to reduce Mg2+ block of steady-state activated GluN1/2A receptors 
expressed in oocytes (Marwick et al., 2015). GluN1/2BN615I was originally shown to reduce 
Mg2+ block of GluN1/2BN615I receptors activated under steady-state conditions in Xenopus 
oocytes (Lemke et al., 2014). GluN2BV618G eliminates Mg2+ block of steady-state activated 
GluN1/2BV618G receptors (Lemke et al., 2014) (Fedele et al., 2018). When overexpressed in 
hippocampal neurons, the GluN2AV618G mutant subunit resulted in EPSCs that exhibited no 
change in the decay rate, a modestly reduced sensitivity to block by 1.2 mM Mg2+, and an 
unchanged memantine sensitivity (Fedele et al., 2018). 
Altered functional channel properties of GABAAR and NMDAR 
α1T10’Iβ2γ2L and α1D192Nβ2γ2L GABAARs compromise effective neuronal inhibition by 
accelerating the decay rate of IPSCs. Whole-cell current recordings of α1D192Nβ2γ2L 
GABAARs revealed accelerated whole-cell deactivation and desensitisation (Lachance-
Touchette et al., 2014). 
GluN2AN615K mutation slowed the decay rate of GluN1/2A/2B-mediated EPSCs, 
resulting in an enhanced cation influx rate which would dramatically increase neuronal 
excitability and contribute directly to the epilepsy phenotype. The peak magnitudes of 
EPSCs mediated by GluN1/2A/2BN615I receptors were significantly larger. This will also 
enhance neuronal excitability by increasing the amount of cation influx during each synaptic 
event. A subsequent study confirmed the loss of Mg2+ block but also demonstrated that the 
mutation reduced the Ca2+ influx rate and enhanced memantine block of steady-state 
activated GluN1/2BN615I relative to GluN1/2B receptors (Fedele et al., 2018).  
EPSCs mediated by GluN1/2BV618G receptors exhibited faster decay rates and bigger 
current size than those mediated by GluN1/2B receptors. Other groups previously showed 
that this mutation eliminates Mg2+ block of steady-state activated GluN1/2BV618G receptors 
(Lemke et al., 2014) (Fedele et al., 2018). Although GluN2BV618G has little effect on the Ca2+ 
influx rate, it does render steady-state activated GluN1/2B receptors highly permeant to 
Mg2+ while dramatically impairing memantine block (Fedele et al., 2018). 
Effects of mutations on the efficacy of common anti-epileptic drugs  
Midazolam and carbamazepine are commonly used to treat symptoms of epilepsy 
and both drugs potentiated α1β2γ2L and α1D192Nβ2γL GABAARs by slowing the IPSC decay 
rates. The situation is evidently different for α1T10’Iβ2γL GABAARs. Here both drugs failed to 
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have any modulatory effect on IPSCs. This suggests that, irrespective of where on the 
receptor the two tested drugs bind, the signal transduction for both drugs is ablated by the 
α1T10’I mutation. This result is similar to that of a benzodiazepine-resistant epilepsy-causing 
mutation in the γ2 subunit (Wallace, 2001) and suggests that benzodiazepine administration 
for some epilepsy-causing GABAARs may be an ineffective treatment. As carbamazepine 
and midazolam are routinely used to treat epilepsy, this study suggests that neither 
midazolam nor carbamazepine would be effective in treating individuals harbouring the 
α1T10’I mutation. 
The GluN2BV618G mutation results in a relatively high degree of memantine 
resistance. Memantine did not significantly block EPSCs mediated by GluN1/2BV618G 
receptors. Whilst 10 µM memantine significantly enhanced the EPSC decay rate of 
GluN1/2A/2B receptors, it had no effect on mutant GluN1/2A/2BV618G receptors. This result 
can also explain the lack of beneficial treatment response in patients with GluN2BV618G 
mutations where memantine was added to the anti-epileptic drug regimen (Platzer et al., 
2017). 
 
Ⅲ: Future anti-epileptic drugs 
SAHA was previously shown to correct the protein folding and thereby enhance the 
surface expression of α1A295D-containing GABAARs in HEK293 cells (Lachance-Touchette 
et al., 2014). Using whole-cell electrophysiological recordings, they showed that the same 
SAHA treatment produced GABA-gated currents with saturating magnitudes that were up to 
10 % of those mediated by WT receptors (Di et al., 2013). Our study demonstrated that 
SAHA (100 nM for 3 days) restored the functional expression of α1A295Dβ2γ2L GABAARs in 
HEK293 cells to the extent that the peak magnitudes and decay time constants of 
spontaneous IPSCs mediated by these receptors were not significantly different to those 
mediated by α1β2γ2L GABAARs. This dramatic effect suggests SAHA may be worth 
investigating as a treatment for epilepsies caused by this mutation and a possible new 
direction for epilepsy therapy. 
Compounds selectively targeting α5GABAARs that have been identified here have 
the potential for further development as clinical treatments for a number of CNS disorders. 
Positive modulators of α5GABAARs have shown promising results in treating cognitive 
symptoms of schizophrenia (Gill et al., 2011) and age-related dementia, such as Alzheimer’s 
disease (Koh et al., 2013). Furthermore, selective α5GABAAR negative modulators have 
proven valuable as cognition enhancers (Collinson et al., 2002; Atack, 2011), as well as in 
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post-stroke recovery (Clarkson et al., 2010) and prevention of amnesic side effects resulting 
from general anesthaesia (Nutt et al., 2007). TB-21007 preferentially inhibited IPSCs 
mediated by α5β3γ2L GABAARs with an efficacy of -38 %. It exhibited the highest selectivity 
for α5β3γ2L GABAARs over other α5-containing isoforms. When delivered intraperitoneally 
to rats, TB-21007 enhanced cognitive performance without the anxiogenic or pro-convulsive 
effects usually associated with non-specific GABAAR inverse agonists (Chambers et al., 
2003). MRK-016 selectively reduced the IPSC decay time constant in α5β3γ2L GABAARs 
and also reduced the magnitude of IPSCs mediated by α5β1γ2L and α5β2γ2L GABAARs.  
As a negative α5GABAARs modulator, α5IA used for Down syndrome (Braudeau et al., 
2011; Atack, 2010; Braudeau et al., 2011). RM68, developed by a collaborator, is potent α5-
GABAAR modulator and selectively inhibited IPSCs and tonic current mediated by α5β3γ2L 
GABAARs.  
 
CONCLUSION 
In this thesis, I provide a characterisation of IPSCs and EPSCs mediated by pure 
populations of α1β2γ2L, α5β3γ2L, α5β2γ2L, α5β1γ2L, GluN1/2A, GluN1/2B and 
GluN1/2A/2B receptors. The physiological and pharmacological characterisation was also 
performed on GABAARs and NMDARs that incorporated hereditary epilepsy mutations and 
allowed me to make new findings regarding their mechanisms of epileptogenesis and its 
possible reversal.  
Three mutations in GABAAR resulted in loss of inhibitory input. These mutations 
would enhance the tendency of recurrently connected excitatory neurons to transition, via 
positive feedback, into synchronous hyperactivity and could thus explain the epileptogenic 
mechanism for these mutations. The mutations in NMDARs each resulted in an enhanced 
cation influx rate which would dramatically increase neuronal excitability and contribute 
directly to the epilepsy phenotype. Importantly, the mutations also reduced the potency of 
the use-dependent blocker, memantine, with the GluN2BV618G mutation having the largest 
deleterious effect by virtue of its complete ablation of memantine inhibitory efficacy in the 
GluN1/2BV618G receptor. α1T10’I, was found to render GABAARs insensitive to the standard 
anti-epileptic drugs, midazolam and carbamazepine. Finally, I found that SAHA at clinically 
relevant concentrations restores surface expression of α1A295Dβ2γ2L GABAARs to the point 
where they mediate IPSCs with waveforms and magnitudes comparable to those mediated 
by α1β2γ2L GABAARs. This implies SAHA may be worthy of investigation as a treatment for 
epilepsies caused by this mutation. 
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The findings here explain the effects of epilepsy mutations on the major synaptic 
GABAARs and NMDAR isoforms, and suggest that other subtype-selective NMDAR 
antagonists that bind outside the channel pore should be explored as candidates for 
personalised therapeutics.  
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